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SUMMARY
Oral tolerance describes the down-regulation of the systemic immune response to antigens
that are encountered by the oral route. It is a well described phenomenon in many animal
studies, but there is little work on oral tolerance in humans. Animal studies suggest that there
are several different immune mechanisms that mediate oral tolerance, including clonal
deviation, active suppression, clonal anergy and clonal deletion. There are several factors
that influence which mechanism induces the production of tolerance including the type of
antigen, the animal model used and most critically the length and dose of feeding. Oral
tolerance has been shown to occur in humans, but there are very few published studies
investigating the phenomenon.
This thesis describes my work in developing a protocol to investigate oral tolerance to
soluble protein antigens in humans. I investigated oral tolerance to two protein antigens -
namely keyhole limpet haemocyanin (KLH) and ovalbumin (OVA). KLH is a neoantigen
that is not normally encountered by humans, and therefore allowed me to investigate oral
tolerance to low dose feeding. A control group was immunised with KLH and the immune
response was assessed by testing humoral responses, delayed type hypersensitivity (DTH)
responses and in vitro lymphocyte proliferation. To assess oral tolerance, a study group was
fed a course of KLH prior to receiving the same immunisation schedule. Three feeding
schedules were used. The immune response was measured in the same way as the control
group and any differences between the two were attributed to oral tolerance.
Immunisation with KLH caused a good immune response with positive DTH responses, the
production of anti-KLH IgG and IgA and detectable in vitro lymphocyte proliferation. The
immune response in the group fed the lowest dose of KLH (lOmg of KLH fed for 10
consecutive days) showed no differences from the control group. After feeding the
intermediate dose ofKLH (50mg ofKLH fed for 10 consecutive days), there was detectable
in vitro lymphocyte proliferation, but no humoral response. After immunisation the DTH
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responses were significantly reduced, the in vitro lymphocyte proliferation responses were
unchanged and anti-KLH IgG, but not IgA, production was increased compared to the
control group. These changes demonstrate that oral tolerance in the T cell compartment does
occur in humans. The group fed the largest dose of KLH (50mg of KLH fed for 15 days in
two separate blocks) had detectable in vitro lymphocyte proliferation after feeding. After
immunisation, there were reduced DTH to KLH, detectable anti-KLH IgG and IgA (but not
significantly different from the control group) and detectable in vitro lymphocyte
proliferation. Compared to the group fed the intermediate dose of KLH, the in vitro
lymphocyte proliferation was significantly greater after feeding, but significantly less after
immunisation. Thus oral tolerance in the T cell compartment was also demonstrated in this
group.
The mechanisms responsible for the induction of tolerance are unknown. The results above
are consistent with the induction of an immunoregulatory cell, although they would also be
consistent with the induction of other mechanisms of tolerance. Efforts were made to
identify this putative immunoregulatory cell by assaying the cytokine profile produced from
cell cultures, by measuring the levels of IgG subclasses induced and by using flow cytometry
to identify cell surface markers of cells cultured with KLH in both the control group and the
KLH-fed groups. The data obtained could not identify any immunoregulatory cell.
OVA is a common dietary protein and was used to investigate oral tolerance to prolonged
courses of feeding. Volunteers were immunised with OVA using the same schedule as that
used for KLH and the same assays were used to investigate the immune response. Two doses
of immunisation were used. At baseline (i.e. after feeding) there were low levels of anti-
OVA IgA and IgG but no detectable in vitro lymphocyte proliferation. The lower dose
immunisation schedule did not cause any detectable immune response. The higher dose
immunisation schedule did not induce any detectable in vitro lymphocyte proliferation
response or DTH response, but did cause an increase in either anti-OVA IgG or IgA in three
of the four volunteers investigated. These results suggest that oral tolerance to OVA is more
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pronounced than to KLH. One can hypothesise that different mechanisms of tolerance such
as clonal anergy have been induced. Attempts to provide supportive evidence for this
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1 AIMS OF THIS THESIS
One of the mysteries of the immune system is that ingested food antigens do not produce an
immunological reaction in the small intestinal mucosa. In some way, we develop tolerance to
the numerous antigens presented to us in our intestines but the mechanisms by which this is
accomplished, particularly in humans, are obscure. In some way, orally encountered antigen
causes down-regulation of the systemic immune response to that antigen. Oral tolerance is
likely to have evolved as a protective mechanism to prevent the development of wasteful,
and possibly harmful, immune reactions to harmless, ingested antigens (such as those in food
proteins) in the gut mucosa. It is a very robust phenomenon that occurs with many different
antigens and in many different animal species. The mechanisms leading to oral tolerance are
being elucidated in animal models. It appears that several different mechanisms of tolerance
production occur in different models and even within the same model. Factors that influence
the type of tolerance produced include the animal model system used, age, species and the
type and dose of antigen given.
Oral tolerance may be important in clinical practice in two ways. Firstly, diseases of
gastrointestinal inflammation such as coeliac disease and inflammatory bowel disease (IBD)
may result from a breakdown of tolerance. An improved understanding of oral tolerance may
therefore offer new insight into the pathogenesis of these diseases, and potentially offer new
immunomodulatory opportunities for their treatment. Secondly, feeding antigen offers a
cheap, safe way to suppress immune responses in an antigen specific manner. Investigators
have therefore suggested that oral tolerance could be used to treat many diseases of abnormal
inflammation and particularly autoimmune diseases. This method of treatment has been
successfully applied to animal models of autoimmune disease, but has not yet proved
successful in humans. These two areas of clinical applications have resulted in an interest in
oral tolerance, and led to a plethora of animal studies into the phenomenon.
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Oral tolerance has been demonstrated in humans. However, 1 am aware of only one study
investigating oral tolerance in humans in a controlled maimer, and no published studies
looking at the mechanisms of induction of oral tolerance in humans. The aims of this thesis
therefore are as follows:
1) To develop a model to confirm that tolerance does indeed occur in humans.
2) To assess the effect of oral feeding on different aspects of the systemic immune
response, including cellular and humoral immune responses.
3) To assess the effect of different doses and types of antigen on the development of oral
tolerance.
4) To develop theories of the mechanisms of tolerance production by comparing the type of
immune response generated to those found in animal model of tolerance.
5) To develop experimental protocols to test one or more of these theories.
In this thesis, I will review the literature on oral tolerance, concentrating particularly on the
animal studies examining the mechanisms of induction of tolerance. I will then detail my
experience of developing a protocol to investigate oral tolerance in humans. I will also
present my experience of the effects of altering the type and dose of antigen on the immune
responses of oral tolerance. The possible mechanisms of tolerance induction in humans will
be discussed and experimental protocols devised to attempt to investigate which of these
mechanisms is relevant to humans will be presented.
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2 INTRODUCTION AND LITERATURE REVIEW
2.1 A BriefHistory ofOral Tolerance
2.1.1 A Definition of Oral Tolerance
Oral tolerance can be defined as the down-regulation of the systemic immune response to a
specific antigen when that antigen is encountered by the oral route.
2.1.2 An Introduction to Tolerance
The immune system has evolved to detect and destroy harmful invasive organisms such as
viruses, bacteria and parasites. A powerful array of defensive mechanisms has evolved to
neutralise and kill such organisms. To prevent these destructive mechanisms being induced
to non-pathogenic antigens, the immune system has to be able to recognise these antigens as
harmless and avoid mounting a potentially damaging response to them. The mechanisms of
tolerance have developed to allow this to happen. The most important form of tolerance is
self-tolerance. The body can recognise self-antigens and avoid mounting an immune
response to them. If these mechanisms fail, the result is auto-immune disease, with all the
deleterious health effects that follow.
Other antigens apart from self antigens are also harmless, and immune responses to them are
wasteful or damaging. One such group of antigens is that encountered at mucosal sites
including dietary antigens that are absorbed through mucosa of the gastrointestinal tract.
These antigens are harmless and indeed an immune response against them can be positively
dangerous to the host, as is demonstrated by the gastrointestinal damage that is caused by the
immune response to gliadin in coeliac disease. This thesis looks at the mechanisms of oral
tolerance, which have evolved to prevent immune responses to orally encountered antigens.
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2.1.3 The Early History of Oral Tolerance
There are anecdotal reports dating back to the last century when South American Indians
were said to eat the leaves of poison ivy plants to prevent the development of contact
sensitivity reactions later1. Although at the time these reports were treated with scepticism or
assumed to be due to the superstitions of a primitive people, a rational, scientific explanation
for this behaviour came with the early studies of oral tolerance. The first scientific report
describing oral tolerance was published at the start of the century when it was found that
guinea pigs prefed ovalbumin (OVA) did not develop anaphylaxis when inoculated with it
systemically, whereas non-fed controls did2 3. In 1946, Chase tried a variety of ways to
reduce the severity of contact hypersensitivity and was surprised to find feeding animals
(guinea pigs in this case) the sensitisor prior to cutaneous exposure reduced the severity of
the subsequent response4. He went on to demonstrate the antigen specificity of the response
by showing that prefed animals still developed contact hypersensitivity to unrelated
chemicals. This antigen specificity of oral tolerance is an important feature of the
phenomenon that has been consistently demonstrated over the years.
2.1.4 The Range of Oral Tolerance
Subsequent investigators have confirmed the concept of oral tolerance and expanded it in a
number of important ways. Firstly it has been shown to occur in many different species,
including mice5'6, dogs7, pigs8 and humans9. Secondly, it was found that humoral as well as
cell mediated immunity (CMI) could be affected10. Indeed, both systemic and secretory
humoral immunity could be suppressed11. Indirect evidence that oral tolerance of secretory
immunity can be induced is provided by the observation that secretory immunoglobulin (Ig)
A antibodies to food antigens are rare in humans12. A wide variety of antigens were shown to
produce a similar response, including contact sensitisers4;5;13, soluble proteins9'10 and
particulate antigens such as heterologous red blood cells11'14, or bacteria6. Lastly, it was
shown that tolerance could be induced in animals that had already had a systemic immune
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response stimulated by parental injection of the same antigen15'16. These findings confirmed
oral tolerance to be a widespread and reproducible immune response.
2.2 The Immune Features ofOral Tolerance
There are, however, a number of differences between oral tolerance induced in the humoral
and cell mediated limbs of the immune system. CMI appears to be the easier to suppress, and
as little as one dose of antigen administered orally is required in some experimental
models6'17. The response of the systemic humoral system to oral antigen is more complex. In
certain experimental models, the level of circulating antibody rises in response to oral
antigen10"18. Priming occurs in other cases - i.e. although there is no difference in antibody
levels after feeding, the antibody response is of greater magnitude than it would otherwise
have been following subsequent parenteral exposure9. In other cases, the systemic antibody
response is reduced after subsequent parenteral exposure15'19. Different classes of Ig also
differ in their susceptibility to tolerisation. IgE on the whole is easy to suppress, with IgG
having an intermediate position and IgA being the hardest to suppress and in fact levels can
often be primed15 20. Secretory antibody generally is increased or primed after oral
exposure6'9. It is possible in some transfer experiments, however, to demonstrate suppression
even of Peyer's patch Ig responses11. Indirect evidence for the induction of tolerance of
secretory IgA comes from the observation that it is difficult to detect secretory IgA to normal
food antigens12. Another general principle appears to be that the easier it is to induce
tolerance, the more long-lasting it is. For example, CMI can be suppressed for up to 18
months by a single feed in mice, whereas systemic humoral tolerance was initially induced,
but was no longer detected at 6 months17.
In summary the immunological effects of feeding can be summarised as follows:
1) CMI is usually rapidly and easily tolerised
2) Systemic humoral immunity can be activated, primed or suppressed
3) Secretory humoral immunity is usually activated or primed
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These differences between the responses of the humoral and cell-mediated immune
responses have been confirmed in many studies. The potential reasons for this split will be
reviewed below. In the next section I will discuss various experimental factors which may
affect the development of tolerance and in the following section I will consider the
mechanisms of tolerance that may account for these differences.
2.3 Factors Influencing the Development ofOral Tolerance
As described above, oral ingestion of antigen may alter the immune responses to that
antigen, depending on the study protocol used. A variety of factors, which differed between
the studies, seem to be important in influencing the exact immune response seen. These are
discussed below.
2.3.1 Type ofAntigen
The type of antigen involved can have a profound effect on the mucosal immune response.
The most extreme example is when the mucosal immune system is challenged with invasive
bacteria such as Salmonella or Shigella species. In this case, a brisk and vigorous immune
response occurs, with clear survival benefits to the host.
Cholera toxin is a protein from a pathogenic organism which can promote both a systemic
and secretory immune response when given orally2'22. Furthermore, cholera toxin can act as
an adjuvant to increase humoral responses to other antigens if the two antigens are fed
concurrently2122. Cholera toxin can bind to the intestinal cells via a single ganglioside and
cause ADP-ribosylation through the cholera toxin subunit-B (CT-B) subunit of the
molecule23. Both cholera toxin and CT-B can augment the immune response to a conjugated
antigen24. Others report that coupling CT-B subunit to a second protein can dramatically
improve the production of tolerance to that second molecule25, even in animals that have
previously been systemically immunised26. The explanation for these different results is
unclear.
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In contrast to the pathogenic bacteria described above, tolerance can be induced to
commensal bacteria27,28. Non-bacterial antigens also vary in the ease with which they can
induce tolerance. Oral tolerance can be more easily induced by soluble protein antigen than
by particulate antigen. One oral dose of soluble antigen can induce tolerance, whereas it is
more difficult to induce equivalent levels of tolerance to particulate antigens and larger doses
of antigen have to be given6,14. Soluble antigens also vary in the ease with which they cause
tolerance. For example, in a mouse model 0.25-lmg of myelin basic protein (MBP) will
induce tolerance29, whereas only 0.003mg of type II collagen will have the same effect30. It
does appear possible, however, to induce tolerance to most proteins if they are given in the
right dose and for an appropriate length of time. An exception to this rule is T-independent
antigens, which do not induce oral tolerance.
2.3.2 Dose and Feeding Schedule of the Antigen
The dose of antigen is also important. A number of investigators have found that a single,
small dose of protein antigen can tolerise CMI617, although, in certain circumstances, very
low doses of fed antigen can cause priming of delayed type hypersensitivity (DTH)
responses31. Larger doses of antigen are required to inhibit humoral immunity16, and the
larger the dose of antigen, the more quickly and completely tolerance is induced15 32. The
length of feeding also appears to be important. The longer the course of feeding, the more
complete the tolerance becomes, both for cell-mediated immunity33 and for humoral
immunity1034. Short courses of antigen feeding may result in priming of the humoral system,
but with more prolonged feeding tolerance can occur14. As noted above, the different Ig
isotypes appear to differ in their susceptibility to tolerance induction. IgE responses can be
suppressed by a single low dose of antigen. Larger doses of antigen are required to cause the
same effect on IgG and IgA levels13. Frequent low dose feeding appears more effective at
inducing tolerance than a single, higher dose feed15'34"36. The time between oral and
parenteral exposure is also important. Using the same dose of antigen, it has been shown that
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it is necessary to leave an adequate time interval to allow tolerance to develop (of 4-6 days
depending on the antibody isotype studied) before challenging the animal with antigen
parenterally15. This clearly has implications on how oral tolerance is induced and this will be
discussed later.
2.3.3 Immune Status of Animal
Another consideration is whether the animal has previously been exposed to the antigen.
Many studies have fed the animal a particular novel antigen before systemic challenge, thus
inducing a tolerant state in a naive animal. However the effect of oral feeding on an animal
that has already systemically encountered, and therefore mounted an immune response to, a
particular antigen is also important. This situation has clinical implications, particularly in
considering how oral tolerance might be used to treat established autoimmune disease, a
topic which will be discussed later. DTH responses can be suppressed in previously
immunised animals37. The dichotomy of the humoral response between the various antibody
classes becomes even more apparent in previously immunised animals, with IgE levels being
(incompletely) suppressed, no effect seen on IgG levels, and IgA levels substantially
augmented15. Other investigators have examined the effect of dose of feeding on IgG
responses in previously immunised animals. They found that early feeding with high dose
antigen suppressed the IgG response, whereas lower dose feeding, especially if given later,
resulted in priming of the immune response16. The dose required to suppress a DTH response
also appeared to be higher than in the non-immune animal. Multiple low dose feeds appear
to be required to induce oral tolerance in this setting3839. Several reports suggest that the
earlier after immunisation that the feeding took place, the more effective the
suppression16 37 3840. Thus it appears more difficult to induce oral tolerance in previously
immunised animals.
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2.3.4 Species of Animal
Another important variable in these various experiments is the species of laboratory animal
used. Different species vary in the ease with which tolerance can be induced. For example,
rats and mice are very easy to tolerise and often one dose is enough to induce prolonged
tolerance1 ;17. On the other hand, it is difficult to induce tolerance in guinea pigs, which
require higher doses of oral antigen for longer to become tolerant10. Indeed low dose feeding
may result in sensitisation of the immune response. Further, there are reports that ruminants,
such as cows, or rabbits may not develop significant degrees of tolerance18;41.
2.3.5 Age ofAnimal
In addition, the age of the animal appears to be important. For example, in experiments on
guinea pigs, Heppell and Kilshaw found that tolerance in cell-mediated immunity was easily
and rapidly induced by feeding, but that systemic humoral immunity was increased initially
in animals below 3 months of age. With more prolonged feeding however, the systemic
antibody level fell compared with non-fed controls, indicating that tolerance was induced in
this compartment also. A different picture emerged in animals that were first introduced to
the fed antigen when they were older. When feeding was induced at 5-6 months of age, the
systemic antibody level rose and remained high despite continued feeding10. Other
experiments in mice suggest that the mechanisms of tolerance may vary between animals
that encounter antigen when they are young and in adulthood. Tolerance appears to be
mediated by active suppression in adult mice whereas young animals appear to develop
anergy.
The first 7-10 days of life are ones in which oral tolerance may be completely absent:
feeding neonatal mice an equivalent weight-dose of OVA as adults resulted in priming of
both humoral and cell-mediated immune (CMI) responses, which is a very unusual response
in adults36. It was initially suggested that an immature immune system was unable to process
antigens so as to induce tolerance. However, further work has suggested that this may be due
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to a regulatory imbalance since the failure to induce oral tolerance can be partially restored
with adult spleen cells42.
Weaning is another period of early life when oral tolerance appears to be incomplete43 and is
independent of the time at which weaning occurs. Interestingly, there are major changes in
the gut immune system at the time of weaning44, which suggests that there may also be a
regulatory cell imbalance at this time.
2.3.6 The Presence of Commensal Bacteria
It has been demonstrated that oral tolerance cannot be induced to sheep red blood cells in
germ free mice but can in normal mice of the same strain45. In other studies, tolerance to
soluble antigen can be induced in germ free mice, but the duration of tolerance is shorter46.
In addition, the feeding of lipopolysaccharide can enhance the induction of oral tolerance47
and induce tolerance in germ-free mice45. Thus the presence of commensal bacteria in the
intestine, or at the very least immunogenic bacterial products, seems to be important to the
induction of tolerance.
2.4 Mechanisms of Oral Tolerance
2.4.1 Introduction
Advances in cellular and molecular biology have improved understanding of the control of
immune responses and allowed the mechanisms by which tolerance is induced to be
investigated. In this section I will outline the various proposed mechanisms of tolerance
production and review the evidence in the literature on how these potential mechanisms
apply specifically to oral tolerance. Firstly however, a brief review of the mechanisms of
induction of an active immune response is included, since an understanding of these is
required to appreciate the theories of tolerance production.
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2.4.2 The Generation of an Immune Response - a Dual Signal Process
Immunocompetent cells can recognise specific antigens. B cells do this via their surface Igs
and T cells do so via the T cell receptor (TCR). Both of these interactions are antigen
specific and the occupation of these receptors is necessary for cellular activation, but
importantly it is not enough to do so alone. A second signal is necessary to complete the
activation process48'49. In the case of T helper cells this can be provided by soluble
interleukin (IL) -1 produced by activated macrophages or T cells50 51. Others suggest that
cell-to-cell contact is required to provide the second signal32. Surface molecules on antigen
presenting cells (APCs), such as the B7 family of molecules, may provide the second signal
in this case53 54.
Once activated, T helper cells can then provide the second signal, or "help", to antigen
specific cytotoxic T cells via IL-2, and provide help for B cells by producing cytokines IL-4
and IL-5. These cells are therefore activated if they also encounter antigen at the same time.
All of these cytokines act in a paracrine manner. The cells involved are grouped close
together in areas of lymphoid tissue such as lymph nodes, which create the optimal
conditions to produce an efficient immune response.
It has been noted that most B cells require "help" from T cells. One exception to this rule is
that certain T-independent antigens can stimulate B cells without T cell help. These antigens
are polyvalent and cross-link surface Ig on B cells which provides enough stimulation to
activate B cell without T cell help. Typically these antigens are bacterially derived and
include peptidoglycan from bacterial cell walls and single-stranded RNA. It is interesting
that these antigens do not induce oral tolerance, which does suggest that T cells are central to
the production of oral tolerance.
A further level of complexity is added by the theory that activated B cells can conversely
give help to T cells. Activated B cells can provide this help, by acting as APCs, presenting
antigen bound to their surface Ig, and providing a second signal. On the other hand, resting B
cells, although they can present antigen via their surface Ig, do not provide co-stimulation49'55
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and therefore do not provide help to T cells. It may be that activated B cells express high
levels ofB7, a potent co-stimulatory molecule, on their surface56. According to this theory, B
cells are crucial in the outcome of an immune response, and provide an important control
mechanism to prevent an inappropriate immune response.
2.4.3 T helper Cell Subsets
From the above section it can be seen that T helper cells have a crucial role in the generation
of an immune response. There is now ample evidence that in the mouse model T helper cells
can be divided into at least two distinct subsets on the basis of the cytokine profile that they
secrete and the effector functions that they mediate. These cells have been termed ThI and
Th2 cells.
2.4.3.1 Th1 cells -TH1 cells secrete IL-2, interferon (IFN)-y and tumour necrosis factor
(TNF)-a57. These cells seem to induce preferentially a CMI response and increase DTH. IL-
2 and IFN-y are major factors which supply help to cytotoxic T cells. In addition it seems
that only TH1 cells can cause a delayed-type hypersensitivity (DTH) response, and that TH2
cells are incapable of producing this type of immune response58. The response of B cells to
Th1 help is variable. Some studies suggest that TH1 cells are incapable of stimulating resting
B cells59. Others show that IL-2 appears to be able to stimulate B cell proliferation and
antibody production in vivo. It seems TH1 cells can increase the IgG2a antibody response
through the secretion of IFN-y50, and this cytokine also appears to inhibit other Ig subclass
responses such as IgGl, which may be induced by TH2 cytokines59. Thus IFN-y may have a
role in Ig isotype switching.
2.4.3.2 Th2 cells - Th2 cells secrete IL-4, 5, 6, and 1057. These cells and cytokines seem
particularly adept at stimulating a humoral response59. IL-4, IL-5 and cell to cell contact are
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required for optimum resting B cell proliferation and differentiation59. The secretion of
certain Ig isotypes are particularly enhanced by TH2 cells, particularly IgA, IgE (for which
IL-4 help appears to be of crucial importance) and IgGl60. In addition IL-4 and IL-5 can
provide help for cytotoxic T cells61, but not for delayed type hypersensitivity (DTH)58.
Indeed, IL-4 and IL-10 act in synergy to inhibit a DTH response induced by ThI cells62.
Lastly, until the recent discovery of eotaxin63, IL-5 was the sole known chemo-attractant for
eosinophils and causes eosinophil proliferation, and thus a Th2 response may also be
important for developing an immune response against parasitic infections.
Thus the type of immune response to an antigen can vary depending on the type of T helper
cell responses produced. A TH1 response will produce a vigorous cell-mediated immune
response, but a poor to moderate humoral response, whereas a TH2 response will have the
opposite effects.
2.4.3.3 Differentiation ofThI and Tn2 Cells
How does this differentiation into T(I1 or TH2 cells occur? Before exposure to antigen, CD4+
T cells appear to secrete IL-2, but only minimal levels of other cytokines64. After short-term
culture, T helper cells can express many cytokines, including IL-2, IL-4, IFN-y and TNF64.
Many T cells obtained directly from experimental animals show this pattern of lymphokine
secretion65. Only after more prolonged culture do cells show the typical pattern of TH1 or
Th2 cytokine secretion discussed above. Cell clones derived from single cell precursors can
be induced to secrete either IL-2 or IL-4, depending on the cell culture conditions66 67. These
results have lead to the theory that there is an immature precursor T helper cell, termed THp.
After short term culture this cell differentiates into a cell which can secrete many cytokines,
including IL-2, IL-4, IL-5,IL-10 and IFN-y. This cell has been termed the TH0 cell66'67. With
prolonged exposure to antigen, this cell is then thought to differentiate into either a typical
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ThI or Th2 phenotype, depending on prevailing conditions at the time of antigenic
stimulation64.
The cause of this switch appears to be the fact that naive T cells will switch on and off
appropriate genes. It seems that those cells which become TH1 cells switch off their IL-4
genes, whereas those that become TH2 cells extinguish their IFN-y genes68. Conversely those
that become ThI cells up-regulate their IFN-y genes and those that become Ti{2 cells up-
regulate their IL-4 gene. This process is not detectable at 20 hours, but is present at 40
hours67.
2.4.3.4 Factors Influencing the ThI To Tn2 Switch
The above observations lead to the question of which factors influence the outcome of this
differentiation pathway? It has been observed that the overall immune status of the animal
will influence the proportion of TH1 to Th2 cells found in subsequent culture. In particular, if
the animal is immunised with an antigen that normally induces a profound TH2 antigen-
specific response, the overall number ofTh2 clones in subsequent culture is greatly increased
and the speed with which they develop is also increased. Conversely immunisations that
induce a TfIl antigen-specific response increase the overall number of TH1 clones observed64.
These results suggested that in vivo factors could influence the outcome of the immune
response.
In in vitro culture it has been observed that the culture conditions can profoundly influence
the type of T cell proliferation seen. Culturing lymphocytes with IL-4 resulted in increased
levels of IL-469 and reduced/unchanged levels of IL-2 being produced70. Adding IFN-y or
anti-IL-4 antibodies to the cell culture resulted in reversal of the pattern of cytokines
• f\Q 71 77
production " . IL-10 has also been shown to inhibit cytokine production from ThI cells .It
may be that, at least in part, IL-10 exerts its action by an effect on macrophages such that
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when they present antigen they do so in such a way that inhibits a ThI response72.
Interestingly IL-10 and IL-4 may act synergistically to down-regulate TH1 functions62.
Conversely, if culture medium contains IFN-y, Th2 cells are inhibited whereas ThI clones
are unaffected, suggesting that this cytokine will promote a TH1 response73'74. IL-12, another
pro-inflammatory cytokine, also promotes a TH1 response68. Therefore, the cytokine milieu
present at the time of the induction of the immune response may critically influence its
outcome by altering the TH1 to TH2 helper cell ratio.
The length of time in culture also affects the type ofT helper cell produced. At an early stage
in their culture, T helper cells respond to IL-2 and IL-4 in a synergic manner. After more
prolonged culture, TH1 clones become more responsive to IL-2 and less responsive to IL-4
than Th2 clones74. It is possible that early on these cells are not fully differentiated (i.e. TH0
cells) and are thus able to respond to both cytokines. With more prolonged culture they
differentiate terminally into, and demonstrate the more classical features of, the individual
subsets of the T helper cell subsets. The polarisation of the immune response seems to
become more pronounced with time, so that chronic immune responses becomes
progressively more directed towards either a ThI or Th2 response. On the other hand short
duration immune responses may be able to show a mixed pattern since the typical Th1/Th2
response only appear' with time as these polarised responses develop.
Although the cytokine milieu at the time of antigen presentation seems to be the most
important factor influencing the TH1/TH2 switch, other factors also seem to be important.
These include the type of antigen, the route of antigen entry and the dose of antigen75.
Clearly if the oral route of antigen administration results in the production of TH2 cells, then
a degree of tolerance, at least for CMI, by immune regulation will be achieved. The evidence
that orally administered antigen can result in tolerance by this mechanism will be discussed
below.
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2.4.3.5 Host Benefits of the Tnl/Tn2 Paradigm
It has been observed that many immune responses to infectious organisms are either
predominantly cell mediated or predominantly humoral. The type of immune response that is
best suited to clearing a particular organism depends on the type of organism involved. For
example cell-mediated immune responses are better able to eradicate intracellular organisms,
whereas extra-cellular organisms are best countered by a combination of cell-mediated and
humoral immunity. Lastly, metazoan infections are best countered by a humoral immunity
with no cell-mediated immune response since the latter may cause more damage to the host
than the organism. The Th1/Th2 responses have clearly evolved to allow this dichotomy of
immune response to occur76'77. Most antigens encountered in the gastrointestinal tract would
be best dealt with by a strong humoral immune response. This will bind toxins and prevent
binding of bacterial to the mucosa by coating any binding proteins. This strategy will keep
noxious substances in the gut lumen. Conversely, a strong cell-mediated immune response
will be potentially harmful to the host, since it may damage the gastrointestinal mucosa.
Thus it can be seen that the most appropriate response to antigens in the gastrointestinal tract
would be a Th2 response. The evidence that this occurs and may account for oral tolerance is
reviewed below.
2.4.3.6 Evidence for T Helper Cell Subsets in Humans
Much of the above work has been done in mice. Studies of clones of human helper cells have
identified clones that correspond broadly with the ThI and TH2 phenotypes observed in mice.
For example it was shown that purified protein derivative (PPD) specific T cells clones
secreted IL-2 and IFN-y, which are typical of TH1 cells. Conversely T cell clones specific for
secretory-excretory antigen of Toxocara canis produced IL-4 and IL-5, which is a pattern of
Th2 cells. These cells persisted with stable cytokine profiles over 6 months in culture78.
Further, the cells appeared not to secrete the opposing cytokines because they lacked
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transcripts for these cytokines, which provides indirect evidence that the genes for these
cytokines were switched off.
In other studies, there were in addition many other clones which seemed to produce a mixed
pattern cytokine profile79. All groups of clones could provide help to B cells producing IgG,
but only IL-4 producing clones (i.e. TH2 phenotype clones) could provide help for IgE
producing B cells79. It has been suggested that human cell cultures persist for longer as a
mixed phenotype before maturing down one development pathway than do mouse cultures80.
This suggests that a mixed TH1 and Th2 response may occur for longer and more easily in a
human immune response than in the murine model.
Lastly, evidence from the immune responses to specific pathogens, or in autoimmune
disease, fit into a predominantly cell-mediated, ThI type response or a predominantly
humoral, TH2 type response76, in exactly the same way as happens in animal models. This
provides further circumstantial evidence for the existence of ThI and TH2 cell types in
humans.
2.5 General Mechanisms of Tolerance
With this background into the production of an immune response, it becomes possible to
postulate various mechanisms of tolerance induction and maintenance. The hypotheses that
have been suggested to explain the principles of tolerance in general will be discussed in this
section. In the following section the evidence that these general mechanisms of tolerance
production can be applied to oral tolerance will be discussed.
2.5,1 Immune Deviation
As noted above, the immune response can to be divided into a TH1 or TH2 response57 58. The
two responses produce different immune profiles and work to suppress the effects of the
other type of T helper cell57. Thus, the production of a TH2 response can be thought of as
producing suppression of cell mediated immune responses, and therefore tolerance of this
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limb of the immune response to that antigen58. This mechanism, termed immune deviation,
does not produce tolerance by the strict definition of the term, but the alteration of the
immune response produced may have a beneficial effect on the host. Thus, in situations
where a cell-mediated immune response may be damaging to the host, the production of a
Th2 cell allows a degree of active immunity while at the same time protecting the host from
an excess immune response77'78. It seems to occur in response to specific infections,
especially parasitic81. It also has been suggested as the reason why the foetus is not rejected
by the systemic immune response76. Evidence that orally encountered antigen causes
immune deviation will be discussed below.
2.5.2 Active Suppression
Another mechanism of tolerance that has been put forward is active suppression. It has been
suggested that there is a sub-population of antigen specific cells that when activated secrete
specific suppressive cytokines. According to this theory these cells, when activated, will
down regulate an active immune response through the actions of these suppressive cytokines.
It is suggested that the mechanism of antigen presentation in the gut favours the production
of suppressive immunoregulatory cells over cytotoxic (and possibly even antibody forming)
cells. Many early investigators postulated that this is the mechanism by which oral tolerance
is induced11; ;82, but it is only in recent years that direct supportive evidence has been
uncovered. Even now the nature of these cells and cytokines is uncertain and, as will be
discussed below, CD4+ and CD8+ cells may both act as suppressor T cells83"85.
2.5.3 Clonal Anergy
Another mechanism of tolerance is "clonal anergy", which has been reviewed by Schwartz86.
This mechanism is based on the dual stimulation theory of lymphocyte activation. One
stimulus is from the antigen itself. B cells recognise the whole antigen via their surface Ig,
whereas T cells recognise antigen fragments in combination with MHC antigens via their T
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cell receptor. The second signal may be from soluble mediators, or from cell surface
molecules which require cell to cell contact to be activated. This has been reviewed in the
section on generation of an immune response.
Crucially, without this second signal, B cells do not produce antibody49 and T cells do not
proliferate or produce IL-2 in response to subsequent antigen exposure, even in conditions
appropriate for immune activation87'88. These lymphocytes have been rendered anergic.
Anergy is also suggested by the observations that B cells down-regulate the expression of
surface antigen and that T cells down regulate their surface IL-2 receptor55.
The encounter of the T cell with antigen in the absence of co-stimulation does not appear to
be a purely negative event since the cells increase in size and IL-3 production is increased in
cells that encounter antigen in this way before they become unresponsive88. This suggests
that the initial encounter with the antigen causes partial activation with intra-cellular
signalling followed by down regulation and anergy.
The need for the second signal in the activation of an immune response appears to be an
important control on the immune system. It ensures that an immune response is only
stimulated in the presence of inflammation, and thus may prevent an immune response being
generated to harmless or self antigens. This is best illustrated by the fact that self-reacting B
cells have been identified and it is thought to be lack of co-stimulation that prevents them
from producing auto-antibodies49.
Clonal anergy can develop in the thymus89, or to antigens given intravenously or
intraperitoneally90. This review will discuss the evidence that oral administration can result
in the induction of anergy. It has been postulated that in the environment of the
gastrointestinal mucosa, antigen is presented in an atypical manner which leads to anergy91"
93. Thus immunocompetent cells which recognise dietary antigens may become anergic and
unable to mount a systemic immune response in future.
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2.5.4 Clonal Deletion
A fourth mechanism of tolerance induction is clonal deletion. This mechanism is particularly
important in generating tolerance to self-antigens. The major site of clonal deletion occurs in
the thymus as T cells are maturating. Here the T cells undergo rearrangement of their T cell
receptor (TCR) genes by a combination of splicing and mutations. The products of these
genes - i.e. the T cell receptors themselves - are then expressed. Thymocytes express major
histocompatibility complex (MHC) antigens. The newly fonned TCRs come into contact
with these MHC antigens. If they bind to them too strongly, they are likely to do so outside
the thymus and thus possibly induce an autoimmune reaction. Conversely if they bind them
too weakly, they will never be able to participate in an immune response even if the MHC
molecules present an antigen fragment. Therefore, if the TCRs bind MHC too strongly or too
weakly in the thymus, that cell is induced to undergo apoptosis or "programmed cell death".
It is only if they fall in the useful middle ground that they receive the required stimulus to
continue to mature and eventually leave the thymus89 94.
As can be seen from the above brief review, much of the work on clonal deletion suggests
that it occurs in the thymus and is responsible for maintaining self-tolerance. For a long time
it was felt that clonal deletion did not occur in the periphery94. Recent evidence suggests that
this may not be the case, and clonal deletion can occur in response to oral antigens. The
evidence for this will be discussed below.
2.6 Immune Mechanisms ofOral Tolerance Production
Evidence exists to support a role for all of these mechanisms in the induction of tolerance,




This subdivision of T helper cells into TH1 and Th2 subtypes offers a potentially useful
explanation for the observations that the different limbs of the immune response behave
differently in response to oral antigens. Cell mediated immune responses are frequently
suppressed, but the humoral responses can be elevated, primed or suppressed. It may be that
the presentation of antigens via routes that induce tolerance results in a predominately TH2
response thus skewing the immune reaction towards a humoral response and reducing the
cell mediated effects, particularly DTH. This hypothesis is supported by the observation that
the antigen specific TH2 mediated IgGl production is maintained whereas the TH1 mediated
lgG2a response is inhibited by feeding of that antigen93. The humoral response would have
the benefit of binding any bacterial toxins or coating bacterial binding sites in the gut lumen
and thus exclude potentially harmful antigens from the body. At the same time, the reduction
of the cell-mediated immune reaction may protect the gut from a damaging inflammatory
response to harmless antigens. Thus the Th2 cells may be acting as active suppressor cells
(see below).
2.6.2 Evidence for Active Suppression in Oral Tolerance
2.6.2.1 Cyclophosphamide
Early evidence for the existence of suppressor T cells was derived from the observation that
pre-dosing animals with cyclophosphamide abrogated the subsequent attempts to induce oral
tolerance. Evidence that cyclophosphamide selectively affects T suppressor (Ts) cells is
quoted from both in-vitro9 , and in v/vo97'98 work. These studies all suggest that at doses of
about 100 milligrams (mg)/kilogram (kg)/mouse, cyclophosphamide up-regulates the
immune response by inhibiting Ts precursor cells.
This work was extended to oral tolerance where cyclophosphamide has been shown to
prevent the induction of oral tolerance if given to mice before feeding occurs. An experiment
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in which mice were fed high or low dose OVA before immunisation showed that high dose
feeding resulted in tolerance in systemic CMI and serum IgG and IgM responses whereas
low dose feeding resulted in tolerance in systemic CMI and, to a lesser extent, serum IgM
responses. Pre-treating these animals cyclophosphamide, given intra-peritoneally, resulted in
the complete blockage of tolerance induction in the low dose fed group, whereas that of the
high dose group was only partially blocked". These results support the idea that the separate
arms of the immune system are controlled differently, as suggested by the evidence
discussed above. Further it may be that low dose feeding induces Ts cells which act
primarily on cell mediated responses, and that it is these responses that are inhibited by
cyclophosphamide. As will be discussed below, perhaps higher dose feeding induces
different mechanisms that may not be disrupted by cyclophosphamide.
2.6.2.2 Transfer Experiments
The ability to transfer tolerance from an animal that has been fed a specific antigen to a naive
animal is a further powerful line of evidence that active suppression occurs, and many of the
studies quoted used transfer experiments to help elucidate the mechanisms of tolerance.
Many early experiments showed that transfer of cells from the Peyers' patches, peripheral
lymph nodes or spleens of pre-fed animals could transfer tolerance to naive control
animals6'11'13'32'34'82'100.
In addition some authors suggested that transfer of serum could transfer tolerance. There
appear to be two situations in which serum can transfer tolerance. Firstly, it occurs when
serum is taken two weeks after the commencement of feeding101 and the tolerogenic factor
may be antigen-antibody complexes. Other authors report failing to transfer tolerance with
serum taken at this time33. The second situation in which serum could transfer tolerance was
when serum was taken one hour after a single feed of antigen such as OVA102. The factor
responsible for the transfer of tolerance seemed to be OVA itself, since the ability to transfer
tolerance was removed if the serum was treated with Sepharose beads coated with anti-OVA
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antibody, thus removing OVA from the serum103. These experiments suggest that processing
antigen by the gastrointestinal immune system is crucial in determining tolerance. These
ideas will be discussed in detail later in this thesis.
In the majority of the studies examining cell transfer, it was felt that the suppressor cell was
a T cell since the cells were susceptible to anti-rat lymphocyte serum100 or anti-Thy 1.2
antibodies and complement11'82. In at least one experiment, it was suggested that B cells
could also transfer tolerance since these cells rosetted antibody/complement coated red blood
cells and their resistance to anti-9 serum plus complement13. Other authors have been unable
to reproduce this finding82. The suppressor T cells were initially found in Peyers' patches
and, after 1-2 days, in the peripheral lymph nodes20'100. After 4 days however, cells from
these sites were no longer able to transfer tolerance, but cells from the spleen or thymus
could100. These findings suggest that suppressor cells migrate from the gut, where they are
presumably induced, to more distant lymphoid sites. Other models give similar results that
agree with this hypothesis13.
All the researchers that investigated this subject found that transfer was always antigen
specific, which is further evidence that oral tolerance is antigen specific. A further feature of
the transfer of tolerance was that it appeared to affect the afferent limb of the immune
response since transfer of cells had to take place before or immediately after systemic
challenge of the recipient animal with the antigen to transfer tolerance32 33.
2.6.2.3 Bystander Suppression
Another observation that added weight to the theory that active suppression was involved in
oral tolerance was termed "bystander suppression". In experimental animals an active
immune response was evoked to an antigen and oral tolerance was induced to an unrelated
antigen. When the antigen to which an active response had been raised was added to a cell
culture system, cell proliferation was seen. No proliferation was seen when the tolerising
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antigen was used (as would be expected). When both antigens were added to the same
system, no response was seen to either antigen83. Thus some active component induced by
the tolerising antigen must be suppressing the active immune response - causing bystander
suppression. Another example of bystander suppression comes from the observation that an
animal made orally tolerant to a protein that is subsequent injected linking to a hapten does
not produce an immune response to either antigen or hapten32. More recent reports by the
same group and others have confirmed the presence of bystander suppression104 105. It is
suggested that cytokines released by suppressor cells produced by orally feeding antigen can
act in a non-specific manner to down-regulate all immune responses, provided that the
suppressor cells are activated in an antigen specific manner initially.
Other investigators have used conjugated antigens such as dintrophenylate (DNP)-OVA.
Animals were made orally tolerance to OVA. Immunisation with DNP-keyhole limpet
haemocyanin (KLH) resulted in good immune responses to DNP being generated, whereas if
DNP-OVA was injected then the immune response to DNP was reduced. Further if DNP-
KLH and DNP-OVA were injected together, even if the injections took place at different
sites or at different times, the immune response to DNP was reduced106. These authors argue
that since this suppression seems to operate over a larger distances and times, the cytokine
mediated theory for bystander suppression cannot fully explain their observations. They
postulate than an idiotypic network theory of immune response may be better able to explain
their results.
Finally, a more recent suggestion is that bystander suppression may be mediated by the down
regulation of APCs that are then unable to present antigen and provide help for CD4+ cells
recognise unrelated antigen107;108.
2.6.2.4 The Identity Of The Suppressor T cell
The nature of the T suppressor cell has caused considerable controversy. Many workers have
identified it as a CD8+ cell83109"111. However, others report that CD8-depleted animals could
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still develop oral tolerance112"114, although there was reduction of local tolerance, as manifest
by normal mucosal IgA production, in CD8 deficient mice114. In other models, CD4+ cells
were the mediators of oral tolerance84'115'116. Depletion of CD4 cells with anti-CD4
antibodies prevented tolerance induction84 and a CD4+ deplete strain of mouse did not
develop tolerance117. One report suggested that both CD4+ and CD8+ cells could transfer
tolerance separately in one experimental model112.Thus it seems that both CD4+ and CD8+ T
cells can act to mediate oral tolerance in different models, and possibly are complementary
to each other in maintaining tolerance.
Other reports suggest that y8 T cells may be important in the production and maintenance of
oral tolerance. They demonstrated that the production of tolerance could be blocked by the
use of an anti-yS TCR monoclonal antibody, in both in vivo, and in vitro transfer
experiments118119, and one strain of y8 cell knockout mice do not develop oral tolerance119.
Furthermore adoptive transfer of y8 cells from animals fed peptides fragments of S-ag
ameliorated experimental autoimmune uveitis120. These reports are not consistent with other
experimental models which suggest that yS T cells act as T helper cells or counter-suppressor
cells and it has been suggested that y8 T cell subsets can have different functions depending
on the prevalent conditions at the time of activation. Finally others report that y8 T cell
deficient mice have a reduced IgA response to oral antigen, leading these authors to postulate
that y8 cells have a specialised role in controlling mucosal immunity121.
2.6.2.5 The Role ofCytokines in Active Suppression
The above evidence suggests that, when animals are fed oral antigen, suppressor cells are
induced. The next question is how do these cells exert their action? It is clear that antigen
specific triggering of these cells is required to induce tolerance, since antigen specificity is
an important feature of oral tolerance that has been identified in many studies as discussed
above. Once triggered, suppressive soluble mediators or cytokines may be secreted. For
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example it has been shown that if suppressor cells and effector cells are separated by a semi¬
permeable membrane, which prevents cell-to-cell contact, suppression of the effector cells
still occurs and this must be by the presence of a soluble mediator. Further, these soluble
mediators have been shown to induced bystander suppression using this same system83.
2.6.2.6 The Nature of the Suppressive Cytokines
2.6.2.6.1 Th2 Cytokines -Evidence for Clonal Deviation
Thus there is plenty of evidence that suppressive factors are involved in tolerance. The next
stage was to identify them. Theoretically the immunological effects of oral tolerance in many
models, including the suppression of CMI and the priming of humoral immunity, could be
mediated by switching the T helper response towards the TH2 type response. Evidence to
support this hypothesis came later when cytokine analysis became possible. Examples of this
type of cytokine work come from experimental models of autoimmune disease, where the
primary end-point of the effectiveness of oral tolerance is a reduction in the observed
severity of that disease. For example, non-obese diabetic (NOD) mice become diabetic
spontaneously at about 15-20 weeks of age. The disease is characterised by an inflammatory
infiltrate of CD4+ T cells that secrete TH1 type cytokines into the pancreatic islets. Feeding
these mice insulin from 5 weeks of age reduces the insulitis and abrogates the disease.
Cytokine analysis showed increased expression of IL-4 and IL-10 which are TH2 cytokines,
and transforming growth factor (TGF)-(3. There was a parallel fall in the TH1 cytokines IL-2,
IFN-y and TNF-a122. Other authors report similar findings. For example, feeding myelin
basic protein induced a T cell that produced IL-4 and IL-10 ( i.e. TH2 type cytokines) and
inhibited TH1 induced autoimmune encephalitis85. Another report shows that feeding of
OVA caused increased IL-4 messenger ribosomal nucleic acid (mRNA) expression, but
reduced IFN-y mRNA expression123. Taken together, these results suggested that oral
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tolerance could occur by switching the immune response from a harmful TH1 response
towards a safer Th2 response.
Further evidence that a switch from a TH1 to a TH2 based response may be important in oral
tolerance is supported by the finding that some of the effects of oral tolerance could be
inhibited by the administration of anti-IL-4 antibodies at the time of tolerance induction124,
and giving IL-4 itself at the time of tolerance induction can enhance oral tolerance123. As
discussed above, IL-4 is a TH2 cytokine that can inhibit the production of THlcells. Therefore
blocking IL-4 may influence the balance between the ratio of TH1 to TH2 cells, resulting in
an increased ThI response, and thus abrogate tolerance. Other studies have looked at the
effect of giving pro-inflammatory cytokines to orally tolerant animals at the same site and
time as an immunising injection. They found that IL-12 was able to reverse tolerance,
although IL-2, IFN-y and GM-CSF could not126. Others have found that giving IL-12
neutralising antibodies could promote oral tolerance127, which again suggests that IL-12 may
inhibit oral tolerance. IL-12 may mediate its effect in part by changing the local immune
environment such that TH1 responses are promoted and TH2 type responses inhibited.
Other observations do not fit with the theory that oral tolerance may be mediated by immune
deviation towards a TH2 type response. For example, IgE responses are often dramatically
reduced by oral feeding15;2°, and yet IgE is regarded as a TH2 mediated response. Also
tolerance to intranasal antigen can be induced even in the presence of anti-IL-4 antibodies,
which should inhibit Th2 responses128. Furthermore peripheral tolerance can be induced by
feeding in STAT6 knockout mice129. STAT proteins are deoxyribonucleic acid (DNA)
binding proteins involved in cell signalling. STAT6 is involved in IL-4 signalling and thus
STAT6 deficient mice are functionally deplete of TH2 cells. Oral tolerance is also normal in
IL-4 knock out mice128 130. These results suggest that tolerance can be mediated in the
absence of TH2 cells. Although oral tolerance was induced by feeding a large dose of
antigen, and therefore may be mediated by clonal anergy (see below), it has been suggested
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that other cell type(s), related to but distinct from TH2 cells, may be the mediator of oral
tolerance.
2.6.2.6.2 Th3 Cells and Transforming Growth Factor-B
Other work has suggested that different cytokines may be important in oral tolerance
production. One such cytokine is TGF-p. Activated T cells131 and B cells132 appear to have
the ability to secrete TGF-p. In vitro work suggests that TGF-p can inhibit IL-2 dependent T
cell proliferation and suppress B cell proliferation and antibody secretion131. Thus, TGF-P
seems likely to be an important suppressive cytokine in vivo. Levels of this cytokine are
increased in many models of tolerance29'133'134. Further neutralising antibodies to TGF-P
prevent the production of tolerance by effector cells'15;I35;136. The cells that secrete TGF-P
were found to be CD4+ cells in the majority of these reports.
Thus it may be that the production of antigen specific TGF-P secreting cells by the
gastrointestinal immune system is an important mechanism of tolerance induction.
Supportive evidence that this may be the case comes from experiments that have shown that
feeding more prolonged doses of antigen results in a fall in both ThI and TH2 cytokines,
whereas TGF-P levels rise133. The authors suggested that this may represent a specific cell
type with suppressor properties and they have suggested that this cell be termed the T helper
3 (Th3) cell133. Similar TGF-p secreting antigen specific cells have been detected in humans
fed myelin137. It has been reported that these cells also need IL-4 as a growth factor125, which
may explain why anti-IL4 can inhibit oral tolerance as discussed above. Therefore TGF-p
secreting TH3 cells may be responsible for inducing oral tolerance in some experimental
models.
It should be noted that in at least one experimental model using TGF-P 1 knockout mice oral
tolerance could still be induced138 and therefore there must be other mechanisms of tolerance
induction in this model.
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2.6.2.6.3 Tpl Cells and IL-10
Recently a further population of regulatory T cells have been identified by repeatedly
stimulating OVA specific naive CD4+ cells obtained from afl T cell receptor transgenic
mice139. These cells secrete high levels of IL-10 and IL-5, some TGF-p and IFN-y,
proliferate poorly in response to antigen stimulation and have been termed TR1 cells139. Cells
secreting a similar TR1 cytokine profile could also be generated from human blood if
stimulated with APCs and IL-10139. IL-10 is a potent suppressor of TH1 cell functions and
can inhibit Tgl mediated disease such as IBD in vivo139. These properties are similar to the
effects observed in studies on oral tolerance and have led to speculation that such cells may
be induced by encounter of antigen at the gastrointestinal mucosa.
2.6.2.7 Summary of Work Suggesting that Suppressor Cells May Play a Role in Oral
Tolerance
There is thus good experimental evidence, principally from transfer experiments, that
suppressor cells exist and are important in mediating oral tolerance. Further work has
suggested candidate suppressor cells and these include TH2 cells, which can suppress the TH1
cells, Th3 cells which produce TGF-P and may act as more generalised suppressor cells and
possibly Tr1 cells that modulate the immune response principally through the secretion of
IL-10. In addition CD8+ T cells have been shown to transfer tolerance, and may do so by
producing a similar array of cytokines140, although the evidence that this occurs in the
context of oral tolerance is so far lacking.
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2.6.3 Evidence for Clonal Anergy in Oral Tolerance
Initially most experimental studies suggested that suppressive mechanisms were the cause of
the observed tolerance for the reasons outlined above. Experimental evidence that this was
not always the case started to emerge.
2.6.3.1 Failure to Transfer Tolerance
Whitacre et al developed an experimental system using experimental autoimmune
encephalitis (EAE) in rats141. They demonstrated that feeding myelin basic protein resulted in
decreased clinical signs when these mice subsequently had EAE induced. They were unable,
however, actively to transfer tolerance using cells derived from the spleen, lymph nodes or
Peyers' patches or indeed using humoral elements. Further these mice were not protected
from EAE when lymphocytes from other non-fed, diseased mice were transferred into them.
Both these observations suggest active suppression did not occur in this experimental
system. They also showed that lymphocytes derived from the spleen and lymph nodes of pre-
fed animals had a reduced proliferative response in vitro and produced less IL-2 when
stimulated. As discussed, these are both features of anergic cells, and Whitacre et al argued
that this might be the explanation for the type of tolerance they were seeing in their system.
Furthermore they reported that changes in one amino acid in a tolerogenic peptide
dramatically reduced the ability of that peptide to protect against EAE compared to when the
original peptide was used. Thus there appeared to be exquisite peptide specificity when
inducing oral tolerance which they again suggested implied that clonal anergy rather than
bystander suppression was the mechanism of tolerance induction142.
Finally, another group of investigators demonstrated that oral tolerance to OVA could be
induced in mice pre-treated with cyclophosphamide143. Tolerance could not be transferred by
cells obtained from pre-treated animals. The authors argued that cyclophosphamide
destroyed T suppressor cells and therefore tolerance could be induced by means other that
active suppression.
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2.6.3.2 Reversal of Tolerance With 1L-2
The findings discussed above have been confirmed144, and extended to show lack of
bystander suppression both in vivo and in vitro. The cells also showed reduced ability to
produce IL-2 receptors in addition to reduced IL-2 secretion, both of which are features of
anergic cells. In addition, pre-culturing peripheral lymph node cells with IL-2 resulted in a
return of the ability to proliferate in response to fed antigen demonstrated in vivo and in
vitro, which suggested that anergy was being overcome by this powerful stimulus144'145.
2.6.3.3 Direct Evidence for Clonal Anergy as a Mechanism ofOral Tolerance
The above results strongly suggest that clonal anergy can be responsible for oral tolerance
production. Direct evidence for the presence of clonal anergy was derived from observations
on OVA specific TCR transgenic lymphocytes that were transplanted into mice. These mice
were fed OVA and the effects on the transgenic lymphocytes were monitored. It was shown
that these lymphocytes were not deleted, but that they had reduced proliferative responses
following feeding. This did not appear to be due to suppressive factors and the authors
concluded that the effects were due to clonal anergy146. Further studies suggest that clonal
anergy is not a passive process, since cells that encounter antigen presented orally show an
increase in size and a transient up-regulation of IL-2 production and expression of activation
markers such as CD69147. Subsequently, there is a marked reduction in IL-2, IL-10 and IFN-
y production and a failure to respond to antigen in vitro141. These results suggest that there is
active differentiation of antigen specific T cells towards the anergic state when antigen is
encountered orally.
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2.6.3.4 T Helper Cell Subsets and Clonal Anergy
Further work suggested that the subsets of T helper cells vary in their susceptibility to
anergic stimuli. TH1 cells appear to become anergic more readily than TH2 cells, with lower
doses of antigen being required148149. This suggests that clonal anergy of TH1 cells after
antigen feeding may allow TH2 immune responses to be manifested further without
competition from TH1 cells. This also led to the hypothesis that both clonal anergy and
immune deviation may work together to enhance oral tolerance. Feeding high dose of
antigen, however, causes both T helper cell subsets to be rendered anergic130.
2,6.4 Evidence for Clonal Deletion in Oral Tolerance
Clonal deletion is thought to be the main mechanism for generating self-tolerance. It is
known to occur in the thymus during maturation of the immune system. For many years, it
was thought not to occur in the mature immune system. Recently, however, there has been
increasing evidence to suggest that clonal deletion can occur in the periphery. It has been
shown in transgenic mice cloned for a particular TCR that recognises OVA, that T cells
numbers fall in the Peyers' patches in response to high dose feeding of 50-500mg per dose of
OVA. This is not due to a migration of these cells to other lymphoid or non-lymphoid
organs. In addition, increased apoptosis was observed in the Peyer's patch at the time of this
fall in numbers suggesting that "programmed cell death" is responsible for the loss of T
cells133. This did not occur when these animals were fed bovine serum albumin (BSA)
suggesting that this mechanism is antigen specific. In addition, the fall was not observed
when non-transgenic mice were fed OVA133. Low dose feeding (0.5mg/feed) failed to cause
any measurable clonal deletion even if the length of feeding was extended to a month133.
Other authors have confirmed the finding of clonal deletion in the OVA TCR-transgenic
127
mouse
How does clonal deletion occur? Apoptosis is a common phenomenon that occurs in many
different tissues. A particular example is that cells with damaged DNA are induced to
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undergo apoptosis by a mechanism involving p53, the so-called guardian of the genome. In
the context of oral tolerance, it has been shown that activation precedes apoptosis as shown
by increased levels of cell marker expression and cytokine production. CD44 is increased
and CD45RB is reduced on these cell surfaces prior to apoptosis, both of which are a sign of
cellular activation. In addition IFN-y, IL-4 and 1L-10 levels are increased before apoptosis
suggesting that both TH1 and TH2 cells are activated. With more prolonged feeding all these
cytokines fall to zero, indicating that apoptosis occurs in both cell types. This suggests high
dose feeding initially activates these immune cells, but further signalling (or possibly lack of
signalling) causes these cells to undergo apoptosis.
The experiments described above use transgenic strains of animal that are fed antigen at
supra-physiological doses. Furthermore clonal deletion was not observed in a different
transgenic mouse model with myelin basic protein TCR150. It is unclear whether the results
from such models can be generalised to non-transgenic models that ingest physiological
quantities of antigen. It has proved difficult to detect clonal deletion in non-transgenic
models due to the small proportion of T cells that are specific for the fed antigen. Recently,
attempts have been made to overcome this problem by transferring a limited number of cells
from transgenic animals into wild-type animals. Clonal deletion has not been reported in
these models147'151. Thus further work is necessary to confirm that clonal deletion can
mediate oral tolerance when antigen is encountered by normal animals in physiological
doses.
2.7 Effect OfDose On The Type OfOral Tolerance Induced
The above review illustrates that in different animal models, different mechanisms of
inducing tolerance have been discovered. Which factors influence the development of
tolerance down one pathway or another? The most important differences between these
studies relate to the dose and duration of antigen feeding. For example, in Whitacre's
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experiments on abrogating EAE, which provided evidence for clonal anergy, there were
several differences from the experiments which described active suppression. These include
the dose of antigen (5mg/feed v. 0.5mg/feed), the fact that it was administered with a
protease inhibitor and the fact that the mice were fed on an empty stomach. All these factors
have the effect of increasing the dose of intact protein that is absorbed by the intestinal
mucosa. This has lead to the theory that low dose feeding results in the production of active
suppression or immune deviation, whereas high dose feeding results in the production of
clonal anergy or clonal deletion152.
One can review some of the early studies on oral tolerance and reinterpret them in the light
of this hypothesis. For example, it explains the differing responses of the systemic humoral
response that were discussed above. Those experiments that showed a rise or priming of the
humoral response may have been observing a ThI to TH2 switch caused by low dose feeding.
On the other hand those studies that showed a fall in humoral responses may have been
observing clonal anergy caused by higher doses of feeding. The results of Peng et al15 show
this split in one study.
These observations have lead to the development of experimental models looking at the
different causes of tolerance related to differences in the dose and length of feeding. One
study worth mentioning in detail is that of Gregerson et al who fed mice high and low dose
of S-ag and measured the effect on disease activity of subsequently induced experimental
autoimmune uveoretinitis (EAU)153. By feeding peptide fragments, they were able to
demonstrate that low dose feeding (250pg/feed) offered protection when EAU was induced
with the whole S-ag or even when a different immunogenic epitope from the S-ag was used.
This finding is likely to represent bystander suppression. In addition, they were able
efficiently to transfer resistance to non-fed animals. Conversely high dose feeding
(5mg/feed) offered protection if the disease was induced with the same epitope as the feed,
but not if a different epitope from the same antigen was used. Further, transfer of resistance
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to EAU was much less effective when cells were taken from high dose animals. These
results suggest that low dose feeding results in active suppression, but high dose feeding
results in anergy. Logically it would seem that the anergic process must affect either the
suppressor cells or the TH cells that provide the necessary "help" to induce them, since
transferring T cells does not result in transfer of tolerance in these systems. Other authors
have confirmed these observations by showing that low dose feeding causes active
suppression, but that high dose feeding causes clonal anergy in an experimental system using
myelin basis protein134.
2.7.1 Mechanisms of Tolerance Combine to Produce Oral Tolerance
Thus it seems that the mechanism of tolerance induced varies depending on the dose of
antigen fed. It seems that in different animal models, clonal deviation, active suppression,
clonal anergy and clonal deletion can all induce tolerance. It seems likely that these
mechanisms can all occur in one species and combine to cause tolerance to most antigens in
most doses encountered. Furthermore, these mechanisms overlap to ensure that tolerance
occurs, as discussed below.
Lowest doses of feeding seem to cause tolerance by clonal deviation, with the production of
a predominantly humoral Th2 response122. Also at low doses active suppressor cells are
formed133. TH2 cells themselves may act as suppressor cells, particularly of DTH80. In
addition, once a Th2 response is produced, it can be self-perpetuating. Naive T cells will be
induced to differentiate into TH2 cells by the TH2 cytokines produced locally. As has been
shown, IL-4 and IL-10 will cause TH1 cytokine genes to be switched off, thus causing the
naive cells to differentiate into Th2 cells5870. More specific suppressor cells, possibly
producing high levels of TGF-P, are also produced133. TGF-P producing cells may be able to
inhibit both cell-mediated and humoral immune responses131'132.
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With more prolonged feeding anergy becomes a more important mechanism to induce and
maintain tolerance. Initially TH1 cells are more susceptible to anergy than TH2 cells149'154.
Thus at this stage, anergy will also help to maintain the balance of the immune response to
the oral antigen towards the antibody producing, TH2 type response. However with further
feeding, TH2 cells also become anergic130 and both limbs of the immune response may
become suppressed.
It is interesting that there is evidence that anergic cells can secrete some cytokines, including
TGF-P and IL-4155. Therefore there may be a stage where anergic cells can secrete
suppressive cytokines, thus providing another area of overlap between active mechanisms of
tolerance production and clonal anergy in the maintenance of oral tolerance134. Other authors
have suggested an alternative mechanism whereby anergic cells can act as suppressor cells.
Using an in vitro assay, these authors showed that human anergic T cells could inhibit
antigen specific and allospecific T cell proliferation. The authors felt that their experiments
suggested that the anergic cells were suppressive in a passive manner by competing for IL-2
and antigen ligands156. Another report suggests that T cells that are rendered anergic by
immobilised anti-CD3 monoclonal antibody could transfer tolerance. In this report
suppressive cytokines were not secreted by these anergic cells and neutralising antibodies to
IL-4, IL-10 or TGF-P did not prevent transfer of tolerance. Furthermore cell-to-cell contact
appeared to be required for transfer of tolerance157. It should be noted that in these
experiments, the anergic cells were not obtained by inducing oral tolerance, and it was an in
vitro system. Therefore these results may not be applicable to in vivo oral tolerance.
However, experiments in a mouse model have shown that CD4+ cells rendered anergic by
high dose feeding could transfer tolerance to SCID or nude mice116. Thus anergic cells may
also act as immunoregulatory cells to control the immune response.
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With further feeding clonal anergy14' and possibly clonal deletion1" may become the
overwhelming mechanism of tolerance production and all aspects of the immune response
are suppressed.
2.7.2 Survival Advantages for This Model ofOral Tolerance
If one considers the type of antigen that is likely to be encountered at a given dose, it seems
that the system outlined above would be of benefit to the host animal. Pathogenic bacteria
and viruses are likely to be encountered for a short time, and possibly at a relatively high
dose. These are not conditions that induce tolerance readily, and are likely to induce a Th2
response. The advantage of a good humoral response is that it will neutralise any toxins or
pathogenic binding sites thus keeping these potentially harmful organisms in the lumen,
while avoiding a cell mediated immune response with potential attendant tissue damage.
Food antigens are encountered over prolonged periods of time and in relatively high doses.
These conditions are ideal for tolerance formation, and are likely to produce clonal anergy.
Therefore, there will be reduced humoral immune response to food antigens. This has
advantages to the host in that these antigens are harmless and therefore any immune response
to them is unnecessary, and indeed wasteful.
Thus this model, with two or more mechanisms of tolerance production that are mutually
compatible and overlapping, provides an explanation which fits with the majority of the
published data. In addition it provides theoretical advantages to the host based on the type of
antigens that are likely to be encountered at the relevant doses.
2.8 Evidence for Oral Tolerance in Humans
The vast majority of the above work has been published in animal models. There is very
little direct work looking at oral tolerance in man. There is one study investigating the
immunological effects of oral antigen exposure directly9. This study used KLH, which is a
neoantigen. A control group was given a sub-cutaneous injection schedule of KLH. The
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active group was fed two 5-day courses of KLH over 3 weeks at a dose of 50mg per day.
The immune response was assessed by measuring DTH, in vitro lymphocyte proliferation
and humoral responses. They found that cell-mediated immune responses were suppressed,
whereas humoral responses were primed. They concluded that oral tolerance did occur in
humans, but made no comment on the mechanisms involved. It is possible however to
suggest that the induction of immunomodulatory cells (?TH2 cells) would explain their
observations.
This is the only completed, controlled study of oral tolerance reported in the literature,
although a pilot study has also been published158. There are other studies that imply the
existence of oral tolerance in humans, included that reported by Lowney159'160. He fed
volunteers a contact sensitisor (dinitrochlorobenzene) before attempting to sensitise them to
this antigen. He found that provided an adequate oral dose was given (greater than 20mg),
there was a reduction in the degree of sensitivity. These experiments clearly suggest that oral
tolerance has developed in the T cell compartment in response to low dose feeding.
Another study that implies the existence of oral tolerance in man is that of Korenblat et aI19.
This group was investigating humoral responses to food antigens. It is well known that there
are antibody responses to food antigens in healthy people. Korenblat et al attempted to
provoke these responses by feeding people high doses of antigen or by giving intra-dermal
immunisation with the food antigen. They found that there was no measurable DTH response
to any of their injections. The humoral responses fell into two categories. One group had low
levels of antibody to start with and showed no rise in antibody levels following further
exposure to antigen. The second group had higher levels of baseline antibodies, and this
group did show a small rise in antibody levels following systemic exposure. These findings
were reported 30 years ago and the authors concluded that the gastrointestinal mucosa
processed antigen in a different way than the systemic immune response. It is possible in the
light of subsequent work to suggest that this difference in processing may be due to the
production of an initial TH2 response - hence producing the detectable levels of antibody
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seen. With further exposure, other mechanisms of tolerance production such as clonal anergy
may be induced. If the anergy affects Th2 cells, then there would be no help provided for the
humoral response thus explaining the failure of the antibody response to increase following
immunisation.
These hypotheses are supported by the fact that antibody levels to food antigens fall with
age151. One can suggest that more prolonged exposure to antigen that occurs with increasing
age results in the production of more powerful tolerance producing mechanisms, which
inhibits further antibody production to food antigens. Prolonged exposure would then
suppress this response. Further indirect evidence that oral tolerance occurs in humans can be
derived from the observation that secretory antibodies to food antigens are rare12.
It thus seems clear that oral tolerance can occur in humans. The only paper that looked at the
immune responses in the laboratory in a controlled study was that of Husby and colleagues9.
Their results could be explained by the production of an immunomodulatory cell response
following encounter with low dose antigen. The studies looking at dietary antigens (e.g.
those of Scott et a/161 and Korenblat et aly>) imply a more profound degree of tolerance, since
the humoral immune responses are suppressed as well. These results infer that the dose of
antigen fed influences the mechanism of tolerance production, in the same way that has been
suggested in animal models (see above). My studies were designed to investigate further the
ability of different feeding schedules to induce tolerance in the different compartments of the
immune system.
2.9 Clinical Implications of Oral Tolerance
2.9.1 Treatment ofAutoimmune Diseases
One area where oral tolerance may be of clinical benefit is the treatment of autoimmune
diseases. By feeding the self-antigen towards which the autoimmune process is directed, one
can in theory down-regulate the immune response and thus abrogate the effects of the
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disease. Oral tolerance is likely to be safe, cheap, free of side-effects and antigen specific
compared to the current treatment of immunosuppressant drugs162.
Many animal models of autoimmune disease have been treated by feeding the oral antigen
towards which the autoimmune response is directed, and shown that the effects of the disease
can be reduced. These include feeding insulin to NOD mice163, giving myelin basic protein
to animals with EAE, a model of multiple sclerosis115'141, feeding collagen to mice with
adjuvant arthritis, a model of rheumatoid arthritis30, and using protein S antigen to inhibit
EAU153. Finally transplant rejection, which is not an autoimmune disease, but is an undesired
immune response to foreign tissue, can be reduced by feeding antigens from the transplanted
organ in the peri-transplant period164'165.
These experiments have been so encouraging that trials of therapy for human autoimmune
disease using oral antigens to induce tolerance have been undertaken. Two preliminary
studies have been published; the first feeding patient with rheumatoid arthritis type II
collagen166, and the second feeding patients with multiple sclerosis myelin antigens167. Both
these trials were preliminary attempts to prove safety, and neither reported any adverse
events. On the other hand, neither trial was large enough to be able to draw conclusions on
efficacy. More recently, larger trials have been published with generally disappointing
results. Most work has been performed on patients with rheumatoid arthritis. One study
randomised 90 patients with early rheumatoid arthritis to receive oral bovine type II collagen
or placebo, but found no statistically significant differences between the two groups. The
authors did claim that a minority of patients had a good response and felt that further work
was justified168. Other authors investigated a group of 190 patients with active rheumatoid
arthritis to receive 6 months of oral bovine type II collagen or placebo. No statistically
significant results were found169. Finally, another group investigated whether oral feeding of
chicken type II collagen would enable the dose of immunosuppressants to be reduced in
patients with stable long-standing rheumatoid arthritis that was controlled on methotrexate.
They found that the group that received oral collagen and discontinued methotrexate had a
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significant deterioration of disease activity compared to those maintained on methotrexate170.
Despite these disappointing results, one trial has reported a positive benefit of feeding type II
chicken collagen. 274 patients with active rheumatoid arthritis were randomised to receive
collagen or placebo and reported that, on one measure of disease severity, there was a
significant improvement in patients that received the lowest oral dose of collagen tested171.
Interestingly, this group observed that the lowest dose of oral collagen they administered,
which was lower than those used in other trials, gave the best results. It is possible that this
dose was most effective at inducing regulatory cells that could modify disease activity.
There is a report of the use of oral retinal S antigen and/or a mixture of soluble retinal
antigens in the treatment of immunosuppressant dependent uveitis. No significant difference
was noted between any of the treatment groups compared to placebo, although there was a
trend towards a more successful tapering of immunosuppressants in the group fed S antigen
alone172.
In many human autoimmune diseases, the exact antigen responsible for the disease is
unknown, and it is likely that more that one antigen is responsible in most cases173. Further,
even if an autoimmune immune disease is initially directed against one antigen, animal
models suggest that there is spread of autoimmunity, both to other epitopes on the same
antigen174 and to different antigens in the same target organ175. Therefore feeding a solitary
antigen may not be able to suppress the whole autoimmune response, particularly if it is not
known if the fed antigen is involved in the autoimmune response. This is particularly true if
clonal anergy or clonal deletion is the mechanism responsible for the tolerance, since these
mechanisms are exquisitely antigen specific for the fed antigen.
The theoretical exception to this rule is the induction an active suppressor cell which may
cause bystander suppression in the organ affected by the disease. At present the
understanding of the mechanisms of oral tolerance in the human is poor. Improving our
knowledge of how oral tolerance occurs in humans may lead to techniques to improve
treatment of autoimmune disease using oral tolerance.
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2.9.2 Diseases of Gastrointestinal Inflammation
There are several diseases of the gastrointestinal tract that are caused by inflammation in the
mucosa of the bowel. Clearly, inflammation to harmless antigens should not occur if oral
tolerance is operating normally. It may therefore be instructive to consider these diseases in
the terms of oral tolerance since this may suggest new theories of pathogenesis. There are
two diseases of gastrointestinal inflammation that will be mentioned here.
2.9.2.1 Coeliac Disease
Coeliac disease is caused by an abnormal immune response to the gliadin fragment of gluten
which is a protein found in many cereals. There is a detectable cell-mediated176177 and
humoral immune response178 to gluten in these patients. Interestingly there is also a
detectable humoral immune response to other antigens including anti-endomysial antibodies
and anti-reticulin antibodies178, which may suggest spread of the immune process between
antigens.
Recently the target of anti-endomysial antibodies has been identified as tissue
transglutaminase (tTG), which is a self-antigen179. The authors suggest that gliadin may be
able to bind to tTG and that the combination is morphologically altered to produce a
neoantigen. The immune response may be initiated against this neoantigen, and then be
propagated by antigenic spread. If this theory were indeed true, this would represent an
unusual and interesting way in which the protective effects of oral tolerance may be
overcome.
2.9.2.2 Inflammatory Bowel Disease
IBD is usually thought of as two similar but distinct diseases; namely ulcerative colitis (UC)
and Crohn's disease (CD). UC affects the colon alone and only involves the superficial
layers. It is suggested that it may be mediated by a TH2 response. CD can affect the whole of
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the bowel, both in length and in wall thickness. The immune responses seem to be due to a
predominantly TH1 response. In each case the antigen towards which the immune response is
directed is unknown, although many candidate antigens have been suggested. These include
lumenal bacteria such as bacteroides, measles vims, paratuberculosis infections and fluoride.
In this condition, one can postulate that the disease is not caused by an immune reaction to a
single antigen, but by a defect in oral tolerance resulting in abnormal immune reactions to
many antigens. There is some evidence that this may occur, since lamina propria
mononuclear cells from patients with IBD reacted to bacterial sonicates of intestinal flora,
whereas control patients and those with non-active disease did not27. This suggests that
tolerance to intestinal flora may have been broken. Further there is evidence that T cells
isolated from gut tissue of patients with CD expressed a TH1 pattern of cytokine secretion.
Control patients and those with UC did not secrete a typical ThI pattern of cytokines180. It is
possible that CD is caused by an early defect in oral tolerance, since it appears to be
mediated by a TH1 response which is abrogated early in the course of antigen feeding in
normal subjects. UC, mediated by a Th2 response, may be due to a later defect in oral
tolerance such as a failure of anergy in the TH2 compartment.
These statements are purely hypothetical, but ideas such as these do provide us, as
gastroenterologists, with an incentive to improve understanding of the mechanisms of
tolerance in humans. The methods devised in this thesis to study tolerance could be applied
to patients with IBD to assess whether oral tolerance is defective in these patients.
2.10 Aims of this Thesis
The literature on oral tolerance in animals suggests that the gut immune system can respond
to oral antigen by producing tolerance by several different mechanisms. Differences in the
type of antigen, the animal model and particularly the dose and length of feeding of antigen
alter the type of tolerance produced. The mechanisms do however appear to overlap and
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therefore ensure that an appropriate type of tolerance is produced in response to a wide
variety of antigens in a wide range of doses.
There is very little work looking directly at the mechanisms of tolerance production to
different antigens and feeding schedules in humans. The aims of this thesis were therefore to
develop a protocol to demonstrate the presence of oral tolerance in humans. Assays to
measur e different aspects of the immune response were developed, including measures of the
humoral and cell-mediated immune responses. Using these assays, I aimed to define the
immunological consequences of oral antigen exposure. Furthermore, I hoped be able to draw
conclusions on the mechanisms of tolerance production in humans by comparing the
immune responses observed in humans to those seen in established animal models.
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3 MATERIALS AND METHODS
3.1 Introduction to Experimental Protocol Used to Demonstrate Oral Tolerance
The protocol that I used to demonstrate oral tolerance was based on that used by Husby and
colleagues in their report of oral tolerance to a neoantigen in humans9. A control group
received an immunisation schedule of two subcutaneous injections of KLH. The immune
response was characterised by assaying for delayed-type hypersensitivity (DTH), anti-KLH
antibody production and in vitro lymphocyte proliferation to KLH. The test group were fed a
course of KLH before receiving the same immunisation schedule as the control group. The
same measures of the immune response to KLH were made, and any differences between the
two groups were attributed to oral tolerance. The timing and dose of immunisations are
shown in table 3.1.
The immune response to a different antigen, OVA, was also measured. OVA is the major
constituent of egg white and is present in the normal British diet. Therefore, this group was
assumed to have previously ingested substantial quantities ofOVA over a prolonged period
and no additional feeding was given. This group was given two sub-cutaneous injections of
OVA in a similar immunisation schedule to that used in the KLH experiments. DTH
responses, anti-OVA antibody responses and in vitro lymphocyte proliferation responses to
OVA were measured. The immune responses to OVA were compared with those obtained in
the KLH experiments.
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3.2 Preparation of Antigens for Immunisation
KLH and OVA were both obtained from Sigma-Aldrich Co and were manufactured to
American Food and Drug Administration standards. They were therefore of a sufficient
standard of purity to be used for immunisation in humans. The injections were prepared in
the aseptic unit of the Western General Hospital. The antigens were dissolved in 0.9%
weight (wt) / volume (vol) sterile saline and the solution was diluted to the required
concentration of antigen. The solution was passed through a 0.45 micrometer (pm) filter
(Millipore) to remove any large insoluble particles, including most bacteria. The required
volume was then drawn up in a sterile syringe and dispensed for use.
All injections were given using a sterile needle and syringe. The immunising injections were
given into the triceps fat pad.
3.3 Inclusion and Exclusion Criteria for Subjects Recruited
Healthy volunteers age 15-50 years were recruited. There were two principal exclusion
criteria. Firstly, the subjects had to have no history of allergy to seafood if they were being
included in the KLH arm of the study or to eggs if they were entering the OVA arm of the
study. Secondly, women of childbearing age were excluded if they were pregnant or
lactating, and had to be using contraception for the course of the study. Informed written
consent was obtained.
3.4 Delaved-Type Hypersensitivity (DTH) Testing
DTH testing was performed by injecting a 10 micrograms (pg) of antigen in 10 microlitres
(pi) of sterile saline intra-dermally into the volar aspect of the forearm. Two measures of
DTH were made. Firstly, the DTH response was graded as positive or negative depending on
whether any induration of the skin was detectable at the site of the injection. Secondly, the
mean diameter of erythema was calculated by averaging the maximum diameter of erythema
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and the diameter of erythema taken at 90° to the maximum diameter. The measurements of
DTH were taken at 24 and 48 hours. All measurements of DTH response were made by the
same observer to eliminate any inter-observer bias. The observer was not blinded as to which
groups the volunteers belonged.
3.5 Measurement ofAntibody Responses
3.5.1 Introduction to the Principles of ELISA
To detect antigen-specific antibody of different isotypes, a five-stage enzyme linked
immunosorbent assay (ELISA) was employed. Briefly, a plastic 96 well microplate was
coated with the relevant protein antigen. This was followed by incubation with a blocking
solution to prevent any subsequent non-specific binding of the antibody to be assayed. Next,
the serum samples under test were added to duplicate wells. Any antigen specific antibody
would bind to the antigen-coated wells. At the fourth stage, an anti-isotype antibody
conjugated to an enzyme was added. Finally, the chromogenic substrate of the enzyme was
added to each well. The absorbance of light at the appropriate wavelength was directly
proportional to the amount of antigen-specific antibody of the isotype under test present in
the sample.
3.5.2 Serum Collection and Storage Prior to Use in ELISA
20 millilitre (ml) of peripheral blood was collected by venepuncture into a plain blood tube
and allowed to clot for at least 10 minutes at room temperature. The tube was centrifuged at
1400 gravity (g) for 10 minutes. The serum was collected and stored at -70°C in 200j.il
aliquots until use.
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3.5.3 Anti-OVA IgG and IgA ELISA
3.5.3.1 Anti-OVA IgG and IgA ELISA Methods
This is a well-established assay in the G1 laboratory and, therefore, the conditions for the
assay had already been developed and optimised. OVA was dissolved in 0.05M carbonate-
bicarbonate buffer pH 9.6 at a concentration of 5pg per ml. lOOpl of this solution was added
to each well of an Immunlon® 2, 96 well flat bottomed microplate and incubated at 22-24°C
for 5 hours. The plate was then washed 3 times with 0.9% wt/vol saline - 0.05% vol/vol
Tween-20 solution, using an automatic plate washer.
Next 100pi of assay diluent (0.9% saline, 1% wt/vol BSA and 0.05% Tween-20 solution)
were added to each well as a blocking solution. The plates were incubated for 2 hours at 22-
24°C. The plates were washed as before.
Serum samples were diluted in assay diluent before use in the assay. For IgA anti-OVA
antibody analysis, samples were diluted 1 in 50, and for IgG anti-OVA antibody analysis, the
dilution was 1:500. lOOpl of each serum sample was added to duplicate wells. The plates
were incubated for 16 hours (overnight) at 4°C.
After washing as before, lOOpl of alkaline phosphatase conjugated anti-human IgG or IgA
goat antibody (Sigma) was added to appropriate wells. Both antibodies were diluted 1:500
with assay diluent before use. The plates were incubated for a further 5 hours at 22-24°C.
After a final wash, 100pi of the chromogenic substrate p-nitrophenylphosphate (PNPP) at a
concentration of Img/ml in diethanolamine (DEA) substrate buffer (10% vol/vol DEA,
0.0005M MgCl2.6H20, 0.02% NaNH?) pH 9.8 was added to each well. The plate was then
placed in an ELISA reader that monitors the plate until the top standard reached an optical
density (OD) of 1 at 405nm, at which time the ODs in all the wells were read at the same
wavelength of light.
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3.5.3.2 Calculation of Values of Anti-OVA Antibody
The GI laboratory has developed known high standards of anti-OVA IgG and IgA by
pooling serum from patients with high titres of these antibodies.
For the IgA anti-OVA assay, the standard was diluted 1 in 265 in assay diluent to give a top
standard of 1600 experimental units (U). Further doubling dilutions were performed down
each plate to a bottom standard of 25U. For the IgG anti-OVA assay, after an initial 1 in 675
dilution to give a top standard of 1600U, the standard was doubly diluted down each plate to
a bottom standard of 25U. A standard curve was fitted to these points using a quadratic
equation. The value for each test sample was derived from the standard curve. Thus the titre
of antibody (in units) in each sample was calculated by comparng the values to those of
A
sample with a known high titre of antibody that was arbitarily given a value of 1600 units.
A
3.5.4 Anti-KLH IgG and IgA ELISA
3.5.4.1 Anti-KLH IeG and IgA EL1SA Methods
KLH was dissolved in 0.05M carbonate-bicarbonate buffer pH 9.6 to a concentration of
lpg/ml. 100pi of this solution was added to each well of an Immunlon® microplate. The
plate was then incubated overnight (16 hours) at 4°C and then washed 3 times with wash
buffer (0.9% wt/vol saline, 0.05% vol/vol Tween-20 solution) using an automatic plate
washer.
lOOgl of a blocking solution (5% vol/vol foetal calf serum (FCS) in phosphate buffered
saline (PBS) 0.01M, pH 7.4) was added to each well, and the plate was incubated for 6-8
hours at 22-24°C. The plate was washed 3 times as before.
Serum samples were diluted 1 in 200 with assay diluent (1% vol/vol FCS, 0.05% Tween-20
in PBS). lOOpl of each sample was added to duplicate wells and the plate was incubated
overnight (16 hours) at 4°C. The plate was again washed 3 times as before.
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Anti-human IgA and IgG-specific, alkaline phosphatase conjugated goat antibodies (Sigma)
were diluted 1:1000 and 1:2000 respectively with assay diluent prior to use. lOOpl of the
appropriate antibody conjugate was added to each well and incubated 22-24°C for 5 hours.
Following a final wash, I OOgl of lmg/ml PNPP in DEA substrate buffer was added to each
well. The plate was then placed in an ELISA reader that monitors the plate until the top
standard reached an OD of 1 at 405nm, when the ODs of all test wells were read at the same
wavelength of light.
3.5.4.2 Calculation of Values ofAnti-KLH Antibody
One volunteer received a secondary immunisation with KLH seven weeks after she had
received the standard immunisation regime. Serum was collected, as described above, 10
days after this injection and aliquots were stored at -70°C. This sample contained high levels
of anti-KLH IgG and IgA and was used as the high standard in each experiment.
The standard was diluted 1:200 with assay diluent to give a top standard of 1600U. Doubling
dilutions of this standard were performed down each plate, to give a bottom standard of 25.
A standard curve was fitted to these points using linear regression for anti-KLH IgG
antibodies and a quadratic equation for anti-KLH IgA antibodies. The value of each test
samples was derived from this standard curve.
3.5.5 ELISA Methodology for Measuring IgGl and IgG2 Anti-KLH Antibodies
The protocol used to measure anti-KLH IgG was adapted to allow measurement of IgGl and
IgG2 subclasses of anti-KLH IgG. Alkaline phosphatase labelled anti-human IgGl and IgG2
antibodies (Southern Biotechnologies Associates Inc) were diluted 1:1000 with assay
diluent, and these solutions were used at the fourth step in the assay. A standard curve was
obtained using doubling dilutions of the high standard obtained as previously described.
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3.6 Lymphocyte Proliferation Assay
3.6.1 Mononuclear Cell Isolation
Peripheral blood was collected by venepuncture into a lithium heparin tube. The blood was
diluted 1:3 to 1:4 with normal (0.9% wt/vol) saline. 15ml of diluted blood was carefully
layered over 5ml of Histopaque 1077 (Sigma) in a sterile universal container and centrifuged
at 500g for 25 minutes. The mononuclear cells, which lie at the Histopaque/plasma interface,
were collected with a sterile pipette and placed in a fresh sterile universal container.
The cells were washed twice in RPMI 1640 medium (Sigma) and recovered by
centrifugation at 500g for 15 and then 12 minutes. The cells were resuspended in 3ml of
culture medium (100ml of RPMI 1640, 10ml of FCS, 2ml of 200 millimolar (mM) L-
glutamine, and 1ml of penicillin-streptomycin solution containing 10,000 units of penicillin
and lOpg of streptomycin per ml (all Sigma)). The number of mononuclear cells was
counted and the concentration of cells was adjusted to 3xl06 cells per ml of culture medium.
3.6.2 In vitro lymphocyte proliferation assay
Antigen solutions were prepared by dissolving antigen in culture medium. KLH was
prepared to a concentration of 10jag per ml and OVA to concentrations of 10 and 100jag/ml.
] 00gl of cell suspension were placed in wells of a 96 well flat-bottomed plate. lOOpl of
appropriate antigen solution were added to triplicate wells. 100j.il of culture medium alone
were added to 3 wells as a negative control, and 100pi concanavalin A (con A), dissolved in
culture medium in a concentration of 6.6pg per ml, were added to 3 wells as a positive
control. The plates were cultured for 98 hours at 37°C in oxygen and 5% C02. For the final 6
hours of culture, 20jal of 3H-thymidine, containing a radiation dose of 50pCu, were added to
each well.
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The contents of each well were aspirated onto Filtermat A filter paper (Wallac), which was
dried for 2 minutes at medium power in a 550 Watt microwave oven. Multiplex scintillation
paper (Wallac) was placed on the filter paper and melted using a hot plate at 90°C. A
betamax scintillation counter was used to quantify the amount of 3H-thymidine incorporated
into the cells in each well. The scintillation from each well was counted for 5 minutes
The proliferation index for each set of triplicate wells was calculated by dividing the mean
scintillation from stimulated cells by the mean scintillation of the negative control. Thus if
there was no antigen specific stimulation, the proliferation index would have a value of one.
3.6.3 Use of Dynabead-Antigen Complexes
In certain experiments, OVA was coated onto Dynabeads M-280 tosylactivated (Dynal UK
Ltd) prior to use in the lymphocyte proliferation assay. Dynabeads are uniform,
superparamagnetic beads coated with super-reactive tosyl groups. The super-reactive tosyl
groups will react with primary amino acid groups on proteins, and thus the beads can be
coated with protein antigen. The magnetic properties of the beads allow them to be easily
manipulated experimentally. The diameter of the beads is 2.8pm, and thus they should be
phagocytosed by APCs.
3.6,3.1 Preparation of Dynabead-Antigen Complexes
The Dynabeads were supplied in an aqueous suspension of 6 x 108 beads/ml. The required
quantity of beads was washed prior to coating as follows. The beads were resuspended,
transferred to an Eppendorf tube and placed in a magnet to remove the beads from
suspension. The supernatant was discarded and the beads were resuspended in 1ml of 0.1M
sodium phosphate buffer pH 7.4 (2.62g NaH2P04xH20 and 14.42g Na2HP04xH20 in
1000ml of distilled water) by mixing for two minutes. The tube was again placed in the
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magnet and the supernatant discarded. The beads were resuspended in sodium phosphate
buffer at a concentration of 6xl07 beads/ml.
To coat the beads with OVA, 500pi of OVA at 60pl/ml in sodium-phosphate buffer were
added to 500pl of the bead suspension and mixed overnight at 37°C. During this time, the
manufacturer reports that 30-80% of protein should bind to the beads via the tosyl group.
The beads were then washed twice in PBS at pH 7.4 with 0.1% wt/vol BSA. A further wash
was performed using 0.2 molar (M) Tris at pH 8.5 with 0.1% wt/vol BSA. The Tris should
bind to any remaining tosyl groups. A final wash with PBS at pH 7.4, 0.1% BSA removed
excess Tris. The beads were stored in PBS, 0.1% wt/vol BSA and 0.02% wt/vol sodium
azide at 4°C until use.
A further quantity of beads was treated exactly as described above but without OVA
dissolved in the coating solution. This sample of beads was used as a control to ensure that
any differences in proliferation were due to OVA and not due to the beads themselves.
3.6.3.2 Use ofComplexes in Lymphocyte Proliferation Assay
Prior to use in the lymphocyte proliferation assay, the beads were washed in PBS to remove
the sodium azide. The beads were resuspended in culture medium at a concentration of 7 x
105 beads per ml giving a concentration of lOpg of OVA coated beads/ml. lOOpl of bead
suspension was added to lOOpl of cell suspension containing 3 x 106 cells/ml in triplicate
wells of a 96 well flat bottom plate. The proliferation assay was performed as described
above. The proliferation index was calculated by dividing the mean scintillation count in the
wells stimulated with OVA-bead complex by that in the wells stimulated with the beads
prepared without OVA.
3.6.4 Use of Lymphocyte Proliferation Assay to Investigate Bystander Suppression
Mononuclear cells were prepared as described above at a concentration of 3x106 cells/ml.
100,000/ml tuberculin PPD (Health Authority) was diluted 1/100 with culture medium. KLH
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(or OVA as appropriate) was dissolved in culture medium at a concentration of lOpg/ml.
Solution of KLH (or OVA) at lOpg/ml and PPD 1000 unit/ml in culture medium were
prepared.
lOOjil of each antigen solution were added to triplicate wells of a 96 well flat-bottomed plate.
100pi of the cell suspension was added, and the assay was performed as previously
described.
PPD is used to inoculate against TB, and therefore will cause a positive proliferation
response in the cells from most people181. A suppression index was calculated by dividing
the mean proliferation of cells cultured with PPD by the mean proliferation of cells cultured
with PPD and KLH (or OVA) together. If there was no detectable bystander suppression, the
suppression index would be one, and if there was bystander suppression, values of greater
than one would be recorded.
3.6.5 Reversal ofAnergy with IL-2
Mononuclear cells were prepared as described above at 3xl06 cells per ml in culture
medium. 1.5 ml of cell suspension was cultured with 75 international units of recombinant
human IL-2 (Sigma) in a 6 well flat-bottomed culture dish for 92 hours at 37°C with 95% 02
and 5% C02. The cells were transferred to a sterile universal. The flat-bottomed well was
washed with RPMI 1640 medium and scraped with a cell scraper to ensure all possible cells
were transferred. The cells were washed twice in RPMI 1640 medium, recovered by
centrifugation at 500g for 10 minutes and finally resuspended in 1.5 ml of culture medium.
OVA was dissolved in culture medium at concentrations of I Opg/ml and lOOpg/ml. lOOpl of
cell suspension and lOOpl of OVA solution were added to triplicate wells of a 96 well-flat
bottomed plate. lOOpl of culture medium and lOOpl of conA at a concentration 6.6pg/ml
were added to cells in triplicate wells to act as a negative and positive control. The plates
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were incubated for a further 98 hours at 37°C with 95% O2 and 5% CO2, and lymphocyte
proliferation was measured by 3H-thymidine incorporation as previously described.
APCs are required for the lymphocyte proliferation assay to work. APCs are adherent and
may stick to plastic wells during the first incubation and therefore may not be transferred to
the wells used for the second stage of the assay. Three different strategies were used to
attempt to overcome this problem. Firstly, a cell scraper was used after the first incubation to
attempt to remove any adherent cells from the plastic and ensure that they were contained in
the cell suspension for the second phase of the experiment. Secondly, 3xl05 mononuclear
cells in lOOpl of culture medium were added to wells in a 96-well plate and incubated for 92
hours at 37°C while other cells were being incubated with IL-2 as described above. After this
incubation, the supernatant was removed and the wells (which 1 postulated would now
contain adherent APCs) were used for the second stage of the experiment as described
above. Lastly, volunteers were venesected again at day 4 and fresh mononuclear cells were
isolated as previously described. lOOpl of culture medium containing 3xl05 cells were added
to the IL-2 pre-cultured cells and antigen to act as APCs for the second incubation.
3.7 Cytokine Profile Estimation
Animal models suggest that some mechanisms of oral tolerance are associated with the
activation of specific T cell subsets, which can be identified by the cytokine profile that they
secrete. I attempted to measure cytokine levels secreted by activated mononuclear cells in
the lymphocyte proliferation assay by the following methods.
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3.7.1 ELISA Measurement ofCytokine Levels in Cell-Culture Supernatant
3.7.1.1 Collection of Samples
lOOpl of culture medium containing 3xl05 mononuclear cells were incubated with lOOgil of
lOpg/ml KLH in culture medium for 90 hours at 37°C in 95% O2 and 5% CO2. The
supernatant was collected from separate wells after 24 and 90 hours of culture and stored at -
70°C until use.
3.7.1.2 EUSA Measurement ofCytokines
Commercial ELISA kits (R&D Systems) were used to measure the levels of IL-4 and IFN-y
in cell culture supernatants. The ELISA was run according to the manufacturer's instructions.
Briefly, a plate pre-coated with anti-cytokine monoclonal antibody was supplied by the
manufacturer. Each cell culture supernatant was diluted 1/10 with the assay diluent supplied.
200pi of each test sample was added to each well and the plates were incubated for 2 hours
(IL-4 assay) or 2.5 hours (IFN-y assay) at room temperature. After washing the plate with the
wash buffer supplied, 200pl of anti-cytokine, hydrogen peroxidase conjugated monoclonal
antibody was added to each well. The plates were incubated for 2 hours at room temperature
and washed. 200pl of a substrate solution containing hydrogen peroxidase and
tetramethylbenzidine was added to each well. After a 20-minute incubation at room
temperature, 50pi of 2N sulphuric acid was added to each well. The OD of each solution at
450 nanometers (nm) was recorded by an automated ELISA reader.
IL-4 and IFN-y standards were provided with each kit. Doubling dilutions of the standard
were performed on each plate, from which a standard curve was generated. The amount of
cytokine in the cell culture supernatants could then be calculated.
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3.7.2 mRNA Expression by Lymphocytes
3.7.2.1 Extraction of RNA from Mononuclear Cell Cultures
mRNA is a very delicate structure, subject to degradation by RNases that can be found on
skin. Therefore all the equipment used in this part of the experiment was RNase free, and
great care was taken to ensure no contamination occurred during the experiment. In addition
the cells were keep on ice throughout the experimental protocol unless specifically stated.
A cell suspension of 3x106 mononuclear cells per ml of culture medium was obtained from
peripheral blood as previously described. Solutions of KLH at a concentration of lOgg/ml,
conA at a concentration of 6.6pg/ml and PPD at a concentration of 1000 international
units/ml were prepared in culture medium. 1.5ml of cell suspension and 1.5ml of each
antigen solution were cultured on separate wells of a 6 well flat bottomed plate for 20 hours
at 37°C in 5% C02 and 95% 02.
The cells were removed from the well by a Pasteur pipette and placed in a sterile universal.
The wells were rinsed with RPMI-1640 medium and a cell scraper was used to remove any
adherent cells from the well which were added to the sterile universal. After a further wash,
the cells were recovered by centrifugation at 500g for 8 minutes at 4°C and resuspended in
0.5ml of RMPI 1640. 0.25ml of the cell suspension was placed in each of 2 large Eppendorf
tubes and 0.75 ml of TRIzol® (GibcoBRL) was added to each tube. TRIzol® is a ready to
use reagent, containing phenol and guanidine isothiocyanate, that disrupts cells membranes,
dissolves cell components and maintains the integrity of RNA. The cells were lysed by
repetitive pipetting.
0.2ml of chloroform was added to each tube, which were mixed vigorously to ensure a good
emulsion and left to stand at room temperature for 2-3 minutes. The tubes were centrifuged
at 12,000g for 15 minutes at 4°C. The mixture separated into a lower phenol-chloroform
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phase and an upper aqueous phase, in which the RNA was dissolved. The aqueous phase was
removed and placed in a fresh Eppendorf.
RNA was precipitated from the aqueous phase by adding 0.5ml of isopropanolol. The tubes
were centrifuged at 12,000g for 10 minutes at room temperature. The supernatant was
discarded and the pellet, containing the RNA, was resuspended in 0.75 ml of 75% ethanol,
prepared with RNase free water. The sample was mixed by vortexing and the RNA was re-
precipitated by centrifugation at 7,500g for 5 minutes at 4°C. Ethanol dissolved any residual
proteins, which were discarded by removing the supernatant, and thus this step cleaned the
RNA. The tubes were vacuum dried for 4-5 minutes to remove any residual ethanol.
Diethylpyrocarbonate (DEPC) treated water was prepared in advance by adding 0.01%
vol/vol DEPC to water in an RNase free glass bottle, allowing the mixture to stand overnight
and autoclaving. 5pi of DEPC treated water was added to each Eppendorf, and the mRNA
was dissolved by heating the tubes to 55-60°C in a water bath for 10 minutes.
To calculate the quantity of RNA obtained, lpl of RNA solution was added to 499pl of
DEPC treated water. The OD of the solution was determined at 260nm, and the quantity of
RNA in pg/ml or nanograms (ng)/pl was calculated using a standard correction factor of 40.
3.7.2.2 Formation of complimentary deoxyribonucleic acid (cDNA) by Reverse
Transcription
3pg ofRNA was transferred to a fresh small Eppendorf tube and the volume was made up to
11 pi by adding the required amount of DEPC-treated water, lpl of oligo-dT primer
(GibcoBRL) was added, and the tube was heated to 70°C for 10 minutes. All mRNA has a
poly-A tail, to which the oligo-dT primer will bind at this temperature.
The tubes were cooled on ice for three minutes, and the solution was collected at the bottom
of the Eppendorf by microfuging each tube for a few seconds. 4pl of strand buffer,
containing 0.25M Tris HC1 (pH 8.3), 0.375M KC1 and 15mM MgC^, were added to each
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tube, along with lpl of nucleotide solution (dNTP) in which each of the nucleotides were
present at a lOmmol concentration, 2pi of 0.1M dithiothreitol (DTT) and 1 pi of Maloney
Leukaemia Virus (MMLV) enzyme (all GibcoBRL). MMLV enzyme is a reverse
transcriptase enzyme isolated from the Maloney Leukaemia Virus. The tubes were incubated
at room temperature for 10 minutes and then at 37°C for 1 hour. The experimental protocol
was designed to allow the oligo-dT primer to bind to all RNA sites with a poly-A sequence,
such as found at the end of all mRNA tails. The MMLV reverse transcriptase transcribes
cDNA from the mRNA starting at sites where the oligo-dT primer has bound. Thus all
mRNA should be converted to cDNA. At the end of the incubation the tubes were heated to
90°C for 10 minutes, which denatures the MMLV enzyme.
The tubes were placed on ice for 10 minutes, lpl of ribonuclease H (3.0 units/ml -
GibcoBRL) was added and the tubes were incubated at 37°C for 20 minutes. Ribonuclease H
breaks down any mRNA in the sample, including any that is in double stranded form with its
cDNA, thus leaving pure cDNA in the sample. The samples were frozen at -20°C until use.
3.7.2.3 Polymerase Chain Reaction fPCR)
The technique ofPCR is designed to amplify small quantities of specific DNA, identified by
complimentary primers to that sequence, by using a DNA polymerase enzyme to copy the
DNA many times. Each cycle of PCR doubles the quantity of specific DNA and thus the
total quantity of DNA rises exponentially. Thus even minor contamination of the samples
can lead to very misleading results. To prevent contamination a dedicated PCR room was
used, separate flow cabinets were used for the steps before and after adding cDNA, and
displacement pipettes were used to prevent aerosols formation.
PCR assays were developed to measure mRNA for actin, IL-2, IL-4, IL-10 and IFN-y. The
PCR conditions were based on, and primer sequences obtained from, the methods used by
Jarvis et at%2. The following solutions were prepared:
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doubly distilled water (DDW).
standard buffer (xlO strength) which contained 200mM Tris-HCl (pH 8.4) and
500mM KC1.
dNTP solution in DDW containing each nucleotide at a concentration of 5mM.
50mM magnesium (GibcoBRL).
Primers specific for the cytokine cDNA (Oberon) were dissolved in DDW to
give a lOmM solution. The primer sequences were those used by Jervis et aln2.
The primer sequences are shown in table 3.2.
Taq DNA polymerase isolated from Thermus aquaticus YT1 (GibcoBRL) at a
concentration of 5units/pl.
cDNA prepared from the cell culture as described above.
The required volumes of standard buffer, dNTP, primers, magnesium solution and DDW
were mixed. Different quantities of each of these solutions were required for each cytokine
PCR assay, and the exact volumes of each constituent used in the different assays are shown
in table 3.3. The tubes were moved to a separate flow cabinet and lpl of cDNA was added.
50pi of paraffin oil was layered on top of the solution in each tube, which were then heated
on a heater block to 94°C for one minute, before being cooled to 80°C. lgl of Taq DNA
polymerase was added to each tube. The contents were mixed in a shaker and the liquid was
pooled at the bottom of the tube with a pulse of centrifugation. This "hot start" technique
was designed to increase the sensitivity of the assay.
The heater block was programmed. Firstly, it was heated to 94°C for 1 minute, which
denatured (i.e. reduced double-stranded DNA to single stranded form) and uncoiled the
DNA. Next it was cooled to 58-60°C for 30 seconds, at which temperature the primers
annealed to the complimentary DNA. Lastly it was heated to 72°C for 45 seconds. At this
temperature, Taq DNA polymerase will bind to any double stranded DNA, such as that
marked by the primers, and replicate the downstream DNA strand. The program was
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repeated from 33-35 cycles, depending on the assay. The PCR products were stored at 4°C
until use.
A sample containing no cDNA was run with each PCR assay performed. This acted as an
important negative control to exclude contamination of the assay by exogenous DNA.
3.7.2.4 Analysis of PCR Products
3.7.2.4.1 Preparation ofAcrvlamide Gel
A 9% wt/vol acrylamide gel was prepared from the following reagents:
lOxTBE containing 1M Tris, 0.9M boric acid and 0.01M EDTA (GibcoBRL). A
1/10 dilution of lOxTBE with distilled water gave a lxTBE solution.
30% wt/vol acrylamide in distilled water (GibcoBRL).
N,N,N',N'-tetramethylethylenediamine (TEMED) (GibcoBRL)
25% wt/vol of ammonium persulfate (APS) in DDW
6ml ofDDW, 3ml of acrylamide and 1ml of lOxTBE were mixed in a plastic universal. 50pl
of25% wt/vol APS and 15gl ofTEMED were added and mixed well. The APS and TEMED
polymerise acrylamide and set the gel in 3-5 minutes. While it was liquid, the solution was
injected between two glass plates held 1mm apart by dividers. A comb was inserted at the
top of the gel to create lanes for the samples and the gel was allowed to set.
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3.7.2.4.2 Separation ofPCR Products on Acrylamide Gel
10pl of each cDNA sample was mixed with 5pi of a loading stain of xylene cyanol and
bromophenol blue dissolved in a glycerol loading buffer. Each sample was added to a lane of
the acrylamide gel. A DNA ladder (GibcoBRL) made of fragments of DNA of known size
was run on each gel.
A 10 amp electric current was passed through the gel. cDNA, being negatively charged, was
attracted to the positive electrode and the speed at which it passed through the gel
corresponds to the size of the cDNA fragment. Xylene cyanol also ran through the gel at the
speed equivalent to a strand ofDNA of 75 base pairs. When this stain reached the bottom of
the gel, which took 90-110 minutes, the current was switched off.
3.7.2.4.3 Quantification of PCR Products
The gel was placed in a bath of 200ml of lxTBE and 20ml of ethidium bromide on a rocker
at room temperature. Ethidium bromide will bind to DNA. After 4-5 minutes, the TBE and
ethidium bromide was drained off and the gels were washed on a rocker with 200ml of
lxTBE for a further 2-3 minutes to remove any excess ethidium bromide.
The gel was placed under an ultraviolet light source attached to a computer running the
molecular analyst program. Ethidium bromide fluoresces under ultraviolet light and so
reveals the cDNA bands. The size of each band could be deduced from its position compared
to the DNA ladder, and could be compared to the expected size ofDNA fragment (see table
3.2). The molecular analyst program will calculate the degree of fluorescence from each
band on the gel which should correlate to the amount of cDNA within each band.
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3.8 Flow Cytometry Analysis of Cell Surface Markings
3.8.1 An Introduction to the Principles of Flow Cytometry
Flow cytometry is a method of analysing physical characteristics of cells in suspension by
focusing laser light onto a single cell at a time. Sensors measure the scatter of the laser light
by the cell. The forward scatter measures cell size whereas the side scatter gives a measure
of cell granularity. Therefore the physical characteristics of individual cells can be measured
and recorded. Furthermore, if the cells are appropriately stained, the cells will fluoresce
under laser light. Using fluorescent labelled monoclonal antibodies that recognised specific
cell surface markers, one can also obtain data on the expression of these call markers on that
cell. The data for all these variables can be stored and processed by computer, allowing one,
for example, to assess the physical characteristics of cells expressing specific cell surface
markers.
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3.8.2 Monoclonal Antibodies Used in Flow Cytometry Experiments
LI
Mouse monoclonal antibodies against desired human molecules were purchased from
Serotec Ltd. Details on the composition and prepatation of each antibody are shown in table
3.4. All antibodies contained 0.1% sodium azide and 1% bovine serum albumin to act as
preservatives and stabilisers. All reconstituted antibodies were stored at 4°C until use.
Table 3.4 - Details of the conjugated monoclonal antibodies used in flow cytometry
experiments. PE=phycoerythrin, FITC= fluorescein isothiocyanate
Antibody Isotype Clone Number Preparation Conjugate
Anti CD4 Mouse IgGl RPA-T4 Dissolve in 1ml
distilled water
PE
Anti CD8 Mouse IgGl LT8 Dissolve in 1ml
distilled water
PE
Anti CD25 Mouse IgGl M-A251 Comes as liquid F1TC
Anti CD45RO Mouse IgG2a UCHL1 Comes as liquid FITC
Anti CD38 Mouse IgGl AT 13/5 Comes as liquid FITC
Anti HLA-DR Mouse IgGl B-Fl Comes as liquid FITC
3.8.3 Cell Preparation, Staining and Use in Flow Cvtometer
Mononuclear cells were prepared from peripheral blood, as described previously, and diluted
to 3xl06 cells/ml of culture medium. KLH was prepared in a concentration of lOpg/ml of
culture medium. 1.5ml of cell suspension and 1.5ml of KLH solution were incubated
together in a 6 well flat-bottomed plate for 92 hours at 37°C in 95% 02 and 5% C02.
250pl aliquots of cell suspension were placed into individual tubes. The cells were pelleted
by centrifugation at 400g for 8 minutes and resuspended in 1ml of PBS. 10pi of fluorescein
isothiocyanate (FITC)-conjugated monoclonal antibody and 10pi of phycoerythrin (PE)-
conjugated monoclonal antibody were added to each tube in the combinations shown in table
3.4 and incubated for 30 minutes at 4°C. The cells were washed twice with PBS to remove
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any excess unbound antibodies, recovered by centrifugation at 400g for 8 minutes and
resuspended in 0.5 ml ofPBS containing 1% vol/vol BSA and 0.1% wt/vol sodium azide.
The flow cytometer was set to analyse the 2-colour fluorescence of FITC and PE and record
forward and side scatter of light. 10,000 cells from each sample were run through the
machine and the data stored on disc and analysed using the CellQuest analysis program.
Table 3.5 - Combination of cell surface markers used in flow cytometry experiments. The
cell cultures were incubated with the above combination of monoclonal antibodies prior to
being analysed by flow cytometry. The negative controls consisted of a mouse monoclonal
antibody conjugated to the appropriate fluorescein which does not bind to human cells will
therefore give information on the levels of non-specific binding of these monoclonal
antibodies to human cells.
Fluorescent Stain
PE FITC
Negative Control Negative Control
CD4 CD25
CD4 CD38
Target ofMonoclonal CD4 CD45RO





3.8.4 Analysis of FACS Scanning Data
Analysis of the data was performed using the CellQuest computer program. The program
was instructed to identify lymphocytes on the basis of their size (forward scatter) and
granularity (side scatter). Subsequent analysis was performed on these cells. The degree of
staining from the FITC labelled antibody bound to each activation marker and PE labelled
antibody bound to CD4 or CD8 was recorded. The amount of stain correlates to the amount
of cell surface marker present. The degree of staining of activation marker was plotted
against the degree of staining of CD4 or CD8. This dot-plot was divided into quadrants to
indicate positive or negative staining. The level of staining required to denote a positive
result was calculated from the amount of non-specific staining on cells incubated with
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control antibody. The number of cells in each quadrant was calculated. Statistical analysis
was performed on the sample from the volunteer prior to encounter with KLH compared to
the sample after eating or after immunisation.
An alternative method of analysis used was to plot the frequency of cells that stained at
different levels for the activation marker and compare the frequency distribution of cells in
the samples taken before and after encounter with KLH. This method may demonstrate more
subtle changes in the level of activation markers than that seen on the dot-plot analysis.
3.9 Statistical Analysis
r
Unless specifically stated in the text, staistical analysis was performed as follows. Mann-U
A
Whitney testing was used to assess differences between continuous variables and Chi-
squared testing was used to compare two qualatitive variables between groups.
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4 DEVELOPMENT OF THE PROTOCOL AND ASSAYS
4.1 Introduction
To demonstrate oral tolerance, a safe immunisation schedule that provoked a systemic
immune response had to be devised, and assays to measure this immune response had to be
developed. This chapter will discuss the work I performed to develop and validate these
assays.
4.2 Development of the Injection Schedule
4.2.1 Work to Establish the Safety ofKLH and OVA for Immunisation
KLH has a long history of being used as a systemic immunogen in humans183, and has also
been fed to humans9. The World Health Organisation (WHO) has recommended the use of
KLH as an antigen for the investigation of immunodeficiency states184. There have been no
reported side effects of KLH in humans. Thus KLH appears to be safe for use in humans.
OVA is a common dietary antigen, to which most people have had prolonged exposure. It
has been used as an immunogen in many animal experiments, and appears to be safe.
KLH and OVA were manufactured by Sigma-Aldrich Co. to American Food and Drug
administration standards, which ensures that no contamination occurred during the
manufacturing process. To ensure no contamination occurred, the preparation of the
immunisations was undertaken by the Western General Hospital aseptic pharmacy
department. Once dissolved, the solutions were passed through a 0.45pm filter (Millipore) to
remove any large insoluble particles, including most bacteria, diluted and stored at 200pg/ml
at 4°C.
Before the start of the project, two test samples were cultured by the bacteriology
department. Both samples demonstrated no growth. Samples were also tested for endotoxin,
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using an established ELISA-based method. Three endotoxin units per ml for KLH solution
and 10 endotoxin units per ml for the OVA solution were detected. These are well within the
safety limits for human injection recommended by the American Association of
Pharmacists185. These data suggested that the preparations of KLH and OVA were safe to
give systemically to humans.
4.2.2 Development of Immunisation Schedule
To demonstrate the induction of tolerance, it was necessary to induce a positive immune
response in the control group. KLH was given at different doses and at different times in
order to find the optimal immunisation schedule. It was found that two injections of 200pg
of KLH given 10 days apart induced a positive DTH response three weeks after the initial
immunisation, and this immunisation schedule was used in all experiments using KLH.
4.3 Development of the In Vitro Lymphocyte Proliferation Assay
4.3.1 Isolation of Cells
The technique used for isolating mononuclear cells worked reliably. 1-3 x 106 mononuclear
cells were isolated per ml of blood venesected. Several samples were tested for
contamination with non-mononuclear cells on light microscopy. The samples tested
contained 0-5% polymorphonuclear granulocytes and 0-1% red cells.
4.3.2 Lymphocyte Proliferation Assay
A series of experiments were performed to determine the optimal conditions of the
lymphocyte proliferation assay. The assay conditions were altered to determine those that
gave the lowest result for the control wells and the highest results for those stimulated with
antigen. The assay conditions that were tested included the concentration of KLH used (test
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range of 1 - lOOgig/ml), the type of FCS used, the length of time in culture (from 48 to 96
hours), and the length of time that 3H-thyimidine should be added before the end of culture
(6-18 hours). The conditions that gave the optimal results are those described in the materials
and methods section. Using these methods, the mean result for the negative controls (i.e.
cells cultured with culture medium alone) was 998.8 counts per minute with a standard
deviation of 812.8.
4.4 Development ofKLH EL1SA
4.4.1 Introduction - Problems and Standards
I developed the KLH ELISA de novo. A significant problem was that I had no known
positive control with which to establish the ELISA. To overcome this problem I used sera
taken from volunteers who had had trial immunisation with KLH as detailed above. In
addition, one volunteer, who had had only one injection with KLH initially, received a
second injection seven weeks later. His serum had a moderately high level of anti-KLH
antibodies and was used to optimise this ELISA in the experiments detailed below.
4.4.2 Experiments to Establish ELISA Technique
Experiments were conducted to test all aspects of the assay, and the conditions chosen were
those that gave the highest values for the post-immunisation samples and the lowest values
for the control and the pre-immunisation samples. Variables that were tested included the
coating concentration of KLH (ranging from lOOpg/ml to O.lpg/ml), the assay diluent
(bicarbonate buffered saline against PBS), the blocking solution (BSA, adult bovine serum
and FCS were all tested at concentration of 1% vol/vol or 5% vol/vol) and the type of plate
used (immulon 1® or immulon 2®). The optimal time for the coating, blocking and
conjugation stages of the assay were also assessed. The optimal concentration of serum (test
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dilutions ranged from 1:50 to 1:3200) and of conjugated antibody (from 1:500 to 1:8000)
were tested.
The optimal results were obtained using the methods described in the materials and methods
section.
4.4.3 Validation of the anti-KLH IgG and IgA ELISA Assays
The within plate co-efficient of variance (C.V.) (=(standard deviation / mean)xl00) was
calculated for the anti-KLH IgA and IgG ELISAs. Two samples, one with high
concentrations of both antibodies and one with low concentrations of both antibodies were
each put in 40 wells of a plate, which was processed by the normal ELISA methods descried
above. The within plate C.V. of the anti-KLH IgG ELISA was 9.4% at a low value of 160
units, and 16.1% at a high value of 550 units. The within plate C.V. of the anti-KLH IgA
ELISA was 9.2% at a low value of 360 units and 3.5% at a high value of 3800 units.
The between plate variation of the ELISA was also calculated based from several samples
run on two plates. The mean variation of these samples between plates was 27.5% for the
anti-KLH IgG assay and 27.8% for the anti-KLH IgA assay. Although these results are
satisfactory, to avoid the increased error of running samples on separate plates, all post-
immunisation samples of both the fed and control groups were run on one plate.
The difference between each serum sample run on the same plate as duplicates were within
10% for the IgG assay, and for the IgA assay three pairs were over this range, but were all
within 12.5%.
On each plate a standard curve was calculated using doubling dilutions of serum taken from
a volunteer after receiving a third immunisation 7 weeks following the second immunisation.
The starting dilution was 1:50 and ran to 1:3200. The standard curve was calculated using
linear regression on a logarithmic/linear scale for IgG. The r-value for fit of the standard
curve produced was between 0.978 and 0.984. For IgA, quadratic regression was used to
obtain the standard curve, and the r-value exceeded 0.999. Examples of typical standard
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curves obtained are shown in figures 4.1a and 4.1b. The positive control sample was
arbitrarily ascribed a value of 1600 units of both anti-KLH IgG and IgA. Several test
samples were above the upper limit of the reference range of the standard curve. These
samples were rerun at a 1:800 dilution to allow the data to be entered into the appropriate
equation.
The above data suggests that these ELISAs are reliable and reproducible.
4.4.4 Validation of anti-KLH IgGl and IgG2 ELISAs
Mouse anti-human IgGl and IgG2 antibodies were purchased and used to adapt the anti-
KLH IgG ELISA to assay these two subtypes. The within plate C.V. was very good. For the
IgGl assay, the C.V. was 7.7% at a value of 550 and 5.6% at a value of 1950. For the IgG2
assay, the C.V. was 9.8% at a value of 540 and 9.8% at a value of 3580. The post-
immunisation samples from all the groups were read on the same plate to remove inter-plate
variability as a possible error.
4.4.5 Validation of the Anti-OVA IgG and IgA ELISA Assays
Previous work in the gastrointestinal laboratory has involved investigating humoral
responses to OVA by quantitative isotype-specific ELISA methods, particularly in disease
states. Therefore assay methods had been previous developed and validated, and these
methods were used in my experiments. In my hands, the within plate coefficient of variation
for the IgG ELISA was 10.6% for a reference specimen at a high value of 1020 units/ml and
13.8% for a specimen with a low value of 55 units/ml. For the IgA assay, the within plate
C.V. was 12.0% at a value of 15 units/ml. All the samples that were compared were run on
the same plate to remove the potential problems of inter-plate variation. In addition any
samples that gave interesting or unusual results were repeated on a separate run to ensure
that the results were reproducible.
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Figure 4.1 - Typical standard curves obtained using the high standard as detailed above. OD
is plotted on the Y-axis and anti-KLH antibody is plotted on the X-axis. Figure 4. la shows a
typical standard curve for IgG and figure 4.1b shows a typical standard curve for IgA. The
mean OD for each test sample is read off the Y-axis and the value in standard units is




5 RESULTS OF EXPERIMENTS USING KLH TO INDUCE ORAL TOLERANCE
5.1 Introduction
In this section, I report the results of the experiments used to demonstrate oral tolerance to a
neoantigen in humans. The protocol I used was based on that of Husby and colleagues and
has been described in the Materials and Methods section. In summary, a control group was
immunised with subcutaneous KLH. The immune responses to KLH were measured by DTH
responses to intra-dermal KLH, in vitro lymphocyte proliferation to KLH and KLH specific
IgA and IgG antibody responses.
KLH was fed to test groups starting 21 days before they received the same immunisation
schedule that was given to the control group. Three different feeding regimes were used;
namely lOmg of oral KLH given daily for 10 consecutive days (KLH-fed group 1), 50mg of
KLH given daily for 10 consecutive days (KLH-fed group 2) and 50mg ofKLH given for 15
days in a divided course (KLH-fed group 3). Any differences between the immune responses
in the fed groups and the control group were attributed to the effect of oral tolerance.
The exact timing of the feeding regime, immunisation schedule and immunological testing
are shown in table 2.1 in the Materials and Methods section.
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5.2 Results
5.2.1 Delayed Type Hypersensitivity Responses
Intradermal administration of antigen led to a DTH response characterised by erythema,
swelling and induration at the injection site and is an in vivo measure of cell-mediated
immunity. Two methods ofmeasuring the DTH response were employed. Table 5.1 shows
the results of DTH response as assessed by the presence or absence of induration in the four
groups and table 5.2 gives the results for the mean diameter of induration of the DTH
response. Photographs 5.1 and 5.2 show typical positive and negative DTH responses at 24
hours.
Table 5.1 - results for presence of DTH responses in pre-fed and control groups after
completion of the immunisation schedule. A positive DTH response was taken as the
presence of any detectable induration. Statistical significance was determined by Fisher's
exact test. There was a significant reduction in positive DTH responses in the two groups
pre-fed the higher doses ofKLH than in the control group.




24 hours 48 hours 24 hours 48 hours
Control group
(n=13)
11/13 10/13 Not applicable
KLH-fed group
1 (n=4)
4/4 2/4 N.S. N.S.
KLH-fed group
2 (n=7)
2/7 0/7 P<0.05 P<0.005
KLH-fed group
3(n=6)
2/6 0/6 P<0.05 P<0.005
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Table 5.2 - results for DTH responses as measured by the diameter of erythema following
intra-dermal injection of KLH in pre-fed and control groups after completion of the
immunisation schedule. There was a significant reduction in the diameter of erythema in the
two groups fed the higher doses ofKLH compared to the control group at 48 hours.





































The results of the DTH responses show that the KLH immunisation schedule used caused a
positive DTH response in the majority of volunteers. There was a significant reduction in
DTH responses after immunisation in the two groups that were pre-fed the higher doses of
KLH prior to immunisation. The group that was fed the lowest dose of KLH showed no
significant reduction in DTH responses compared to the control group, although the numbers
in this group were small.
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Photo 5.1 - A typical positive DTH response is shown. This photo was taken 24 hours after
the intra dermal injection was given. Marked erythema and induration can be seen.
Photo 5.2 - A typical negative DTH response is shown 24 hours after a prefed volunteer (in
this case from KLH-fed group 3) was given the intra-dermal KLH injection. The remains of
the white bleb from the injection can be seen.
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5.2.2 In vitro Lymphocyte Proliferation Responses
In vitro lymphocyte proliferation was the second measure of CMI used in this study. Figure
5.1 shows the results of the lymphocyte proliferation responses in the control and pre-fed
groups as expressed by the lymphocyte proliferation index before and after immunisation,
and (where appropriate) before feeding.
The results showed that there was no antigen specific lymphocyte proliferation before KLH
exposure in any group. The immunisation schedule caused a significant increase of
lymphocyte proliferation in the control group (p=0.0001 compared to pre-immunisation
values). Pre-feeding lOmg of KLH for 10 days (KLH-fed group 1) caused no significant
lymphocyte proliferation but subsequent immunisation again resulted in a positive
lymphocyte proliferation response in the one subject in which the assay did not fail for
technical reasons. Feeding either of the higher doses of KLH (KLH-fed groups 2 and 3)
caused a significant rise in lymphocyte proliferation compared to baseline (p<0.01 for both
groups). After immunisation there was a further significant rise in lymphocyte proliferation
in KLH-fed group 2 (p<0.005). In KLH-fed group 3, a significant level of lymphocyte
proliferation remained after immunisation (p<0.005 compared to baseline) but the level of
lymphocyte proliferation was similar to the post feeding values (p=N.S.).
Figure 5.2 shows the same data expressed by time of testing rather than by group and
without the data from KLH-fed group 1. It illustrates the following additional points. Firstly,
the group fed most intensively had a significantly greater lymphocyte proliferation response
before immunisation (p<0.05) but a significantly reduced degree of lymphocyte proliferation
after immunisation compared to KLH-fed group 2 (p=0.05). The lymphocyte proliferation
index of the control group after immunisation was less than group 2 and greater than group 3
but not statistically different to either.
Lastly figure 5.3 illustrates the relationship between the in vitro lymphocyte proliferation
results and the DTH results at 24 hours (as calculated by the presence or absence of
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Figure 5.3 - Relationship between in vitro lymphocyte proliferation index results and in vivo
DTH testing in the control group and KLH-fed groups 2 and 3. In the control group, there is
a relationship between a negative DTH response, as defined by the presence of any
detectable induration at 24 hours, and a low lymphocyte proliferation index. This
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induration) for the control group and KLH-fed groups 2 and 3. In the control group, the two
volunteers without a positive DTH response also had the lowest levels of in vitro lymphocyte
proliferation. There was no relationship between the DTH results and in vitro lymphocyte
proliferation in either of the KLH-fed groups.
5.2.3 Antibody Response
The anti-KLH IgG and IgA antibody responses are shown in graphs 5.4a and 5.4b
respectively. There was no detectable antibody response in any group before KLH exposure,
as would be expected since KLH is a neoantigen. The control group showed a small, but
significant (p<0.001) IgA response at 10 days (i.e. after the first immunisation with KLH),
but no IgG response at that time. After completion of the immunisation schedule, at 21 days,
there was a highly significant rise in both anti-KLH IgG (p=0.0001) and IgA (p<0.0001).
No anti-KLH IgG or IgA was detected after any of the KLH feeding regimes. The antibody
responses following immunisation in KLH-fed group 1 were similar to the control group. In
KLH-fed group 2 there was a statistically significant rise in anti-KLH IgG after
immunisation (p=0.02), and a trend towards an increased response at 10 days (p=0.07)
compared to the control group, suggesting that this course of feeding primed the IgG
responses. There were no statistical differences in anti-KLH IgA levels compared to the
control group at either time-point. The results for KLH-fed group 3 showed no significant
rise in anti-KLH IgG compared to the control group. The anti-KLH IgA levels were also
unchanged from the control group, although there may have been a trend towards reduced
levels of serum anti-KLH IgA with increasing doses of feeding.
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The graphs illustrate the anti-KLH IgG and IgA responses by group at each time point tested.
The solid bars show the results prior at baseline, the empty bars are after feeding KLH, the
crossed bars are prior to the second KLH immunisation and the speckled bars are at the end
of the protocol. The error bars represent the standard error of the mean. The results illustrate
that immunisation with KLH causes both an IgG and IgA response. In KLH-fed group 2
there is a significant augmentation of the IgG (p=0.02), but not IgA, response after
immunisation. This is not observed in KLH-fed group 3.
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5.3 Discussion ofResults
5.3.1 Rationale for Use ofKeyhole Limpet Haemocvanin
KLH is obtained from the deep-sea crab Megalla crusatacean. This crab is not a normal
constituent of the diet, and therefore KLH is a neoantigen i.e. most people have never had
exposure to it. KLH is a large molecule weighing 50,800 daltons. Furthermore it can
polymerise, increasing its molecular weight up to 27,000,000 daltons186. KLH has long been
used as a systemic immunogen in humans183, and has also been fed to humans9. There have
been no reported side effects to KLH, and indeed the WHO recommends its use in the
investigation of immunodeficiency states184. Thus KLH is a neoantigen, it has a record of
safety in humans use, and a proven ability to provoke a good immune response in humans.
For these reasons, it is an ideal antigen with which to investigate the immune responses to a
new, orally encountered antigen in humans.
5.3.2 Assays Used to Measure the Immune Response
5.3.2.1 Delayed-Type Hypersensitivity Reactions
A DTH reaction is a complex immune response whereby antigen exposure results in an
erythematous, inflammatory immune response caused by the infiltration of lymphocytes,
macrophages and basophils at the site of antigen exposure over 24-48 hours. The DTH
response is induced by Langerhan's cells which sample antigen in the epidermis and migrate
to the dermis. At this site the antigen is presented to primed, antigen specific CD4+ cells
which are activated and produce pro-inflammatory cytokines. Among these is IFN-y, which
activates keratinocytes to express intercellular adhesion molecule-1 and major
histocompatibility class II and secrete IL-6 and GM-CSF. These factors recruit antigen non¬
specific CD4+ T cells and activated macrophages to the site of inflammation. The production
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of a DTH response is a complex process, but does require the presence of antigen specific,
IFN-y producing CD4+ T cells. These cells used to be termed Tdth cells, but are in fact
morphological indistinguishable from other Th cells and have been termed TH1 cells in mice.
Due to this complex pathway, DTH responses take 12 hours to become detectable, reach
their peak at 24-36 hours and subside from 48 hours onwards. I chose to measure DTH
responses at their peak (24 hours) and as they were starting to subside (48 hours). I made all
the measurements of DTH responses to avoid inter-observer variation. Two separate
measures of DTH response were made, namely induration and erythema. The method of
using the presence or absence of detectable induration to measure DTH was that used by
Husby and colleagues in their experiments9. The observations could be subject to observer
bias and so the second method was employed to attempt to reduce this source of bias.
5.3.2.2 In Vitro Lymphocyte Proliferation Assay
The lymphocyte proliferation assay is a well-established in vitro technique of investigating
CMI. The assay relies on the incorporation of tritiated thymidine into dividing cells that have
been stimulated by antigen. The assay is said to rely on the presence of antigen specific T
cells in the test sample. The results quoted in this thesis are the lymphocyte proliferation
index, which is calculated by dividing the uptake of thymidine by the antigen-stimulated
cells by the uptake in unstimulated cells. This is the most common way of measuring
lymphocyte proliferation.
5.3.2.3 Humoral Responses
The humoral arm of the immune response produces antibody which can opsonise and
neutralise foreign antigen. This limb of the immune response was assessed by measuring
KLH specific IgG and IgA antibody production by ELISA, which is a well-established
technique to measure antibody quantitatively.
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It should be noted that the values of IgA and IgG are not directly comparable since the
values of antibody given are not absolute values but are calculated by comparing the test
sample with a standard sample which is ascribed an arbitrary concentration. Therefore,
although the numbers (units) quoted for IgA are higher than those for IgG units, no
conclusions can be drawn about the relative concentration of each Ig in the systemic
circulation.
5.3.3 Discussion of the Immune Responses in Each of the Test Groups
5.3.3.1 Control Group
There is an active immune response to immunisation with KLH comprising both positive
cell-mediated and humoral immune responses in the control group. The positive DTH
response suggests that the immune response in the control group is based on a TH1 type
response.
CMI was assessed by in vivo skin testing and in vitro lymphocyte proliferation assay. In the
control group the two assays correlated in that those with a positive skin test had a higher
lymphocyte proliferation index. Conversely, the two volunteers who had a negative skin test
also had the two lowest values for the lymphocyte proliferation assay. Thus, the in vitro
lymphocyte proliferation assay is indeed a marker ofCMI in the actively immunised control
group.
Antibody response to KLH was induced beginning at 10 days with a significant rise in IgA
levels compared to baseline. IgG levels were not significant elevated compared to baseline
levels at 10 days. After 21 days (and a second injection), both anti-KLH IgG and IgA levels
were greatly raised. The time scale of these responses was typical of a primary immune
response.
In summary the KLH immunisation schedule evokes both cell-mediated and humoral
immune responses.
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5.3.3.2 KLH-Fed Group 1
There was no statistical difference in any measure of the immune response tested between
the control group and KLH-fed group 1. Furthermore, there was no detectable immune
response after feeding alone. Importantly, there were no side effects to either the KLH
feeding or KLH immunisation. These results suggested that feeding this dose of antigen has
no effect on the systemic immune system. Since oral tolerance can occur in humans9, these
results imply that a threshold of fed antigen may be required to induce this effect.
The dose of KLH used in the feeding schedule was lower than that used by Husby in the
previously published trial, where 50mg feeds of KLH were given for 10 days9. Animal
models suggest that the amount of antigen that needs to be ingested to induce tolerance
varies depending on the type of antigen, but that in some models a lower dose of antigen per
weight of animal than the dose of KLH used in my experiments on humans has induced
tolerance30. This experiment was designed to investigate the effects of low dose feeding on
oral tolerance induction in humans and was the principal reason for using such a low dose of
feeding in these initial experiments. A secondary factor for using this low dose was the cost
ofKLH (£250 for 500mg).
In summary, lOmg of KLH fed for 10 days had no detectable effect on the subsequent
systemic immune response to KLH immunisation and suggests that there is a minimal level
of feeding that is required to induce oral tolerance in humans.
5.3.3.3 KLH-Fed Group 2
DTH responses to the immunisation schedule were significantly reduced by feeding 50mg of
KLH for 10 days (see tables 5.1 and 5.2). The reduction appeared to be both in the absolute
numbers that develop a response, as measured by induration at the site of injection, and the
area of erythema. In addition there may have be an attenuation ofDTH response since all the
subjects in whom induration could be detected at 24 hours had a negative response at 48
hours (an observation that also applied to KLH-fed group 3), whereas only 1 patient in the
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control group had a positive response that did not persist for 48 hours. These results suggest
that oral tolerance for DTH had been induced in KLH-fed group 2.
The in vitro lymphocyte proliferation assay showed a positive response after feeding alone
(or before immunisation), which suggests that antigen had been absorbed and recognised by
the gastrointestinal immune system. After immunisation, there is a further significant
increase of in vitro lymphocyte proliferation. The concordance between DTH responses and
in vitro lymphocyte proliferation responses that was seen in the control group was lost (as
was also the case in KLH-fed group 3). These results imply that pre-feeding antigen
stimulates the production of a cell type that is activated in the lymphocyte proliferation
assay, but does not initiate the DTH response.
The antibody results showed priming of IgG, but not IgA, responses by pre-feeding KLH.
Thus, the cell that is activated by feeding appears to modify the systemic humoral immune
response after immunisation.
This combination of results is consistent with the hypothesis that a regulatory cell was
induced by feeding alone and could be detected in the lymphocyte proliferation assay. This
cell modified the immune responses to the subsequent systemic exposure of antigen in such a
way as to reduce in vivo DTH responses but to increase IgG humoral responses.
5.3.4 KLH-Fed Group 3
5.3.4.1 Introduction - Rationale for Feeding Schedule
The results that I obtained from the KLH-fed group 2 showed many similarities to the
immune response observed by Husby9. In particular, DTH responses were reduced and IgG
responses were primed. However, Husby observed that after immunisation, in vitro
proliferation responses were significantly reduced, whereas in my experiments the (non¬
significant) trend was in the opposite direction.
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One possible explanation for these differences is that the exact timings of feeding and
immunisation were different and that although the regulatory cells induced by feeding was
the same in both studies, Husby et al were unable to demonstrate lymphocyte proliferation
because the antigen specific cell was not in the peripheral blood at the time of testing. The
exact timings of the feeding schedule are shown in table 5.3. Alternatively, the differences
may have been caused by an increased production of this regulatory cell as a result of the
increase length of feeding used by Husby, which in turn further altered the balance of the
immune responses away from an active responses, thus reducing lymphocyte proliferation. A
third possible explanation is that the increased length of feeding caused the induction of
additional, or more powerful, mechanisms of tolerance. Animal models have demonstrated
multiple mechanisms of tolerance induction that can be induced by different doses of
feeding132. Lastly, it is possible that the differences between these two results may be due to
methodological differences or statistical chance, although this is less likely because in one
case there is a significant reduction in lymphocyte proliferation, whereas in the other there is
a trend towards increased proliferation.
To attempt to differentiate between these possibilities, I elected to feed a third group of
volunteers an increased course of KLH comprising of 15 feeds of 50mg of KLH, given in
two blocks over 3 weeks. If differences in the assay technique were responsible, the results
should be similar to KLH-fed group 2, whereas, if additional, or more powerful, mechanisms
of tolerance were induced by increasing the fed dose, one would expect the results in this
group to mirror those of Husby more closely.
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5.3.4.2 Results of Experiments on KLH-Fed Group 3
The results from this group confirm that oral feeding induced tolerance of the DTH
responses. Furthermore, this tolerance is likely to be mediated by the production of a
regulatory cell since feeding alone induces a positive in vitro lymphocyte proliferation
response and after immunisation there is a positive in vitro lymphocyte proliferation
response that does not correlate with the DTH response (see figure 5.3).
There were however differences between the results for KLH-fed group 2 and KLH-fed
group 3. Firstly, there was a significantly increased lymphocyte proliferation response after
feeding the higher dose of antigen, which suggests that the more prolonged course of feeding
induced the production of a greater cellular response by the gastrointestinal immune system.
The cells that were detected may be of the same cell type as was induced in KLH-fed group
2 or be due to the production of a different cell type that mediates tolerance. After
immunisation, there was a significant reduction in lymphocyte proliferation response in the
group fed the longer course of KLH compared to KLH-fed group 2. This pattern of
lymphocyte proliferation responses were thus more similar to that demonstrated by Husby
and suggests that the differences between my initial experiments and those of Husby are due
an increase in tolerance cause by increased length of feeding rather than due to differences in
methodology. The increased tolerance may be due to an increase in the activity of
tolerogenic cells produced or due to the production of an additional cell type that mediates
tolerance.
The antibody responses in KLH-fed group 3 showed that anti-KLH IgG responses lie at an
intermediate level between those of KLH-fed group 2 and the control group but were not
significantly different from either. Anti-KLH IgA responses were reduced compared to both
the control group and to KLH-fed group 2, but again the difference was not significant.
There may be a trend towards reduced serum anti-KLH IgA levels by increasing the dose of
feeding prior to immunisation (see figure 5.4b). This potential finding should be validated by
other studies.
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In summary, there is a significant reduction in in vitro lymphocyte proliferation in the group
fed the higher dose of antigen and a non-significant reduction in both IgG and IgA
responses. This pattern of results showing a consistent reduction in all limbs of the immune
response would be consistent with the production ofmore potent mechanisms of suppression
by increased feeding, either by increasing the power of the same mechanism of tolerance of
by the production of additional tolerogenic mechanisms. Potential additional tolerogenic
mechanisms that could be induced include additional immunoregulatory cells or the
induction of clonal anergy or deletion.
5.4 Hypotheses on the Possible Nature of the Regulatory Cells Induced by Feeding
It is possible to hypothesise about the nature of the putative immunoregulatory cell induced
by antigen feeding by comparing the type of immune response to that seen in animal models
reported in the literature (see chapter 2).
One possible cell type that can be induced by feeding animals is the TH2 cell. This cell type,
characterised in most detail in the mouse but also likely to be present in the human, provides
help for humoral responses but inhibits TH1, and hence DTH responses62. Subjects in KLH-
fed group 2 in my experiments demonstrated a primed anti-KLH IgG response but an
inhibited DTH response and therefore it is attractive to hypothesise that the production of a
Th2 response is responsible for tolerance in this group.
The observation that IgA responses to KLH, unlike IgG, are not primed would be an
unexpected finding if the production of tolerance were caused by Th2 cells. Th2 cells, via the
secretion of IL-4 and IL-5, provide help for humoral and particularly IgA responses60. One
may also expect antigen encountered at a mucosal surface to produce an IgA response.
However my results, which failed to demonstrate a priming of serum IgA responses, are
confirmed by the findings of Husby et af. There was no increase in anti-KLH IgA at the end
of their immunisation schedule, although they did observe a transient increase in IgA
responses after a solitary KLH immunisation. Furthermore, IgE responses, which are
94
strongly associated with TH2 responses, are frequently reduced by oral exposure to antigen15.
IgE is the antibody that is most frequently associated with food intolerance. Therefore, even
in animal models in which clonal deviation has been postulated to be responsible for oral
tolerance, the features of the immune response are not always typical of a Th2 response.
There are two potential explanations of these findings. Firstly there may indeed be a
production of a Th2 response to ingested antigen, but that local factors in the gastrointestinal
immune system cause it to be manifested in an atypical way. For example, Husby's results
demonstrated an increase in secretary anti-KLFl IgA after feeding9. Therefore there may be
local factors that cause any IgA produced to be secreted in the gut lumen rather that into the
blood stream, and thus explain why there is no increase in serum IgA. Similar local
mechanisms may exist to prevent the product of IgE and hence protect against food
intolerance. The other explanation is that different cell types are produced in response to oral
feeding.
Another potential candidate may be the TR1 cell. This cell type produces large amounts of
IL-10, and has been shown to down regulate ThI responses, and lesser amounts of IL-5139,
which may conceivably prime the humoral IgG response. Thus this is a second cell type that
may be responsible for the effects on the immune system causes by KLFI feeding schedule 1.
The immune response to systemic immunisation in KLH-fed group 3 was similar to that seen
in KLH-fed group 2 in many, but not all respects. In particular there was a significantly
greater in vitro lymphocyte proliferation response after the feeding regime but a significantly
reduced response after immunisation compared to KLH-fed group 2. There are two potential
explanations for these changes. Firstly, the regulatory cell induced is the same in both
groups, but that more prolonged feeding allows it effects to become more marked, possibly
through stimulating the production of more of these cells or by inducing further
differentiation of these cells into a more potent regulatory cell. The second explanation is
that addition mechanisms of tolerance are induced. I will discuss each of these possibilities
in turn.
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One may postulate that the production of a Th2 response is responsible for tolerance in both
groups. Th2 cells can inhibit the production ofThI responses and ifT cells are induced in an
environment with TH2 cytokines present they are more likely to differentiate down the Th2
pathway69. Therefore one may expect to develop more complete tolerance to TI}1 mediated
immune responses such as DTH with more prolonged feeding if this were the mechanism.
However, one would also expect that the TH2 mediated immune responses, such as antibody
production, would be increased by more prolonged feeding. Furthermore, if there are more
Th2 cells in the systemic circulation prior to immunisation, as is suggested by the
lymphocyte proliferation assay results after feeding, one may expect the post-immunisation
lymphocyte proliferation responses to be greater after immunisation in the group fed the
higher dose of antigen. Neither of these findings were observed which suggests that the
production of a TH2 response is unlikely to be the cause of oral tolerance in both groups.
The production of TR1 cells by oral feeding could be responsible for tolerance in both
groups. This is an attractive hypothesis for several reasons. Firstly TR1 cells can inhibit ThI
functions139 and therefore may inhibit DTH responses. Secondly it is conceivable that TR1
cells may stimulate IgG responses through the expression of IL-5. Lastly, TR1 cells
proliferate poorly in response to antigen139, which may explain the reduced lymphocyte
proliferation seen in KLH-fed group 3. Thus it is conceivable that low dose feeding induces
the production of a TR1 cell and that the more prolonged feeding results in increased
numbers of, or an increased differentiation in, these cells that alter the balance of the immune
response further towards tolerance. The explanation for why there is no further increase in
the IgG response may be that increased differentiation of the TR1 cells results in reduced
production of IL-5 and increased production in IL-10.
Lastly, it was observed that all aspects of the immune response measured were reduced in
KLH-fed group 3 compared to KLH-fed group 2, although not all were significantly so. The
trend of all these immune indicators to fall does raise the possibility that more powerful,
suppressor cells are induced to mediate tolerance. One possibility is that a TH3 type cell was
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induced by feeding. This cell secretes high quantities of TGF-P which can inhibit both TH1
and Th2 functions133. The production of this cell type would be consistent with the immune
response observed in KLH-fed group 3, although it would not explain the results in KLH-fed
group 2 so readily. Thus if TH3 cells are induced in KLH-fed group 3, one has to hypothesise
that more prolonged feeding results in the production of addition mechanisms of tolerance in
addition to those responsible for tolerance in KLH-fed group 2, and which are subsequently
inhibited by the TH3 cells. Alternatively the TH3 cells may differentiate into its mature
phenotype via stages that induce TH2 type responses.
Finally other suppressor cells have been identified in animal models including CD8+
cells110'111 and y8 cells118'119. It is possible that cells of either phenotype may be induced in
humans in response to the more prolonged course of feeding and mediate the immune
responses observed in KLH-fed group 3.
5.5 Summary of Experiments Using KLH to Induce Tolerance
The following conclusions can be drawn from these experiments. From KLH-fed group 1, it
appears that there is aminimal dose of feeding that is required to induce detectable tolerance.
The results from KLH-fed group 2 show that tolerance to DTH can occur in humans and is
associated with priming of humoral responses, a pattern of immune response that may give
most benefit to the host. The detection of cell proliferation in the lymphocyte proliferation
assay after feeding alone suggests that tolerance is mediated through a regulatory cell, and
the pattern of the immune response raises the possibility that this cell may be a Th2 cell or a
Tr1 cell. Volunteers in KLH-fed group 3 showed a reduction in in vitro lymphocyte
proliferation after immunisation compared to KLH-fed group 2. There is also the suggestion
that both IgG and IgA responses were lower in the group fed the higher dose regime ofKLH
and these areas should be addressed in further trials. These changes imply that more
prolonged feeding either induces additional mechanisms of suppression, or that greater
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numbers, or more terminally differentiated, regulatory cells are induced by more prolonged
feeding which further alters the balance of the immune response towards tolerance. Work
that I performed to test these theories is described in chapter 7.
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6 RESULTS OF EXPERIMENTS INVESTIGATING ORAL TOLERANCE TO
OVALBUMIN
6.1 Introduction
Animal studies suggest that there are multiple mechanisms of oral tolerance production. Low
dose tolerance appears to be mediated by the production of active regulatory or suppressor
cells, whereas high dose tolerance may be mediated through clonal anergy or deletion. The
results obtained from the experiments with KLH strongly support the idea that low dose
feeding in humans induces regulatory cells that mediate tolerance. This chapter examines the
results of experiments performed to investigate whether high dose tolerance may be
mediated by other mechanisms in humans. The method chosen to investigate high dose
tolerance was to investigate the immune response to OVA, which is a common dietary
antigen that will have been ingested over prolonged periods of time in the normal diet.




The protocol was designed along the lines of that used for the KLH experiments. The
timings of the immunisations were identical to those that produced a good immune response
in the KLH control group. Two doses of immunisation were used. The first, low dose used
the same dose of OVA as that of KLH (i.e. two immunisations with 200pg/ml). The second
course gave 7.5 times the dose (i.e. two immunisations with 1500pg/ml). The measures used
to assess immune response included ELISA measurement of anti-OVA IgG and IgA
antibodies, in vitro lymphocyte proliferation and DTH responses. The DTH responses were
assessed on consecutive days by the presence of absence of induration and the mean
diameter of erythema. On the first day, a dose of lOpg of OVA in 0.1ml of saline was given.
If there was no detectable erythema, a larger dose of 100pg of OVA in 0.1ml of saline was
given. Readings of DTH responses were taken at 24 and 48 hours. The immunisation
schedule and timing of venesections are shown in table 6.1.
Table 6.1 - Protocol for demonstrating tolerance with OVA. The timing of and doses used in
the immunisation schedule are shown. Also shown are the timings at which the assays to
assess the immune response were performed.
Day Group 1 - Low dose
immunisation
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6.3.1 Delaved-Type Hypersensitivity Testing
The skin-test results are shown in table 6.2. None of the volunteers had a positive skin test as
defined by any detectable induration at the site of intra-dermal injection to either strength of
injections at 24 or 48 hours. Furthermore, there was no detectable erythema in any of the
volunteers to either of the doses of intra-dermal injection. Thus there was no detectable DTH
response to OVA.
Table 6.2- Skin test results to subcutaneous OVA immunisation. The results are expressed as
the number of positive results over the total number of people in that group. There was no
detectable DTH response in any of the volunteers given either immunisation schedule or






Low Dose (Group 1) High Dose (Group 2)
lOpg injection
24 horns 0/10 0/4
48 hours 0/10 0/4
lOOpg injection
24 hours 0/10 0/4
48 hours 0/10 0/4
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6.3.2 Lymphocyte Proliferation Responses
Figure 6.1 illustrates the in vitro lymphocyte proliferation responses before and after
immunisation for both the group given the low dose and the high dose immunisation. There
was no detectable in vitro lymphocyte proliferation to OVA either at the start of the
experiment, i.e. after prolonged oral ingestion ofOVA, or at the end of the experiment after
immunisation with OVA. The results illustrated in figure 6.1 were obtained with cells
stimulated with 100pi ofOVA at 10p.g/ml. There was no detectable lymphocyte proliferation
when OVA was used at a concentration of lOOpg/ml or when it was used in the assay coated
to Dynabeads (data not shown).
Figure 6.1 - In vitro lymphocyte proliferation responses to OVA. There is no detectable
lymphocyte proliferation response to OVA either after feeding of OVA or after













The anti-OVA IgG results are shown in graphs 6.2a and 6.2b, which illustrate the group that
received the low dose immunisation schedule and the high dose immunisation schedule
respectively. Day 1 values indicate the effect of long tenn feeding without active
immunisation, day 11 values the effect of the first immunisation dose and day 21 values the
effect of the full immunisation regime.
Anti-OVA IgG was detectable in the serum of all patients before immunisation in low
concentrations. The low dose immunisation schedule did not cause an increase in anti-OVA
IgG antibody in any of the volunteers. There was an increase in anti-OVA IgG antibody in 2
of the 4 volunteers that received the high dose immunisation schedule of 56% and 73%
respectively above baseline. This result was confirmed when the specimens were run on two
separate ELISAs.
The anti-OVA IgA antibody results for the low and high dose immunisation schedules are
shown in graphs 6.3a and 6.3b respectively. As for anti-OVA IgG, there were detectable
levels of anti-OVA IgA at day 1. Low dose immunisation had no effect on the anti-OVA IgA
antibody concentration. One volunteer who received the high-dose injection schedule had a
47% increase in OVA specific IgA antibody, a result that was also confirmed in two separate
ELISA runs. This was a different volunteer from the two who developed an increase in anti-
OVA IgG, and therefore 3 of 4 volunteers had a rise in Ig levels as a result of high dose
immunisation.
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Day 1 Day 11
Time
Day 21
There are detectable levels of OVA specific IgG detectable before the immunisation
schedule. There is no change in the level of anti-OVA IgG in any of the volunteers given the
low dose immunisation schedule. 2 of 4 volunteers given the high dose immunisation
schedule showed a small rise in anti-OVA IgG levels over baseline.
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Day 1 Day 11
Time
Day 21
Anti-OVA IgA is detectable in the serum of all volunteers prior to immunisation. There is no
change in quantity of anti-OVA IgA in any of the volunteers given the low dose
immunisation schedule. One of the volunteers given the high dose immunisation schedule
had a small rise in level of anti-OVA after the high dose immunisation regime.
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6.4 Discussion of Immune Response to OVA
6.4.1 Rationale for the Use ofOVA
To assess high dose feeding in humans, one has to have available an antigen that can be
taken in high doses and has no toxic effects. KLH would be one possible antigen.
Furthermore the high-dose feeding regime could be compared directly to the control group
and those groups fed the low dose regimes. However, the cost and difficulty of obtaining
KLH, associated with the onus it would place on the volunteers to take KLH for a prolonged
time, made this an impractical option. The alternative approach I used to attempt to
overcome these problems was to investigate the immune responses to a common dietary
antigen that would thus have been encountered in high doses by all volunteers.
I chose to use OVA, which is an antigen derived from hens' eggs and is thus a common
constituent in the normal diet. It is a smaller antigen than KLH, with a molecular weight of
42,700 daltons and it does not polymerise186. OVA was chosen for several reasons. Firstly, it
has been used in the investigation of oral tolerance in many animal models in which it
proved immunogenic and capable of inducing oral tolerance. Furthermore, humans produce
antibodies to OVA, even in health, which suggests that it is antigenic in man. Thirdly,
Sigma-Aldrich Company manufacture OVA to American Food and Drug Administration
regulations and I was able to show it was sterile and endotoxin free (see Materials and
Methods) and hence likely to be safe for use in humans. Lastly, the gastrointestinal
laboratory has previously developed and optimised ELISAs specific for anti-OVA IgA and
IgG.
6.4.2 Potential Criticisms of Experiments with OVA
There are a number of criticisms that can be levelled at these experiments. Firstly, because of
the nature and choice of antigen, it was not possible to have a naive group to act as controls.
The pattern of immune response to OVA was compared to that of the KLH groups to assess
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whether the two are similar or so different as to imply the operation of two different immune
mechanisms. The immune response to OVA as a naive antigen is however unknown and it
cannot be assumed to mirror that of KLH. Thus there will be a speculative element to the
discussion. The ideal experiments to overcome this criticism would be to give prolonged
feeding schedules with KLH prior to immunisation, but funding limitations and the expense
ofKLH prevented me from performing such experiments.
The lack of a positive control raises the possibility that the failure to demonstrate any
positive in vitro lymphocyte proliferation may be due to failure of the experimental
technique rather than true absence of in vitro lymphocyte proliferation. However OVA has
been used, and provoked in vitro lymphocyte proliferation in many animal models of
tolerance. This fact and the fact that the lymphocyte proliferation assay proved reliable in the
KLH experiments suggest that this was not the case. Furthermore, I used a range of OVA
concentrations from 10 to 100pg/ml, in each assay to exclude the possibility that the
concentration ofOVA was too low. Lastly, I also used Dynabeads coated with OVA which
have been shown to increase antigen uptake187. Failure to process and present antigen should
have been overcome by these two techniques and suggest that the in vitro lymphocyte
proliferation results may be valid.
Another methodological criticism is that the immunisation schedule given did not include
adjuvant. Many animal models investigating oral tolerance to OVA used adjuvant in their
immunisation schedules. Although KLH immunisation without adjuvant induced a good
immune response, the same may not necessarily apply to OVA, which is a much smaller
molecule. Previous work suggest that soluble antigen may not be presented in vitro by APCs
and therefore may not cause lymphocyte proliferation187'188. However, soluble OVA alone
can provoke egg allergy, which suggests that in some situations it can be recognised in the
soluble form by the human immune system. Despite these caveats, the failure to provoke an
immune response with the OVA immunisation schedule may be due to the fact that soluble
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OVA is not processed by APCs and therefore is not immunogenic. Repeating these
experiments with OVA plus adjuvant would be very valuable to help verify the experimental
data presented here. Updated ethical approval would be required to perform these
experiments.
6.4.3 The Immune Response to OVA after Oral Exposure
The volunteers who had been immunised to OVA were not naive to OVA at the start of the
experiment because all had eaten OVA as part of their normal diet over a prolonged period
of time. Thus, the data on the immune response to OVA at the start of the experiment
corresponded to the post eating stage of the KLH experiments.
There was a detectable, although low-level humoral response to OVA after prolonged
feeding. This suggests that the gastrointestinal immune system had recognised oral OVA,
and furthermore implies that in some situations soluble OVA is antigenic in humans. There
was, however no detectable in vitro lymphocyte proliferation response after ingestion of
OVA. This pattern of immune response was markedly different to that observed in the KLH
experiments, where the reverse pattern of a detectable in vitro lymphocyte proliferation
response and an undetectable humoral response was found. I postulated that tolerance to
KLH was mediated by the production of a regulatory cell detectable in the lymphocyte
proliferation assay. The different pattern of immune response in the OVA experiments
implies that different mechanisms may be responsible for maintaining tolerance to this
antigen.
6.4.4 Immune Responses to OVA after Immunisation
There was no change in either humoral or CMI after the low dose immunisation schedule.
This was in contrast to the tolerance to KLH where there was a detectable in vitro
lymphocyte proliferation response and priming of the IgG humoral response but no DTH
response. The two possible explanations for the lack of response to OVA immunisation are
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that there were powerful mechanisms of tolerance operating to prevent any immune response
or that the immunisation schedule was not immunogenic. The best way to differentiate
between these possibilities would be to give a group of volunteers OVA with adjuvant, an
experiment for which we did not have ethical approval. The alternative method that I chose
was to give a higher dose immunisation schedule to a trial group of four. There was no
detectable CMI in any member of this group but there was a rise in antibody titre in 3 of the
4 patients. This observation suggests that the immune system did recognised OVA, but
responded poorly. Although the possibility that the poor response is due to the poor
antigenicity ofOVA cannot be discounted, this explanation is less likely because there was a
detectable immune response prior to immunisation and one would expect to a more vigorous
response if the initial findings were caused by an active, non-suppressed immune response.
Therefore I favour the hypothesis that the failure to respond to OVA is caused by the
presence of powerful mechanisms maintaining tolerance.
The two mechanisms of tolerance identified from animal studies that would result in such
non-responsiveness to OVA immunisation are clonal anergy and clonal deletion. The
complete absence of lymphocyte proliferation and DTH responses to OVA are consistent
with either clonal deletion or clonal anergy. The fact that there was a low level of anti-OVA
antibody present suggests that deletion ofB cells had not occurred. Furthermore these B cells
continued to produce low levels of antibody in response to ongoing exposure to antigen as
shown by the observation that antibody levels to food proteins become undetectable if that
food is removed from the diet189. In addition I have shown that in some people, these B cells
can respond to systemic challenge with high dose OVA. These facts suggest that the humoral
immune system can respond to OVA, and therefore clonal deletion is not responsible for this
tolerance.
The humoral response to OVA was very sluggish. For B cells to respond to antigen, co-
stimulation is required from both the antigen and from help which is normally provided by
antigen specific T cells48. Thus this anergy of the humoral response could be due to clonal
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anergy of the B cells themselves or due to lack of T cell help for the humoral responses.
Animal studies suggest that clonal anergy affects T cells more completely and for longer
than it affects B cells17.
The results of these experiments are consistent with the hypothesis that tolerance to OVA is
the result of clonal anergy affecting OVA-specific T-cells. High dose immunisation may
partially overcome this anergy by stimulating these T cells to provide some help for B cell
proliferation probably through the secretion of cytokines. It may seem paradoxical that T
cells can provide help for B cells without proliferating in the in vitro lymphocyte
proliferation assay but there is evidence that anergic T cells can secrete cytokines without
proliferating in other circumstances190 and perhaps this is also occurring here.
6.4.5 Comparisons with Other Studies Investigating Immune Responses to Dietary
Antigens in Humans
There are two reports of immune responses to dietary antigens that are worthy of discussion.
Firstly, Brandtzaeg's group observed that antibody levels to food antigens fell with
increasing age161. There was a wide variation of antibody levels within each age group, but
overall there was a reduction that was statistically significant. One can postulate that the fall
in antibody production is due to an increased total dose of antigen feeding associated with
increasing age, leading to increasing anergy and/or deletion of reactive T cells
The second experiments are those of Korenblat et a/19. They also injected volunteers with a
food antigen, namely BSA. They observed that volunteers fell into either a group with high
initial levels of anti-BSA antibody. In this group immunisation resulted in an increase in
anti-BSA antibodies. The second group had low or undetectable levels of antibody to BSA
and there was no increase in these antibody levels in response to immunisation. Although no
comment is made on the age of each group in their paper, it is possible that older people, or
those that had eaten large quantities of antigen, would have marked clonal anergy and
therefore fall into the latter group. Those who were younger or had eaten less BSA would not
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have developed such profound tolerance and therefore have higher initial antibody levels and
be able to respond modestly to the immunisation schedule and therefore make up the first
group. The results of these studies are compatible with those that I have reported.
6.5 Conclusions of OVA Experiments
In conclusion, there was an absence of CMI to OVA, both after ingestion ofOVA and after
subsequent immunisation with OVA. Humoral responses showed a low level of anti-OVA
IgA and IgG antibodies after ingestion of OVA, but with no or very a sluggish rise after
immunisation. The pattern of immune response was very different to that seen in those
volunteers fed KLH, suggesting that different, more powerful mechanisms of tolerance were
responsible for maintaining tolerance to OVA. This is consistent with other animal studies
which show that more prolonged exposure to oral antigen leads to greater tolerance. Clonal
deletion or clonal anergy are two possible candidate mechanisms.
There are criticisms that can be leveled at this work, and the findings should be confirmed by
further experiments. One (expensive) way to confirm these observations would be to feed a
group of volunteers regular neoantigen, such as KLH, over many months and make serial
measurements of the immune responses to that antigen. This experiment would allow one to
investigate how the immune responses change with increasing length of feeding. It would
also allow one to see at which stage oral antigen alone produces a systemic humoral immune
response and when or if this response starts to fall despite continued feeding.
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7 DEVELOPMENT OF EXPERIMENTAL PROTOCOLS TO TEST HYPOTHESES
OF THE NATURE OF ORAL TOLERANCE IN HUMANS
7.1 Introduction
In this chapter, I attempt to define the mechanisms responsible for the different patterns of
immune responses demonstrated in patients fed KLH and OVA. The key observations that
require explanation are:
1) the suppression of DTH skin tests in subjects fed a neoantigen while the lymphocyte
proliferation responses and antibody production remained detectable.
2) The almost complete suppression of DTH skin tests, lymphocyte proliferation responses
and antibody production to a dietary antigen fed over a lifetime.
Animal models suggests that clonal deviation (i.e. the switch from a ThI to a TH2 mediated
response), production of regulatory cells, clonal anergy and clonal deletion are all
mechanisms mediating oral tolerance in different experimental conditions. The following
experiments were designed to attempt to differentiate which of these mechanisms may be
responsible for the oral tolerance induced by KLH and OVA in normal human subjects.
7.2 Experiments to Assess Clonal Deviation in KLH-Fed Group 2
7.2.1 Summary of Immune Response in KLH-Fed Group 2
Feeding volunteers 50mg of KLH for 10 days before challenging the systemic immune
system with an immunisation schedule ofKLH resulted in the reduction of DTH, unchanged
in vitro lymphocyte proliferation and priming of anti-KLH IgG (but not IgA) response
compared to a control group that received only the immunisation schedule. The pattern of
immune response would be consistent with the postulate that feeding induced clonal
deviation from a TH1 to a TH2 type immune response, and that these Th2 cells mediated the
observed changes in the immune response.
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Th1 and TH2 cells are morphologically and phenotypically identical, but secrete different
cytokines which defines their different functional characteristics57. Therefore, to investigate
the hypothesis that clonal deviation is responsible for tolerance in KLH-fed group 2, I
designed experiments to check possible differences in the cytokine profile of the cells taken
from the groups fed KLH compared to controls.
7.2.2 Cytokine Production by Lymphocytes Measured by ELISA
The cytokine profile permits identification of the T helper cell subset. TH1 cells produce IL-2
and IFN-y, whereas Th2 cells produce IL-4, 5 and 1057. I chose to measure the levels of IL-4
as a Th2 marker and IFN-y to identify ThI cell activity in the cell culture supernatant of cells
stimulated with KLH after 24 and 90 hours of culture. These time points were chosen
because IL-4 production peaks at 24 hours and IFN-y production peaks at 48-96 hours. The
samples were tested using a commercially available ELISA kit. Cell culture supernatants
were collected from the cell cultures of the control group before and after immunisation and
from those in KLH-fed group 2 before and after feeding and after immunisation. I postulated
that if clonal deviation was caused by feeding, there should be an increase in IL-4 and
decrease in IFN-y after feeding and immunisation in the pre-fed group compared to the
control group.
7.2.2.1 Results
Samples from all seven volunteers in the KLH-fed group 2 and from eight members of the
control group were included. There was no detectable IL-4 in any of the specimens. Three
specimens had very low levels of IFN-y - namely one control group specimen after
immunisation, one sample taken after eating KLH alone and one sample from a pre-fed
volunteer after immunisation. There was no detectable IFN-y in any other sample. Thus there
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was no consistent pattern and all the positive samples gave values at the lower end of, or
even just below, the lowest standard sample.
7.2.2.2 Discussion
A positive control was provided for both IFN-y and IL-4. Both these control samples gave
positive results which suggests that the assay did work in my hands. Thus the disappointing
lack of results suggests that neither of these cytokines are produced or that they are produced
in insufficient quantities to be detected in this assay. Husby also tried to investigate cytokine
levels using cell culture supernatants9. In their experiments they used cytokine dependent
cell-lines to measure cytokines, but they were also were unable to demonstrate the presence
of any cytokines. IFN-y and IL-4 can be difficult to detect and therefore the assays used by
both Husby's group and me may not have been sensitive enough to detect the physiological
quantities of cytokine produced in cell culture.
In summary, no conclusions on the nature of the tolerance in KLH-fed group 2 can be
inferred from these experiments
7.2.3 IgG Subclass Levels
Another possible method to show whether clonal deviation from a ThI to Th2 based immune
response has been induced by feeding is to detect differences in antibody response produced.
Th1 and TH2 cells both, to varying degrees, provide help to B cells. In animal models, the
type of humoral response produced, and in particular the Ig subclasses that are produced,
vary depending on the type of T cell help provided. In the mouse, TH1 cells stimulate an
IgG2a response, mediated by IFN-y. TH2 cells stimulate an IgGl response mediated by IL-4
and IL-580.1 therefore postulated that if clonal deviation was responsible for oral tolerance to
low dose feeding, there might be differences in IgG isotype production between the fed
groups and the control group.
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In humans, the relationship between T helper cell subset and IgG isotype production is not
well established. Furthermore, the isotypes of IgG vary between mice and humans. Therefore
it is impossible to draw direct parallels between any results in my experiments and those in
the mouse. However, any differences in the IgG isotype produced in the different groups
would imply that there are different mechanisms controlling the immune response and
provide some indirect evidence for clonal deviation.
7.2.3.1 Results
The IgGl levels after injection are shown in figure 7.1a and the IgG2 post-injection levels
are shown in figure 7.1b. Although I performed this experiment to look primarily at KLH-
fed group 2, the results from all the groups will be presented and discussed here for
simplicity. The horizontal bars represent the median value for each group. There is no
statistical difference in IgG lor IgG2 levels between any of the groups.
7.2.3.2 Discussion
These results are not statistically significant and therefore do not provide supportive
evidence for the hypothesis that oral feeding induces clonal deviation towards a Th2 cell
response. There are a number of potential explanations for this result. Firstly, the numbers in
each group are small, and the spread of results wide. It is therefore possible that the failure to
obtain a positive result is due to type II error. Secondly there is no evidence that TH1 and Th2
cells cause isotype switching to different types of IgG in humans. Therefore, even if clonal
deviation is induced by low dose feeding, further work on the effect of Th2 cells on IgG
isotype switching would be required to interpret this data properly. Lastly, it is possible that
oral tolerance in KLH-fed group 2 is produced by a mechanism other than clonal deviation. I
have hypothesised that immunoregulatory cells may be induced by feeding KLH. Other
candidate immunoregulatory cells (e.g. TR1 and TH3 cells) on the different compartments of
the immune system requires further investigation.
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The graphs illustrate the values of anti-KLH IgGl and IgG2 for each volunteer in each group
at the end of the immunisation schedule. The lines represent the median value in each group.
There were no statistically significant differences between any of the groups, although the
range of values in each group was large.
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7.2.3.4 Conclusions
In summary, the pattern of immune response observed after feeding in KLH-fed group 2 is
suggestive of the induction of clonal deviation towards a TH2 type immune response by low
dose feeding. I attempted to provide supportive evidence for this hypothesis by assaying for
the cytokine profile after feeding and by assessing whether the type of IgG subclass differed
from the control group. I was unable to detect any significant levels of IFN-y or IL-4 in the
cell culture supernatants and there were no significant differences between the IgG
subclasses produced.
There are two possible explanations for my failure to provide supportive evidence for the
production of clonal deviation. Firstly, the experimental techniques may not have been able
to detect clonal deviation in humans. Alternatively, it may imply that different mechanisms
of tolerance are induced, such as the production of alternative regulatory cells. Further work
is therefore necessary to investigate the possibility that clonal deviation can occur in humans
and in parallel to assess whether alternative types of regulatory cells such as TH3 or TrI cells
are produced.
7.3 Evidence for Mechanisms of Tolerance in KLH-Fed Group 3
7.3.1 Summary of Immune Response in KLH-Fed Group 3
Feeding volunteers 50mg ofKLH for 15 days followed by systemic immunisation resulted in
an absent DTH response compared to the control group, but an unchanged in vitro
lymphocyte proliferation response and humoral response. The in vitro lymphocyte
proliferation response after immunisation was significantly reduced compared to that in
KLH-fed group 2, and both anti-KLH IgA and IgG responses were lower, although not
significantly so. These results suggest that more prolonged feeding induced more profound
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suppression. This may result from either an increased production of the same regulatory cell
in the KLH-fed group 2 or from the induction of an additional mechanism of tolerance.
It is unlikely that an increased TH2 response is responsible for tolerance in both these groups
since one would expect a Th2 response to provide increased help for a humoral response and
therefore increased production of antibody. It is more likely that another regulatory cell is
responsible and the likely candidates that have been identified in animal studies are the so-
called Th3 cell, the TrI cell or an active suppressor cell. The experiments described in this
section were designed to explore these possibilities.
7.3.2 Cytokine Production Measured by Cytokine mRNA Production
Cytokine production offers a powerful method of investigating the type of immune response
produced and one that yielded powerful evidence of the mechanisms of tolerance production
in many animal models. In the previous section, I reported failure to detect cytokines in
KLH-fed group 2 using an ELISA based method, possibly because the assay was not
sensitive enough. I therefore developed a PCR method to measure cytokine mRNA as a
potentially more powerful assay to detect cytokine production.
PCR assays are much more sensitive that ELISA techniques and may detect even modest
increases in cytokine production. However, there are several drawbacks in using these
techniques. Firstly, PCR detects cytokine mRNA rather than the cytokine itself. Although the
quantities of the two should correlate closely since cytokine production is transcribed from
its mRNA template, this may not always be the case. Another significant problem is that it is
very difficult to get accurate quantitative results. The multiple amplification stages in PCR
result in even very low levels being detected and it can be difficult to compare the quantity
of initial cytokine mRNA between different samples. I used a computer based analysis
technique to attempt to overcome this problem, which is not a quantitative technique and the
results therefore have to be interpreted with caution.
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7.3.2.1 Development of the PCR Assays
The methods used were derived from those of Jarvis et alm and the primers used were the
same. A series of experiments were run to optimise the concentration of magnesium and
primer, the annealing temperature and the number of PCR cycles for use in our laboratory.
cDNA derived from cells that had been stimulated by con A (a non-specific T cell mitogen)
was used as a positive control to optimise the assays for cytokine mRNA. Attempts to
multiplex the primers - i.e. run actin and cytokine PCR assays in the same tube - failed
probably because of primer dimerism.
It proved difficult to develop a standard assay to detect IFN-y and IL-10 mRNA. A hot start
technique was developed with success. This technique involved adding the Taq DNA
polymerase to the sample at a temperature of 80°C. This ensures that the entire DNA is fully
unravelled, and therefore the primers bind more specifically to their complimentary
sequences. At lower temperatures the primers may bind more non-specifically and give false
bands. The technique was also successfully applied to IL-2 and actin and was used in all
experiments.
The IL-4 mRNA PCR assay proved difficult to optimise. Changes to the annealing
temperature and number of PCR cycles were made in an attempt to get clear bands of the
predicted size. Even with these conditions, a double band was produced and the IL-4 PCR
assay proved to be the least reliable.
7.3.2.2 Reliability of the PCR Assays
The PCR method used is not a quantative technique. I therefore had to attempt to establish
that the results are valid and reproducible. A coefficient of variance could not be calculated
because of the small amounts of cDNA produced from each sample. Several methods were
employed to overcome this problem. Firstly, controls were used which should give high
values. The fact that high levels were obtained in these samples, as will be discussed below,
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is encouraging and suggests that the assay can detect samples containing high amounts of
mRNA. Secondly, all samples were run twice and results from each run were compared. The
mean variability between the same sample run on different runs was 88% for IL-2, 71% for
IFN-y, 37% for IL-10 and 76% for IL-4. These results are shown graphically in figures 7.2a-
d. Thus, the correlation between the individual values run on separate gels was sub-optimal.
Part of the variability between runs may have been due to different degrees of staining with
ethidium bromide on different gel. To remove this source of error, I ran and developed all
the samples that I was going to compare on the same gel. Furthermore, all samples were run
on two different occasions and the pattern of results seen on each occasion was similar.
Therefore, the pattern of results obtained from the different groups may be a true reflection
of the absolute level ofmRNA in each sample.
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Figures 7.2a-d - these graphs show the reproducibility of the IL-2 mRNA, IFN-y mRNA,
IL-10 mRNA and IL-4 mRNA PCR assays respectively. Each sample was run on two sperate
occasions, labelled 1st rub and 2nd run. The values given are of counts per minute of
fluorescence under ultra-violet light recorded by the molecular analyst program. The results
for the PCR products obtained at each assay were compared by linear regression to assess
reproducibiliy.
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7.3.2.3 Results ofTesting for Cytokine mRNA
The cytokine mRNA levels and actin levels are shown in graphs 7.3a-e. A typical gel is
presented with each figure (photos 7.1a-e) to illustrate the pattern ofbands obtained.
The actin results showed that a consistent level of actin mRNA was obtained from each
sample. The results for IL-2 and IFN-y showed that there was increased production of these
pro-inflammatory cytokines in the control group after immunisation compared to pre-
immunisation. Furthermore, stimulating cells with conA or PPD also results in an increased
production of mRNA of these pro-inflammatory cytokines compared to that produced by
unstimulated cells. Feeding alone did not increase the levels of these cytokines. After
immunisation of the pre-fed group, there was a trend towards increased IL-2 mRNA
production, although not to the level seen in the control group, whereas IFN-y levels were
not increased over baseline. There was no statistical difference between mRNA IL-4 levels
in any of the groups. There was a very wide range ofmRNA IL-10 levels at baseline. All the
samples tested after immunisation of the control group show mRNA IL-10 levels at the
upper limit of baseline levels. There was a significant reduction of IL-10 mRNA levels after
feeding and after immunisation of the KLH-fed group compared to the control group after
immunisation.
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Pictures 7.1a - 7.1e show typical gels obtained for the actin, IL-2, IFN-y, IL-10 and IL-4
assays respectively. On each gel, lanes 1 and 2 contain a pre- and post-immunisation sample
from a volunteer in the control group. Lanes 3 and 4 are from pre- and post-immunisation
samples from a second volunteer in the control group. Lanes 5, 6 and 7 contain the pre-
feeding and pre- and post-immunisation samples from one volunteer from KLH-fed group 3
and lanes 8, 9 and 10 contain samples from another volunteer in this group at the same time-
points. Lanes 11 and 12 contain 2 samples from 2 separate cell cultures stimulated with
conA. The last lane in the gel (except on the actin gel where it is on the left) contains a
sample run with no cDNA and acts as a negative control. The DNA ladder, used to
calculated the size of the samples of cDNA can also be seen on each gel. The size of each
rung of the DNA ladder, in base pairs are shown in the adjacent text boxes.
Figure 7.3a - 7.3e show the individual levels of actin, IL-2, IFN-y, IL-10 and IL-4
respectively at each time point, expressed as the level of fluorescence detected by the
molecular analysis program in counts per mm3. Samples from all subjects prior to KLH
exposure are included in the pre-antigen group. The next column shows the values obtained
after immunisation in the control group. The samples from KLH-fed group 3 after the
feeding schedule and after immunisation are shown in the next 2 columns. Finally the
positive controls of samples stimulated with PPD and conA are shown.
The results illustrate that a consistent level of actin cDNA is obtained from each sample. IL-
2 and IFN-y levels are increased after immunisation in the control group (p<0.01 and 0.07
respectively), but IL-10 and IL-4 levels are not raised.
After feeding there is no detectable rise in any cytokine compared to baseline, and IL-2, IFN-
y and IL-10 levels are significantly less than the control group after immunisation. After
immunisation ofKLH-fed group 3, there is a trend towards increased IL-2, but not IFN-y and
IL-10, compared to baseline. The levels of IL-10 are significantly less than the control group
after immunisation.
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Picture 7.1e - Typical results of from an IL-4 PCR experiment.











7.3.2.4 Discussion ofCytokine mRNA Production
7.3.2.4.1 Validity of the Assays
There are a number of problems with using this technique to assay cytokine production that
have been referred to in the introduction. Firstly, this technique tests for cytokine mRNA
rather than the cytokine itself. Secondly this is not a quantitative PCR technique and
therefore comparisons between the groups may be misleading. Lastly, the PCR technique is
so sensitive that even small amounts ofmRNA can be detected. This final point is illustrated
by the fact that cytokine mRNA for each cytokine tested for is detected even from
unstimulated cells that do not produce a response in the lymphocyte proliferation assay.
Indeed, at baseline there was a wide range of cytokine mRNA values particularly for IL-10
mRNA, which in turn reduces the likelihood of obtaining statistically significant results in
such a small sample size.
Some of the results do suggest that the assays may indeed give an accurate reflection of the
cytokine levels. Firstly, the levels of actin mRNA from each sample was constant. Actin is a
molecule important in maintaining the cell cytoskeleton and therefore should be produced in
equal quantities in all groups regardless of whether the cells are stimulated by antigen or not.
The presence of similar levels of actin in all groups suggests that the extraction process for
mRNA worked well.
Cells stimulated with conA and with PPD were used as positive controls. ConA is a non¬
specific T cell mitogen and PPD has been used in the immunisation programme against
tuberculosis and therefore both these antigens should activate T cells. In both cases there was
a significant increase in IL-2 and IFN-y mRNA compared to non-activated cells. These
results also suggests that these assays worked well. There was no increase in IL-10 or IL-4
production in cells stimulated with either of these antigens. This is consistent with a TH1 type
response to these antigens. However, it is possible that the IL-4 and IL-10 mRNA assays are
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not as reliable and the lack of a positive control suggests that the results of these two assays
should be treated with caution.
Lastly all the samples were run on two separate occasions and the pattern of results was
similar in each, which suggests that the assays gave reproducible results.
7.3.2.4.2 Cytokine mRNA Production in the Control Group
Immunisation with KLH caused a positive immune response detected by positive DTH skin
tests, in vitro lymphocyte proliferation and antigen specific IgG and IgA. This was
associated with the production of significantly increased amounts of IL-2 mRNA in cell
culture along with a trend towards increased amounts of IFN-y mRNA. There was no
increase in IL-4 or IL-10 mRNA, although the levels of IL-10 mRNA were all in the upper
range of the wide band of levels seen in the control group. These results are consistent with
the production of a predominantly TH1 immune response following immunisation with KLH
and is what one would have predicted. Furthermore, the subject whose cells produced the
lowest levels of IL-2 and IFN-y mRNA to KLH had a low in vitro lymphocyte proliferation
result of 1.8 which implies that samples that fail to proliferate in the in vitro proliferation
assay in response to KLH do not produce large quantities of cytokine mRNA.
7.3.2.4.3 Cytokine mRNA Production in the KLH-Fed Group
After the feeding regime of KLH there is no increase in IL-2 or IFN-y mRNA compared to
baseline and a significant reduction in both compared to the control group post
immunisation. Feeding did result in an increase in in vitro lymphocyte proliferation and I
hypothesised that this represented the production of an immunoregulatory cell (discussed in
chapter 5). The differences in IL-2 and IFN-y mRNA production suggest that this is a
different cell type to that induced by immunisation and would be consistent with this
conclusion.
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Possible candidates for this immunoregulatory cell include the TH2 cell and the TR1 cell.
There is no increase in IL-4 or IL-10 mRNA levels over baseline. Indeed there is a
significant reduction in IL-10 mRNA compared to that seen in the control group after
immunisation. Both these cytokines are produced by TH2 cells80 and IL-10 is produced by
Tr1139; thus these results fail to provide supportive evidence that either of these regulatory
cells are responsible for low dose oral tolerance in humans. Either the assays for these
cytokine mRNA levels are not reliable, a possibility that has to be considered particularly in
the absence of a positive control, or a different type of regulatory cell may be responsible for
tolerance. One possible candidate would be the TH3 cell which exerts its actions via the
secretion of TGF-J3133. Clearly, this area would benefit from further work.
After immunisation of the pre-fed group, the pattern of cytokine mRNA production showed
a more confused pattern. There was a trend towards increased IL-2 mRNA over baseline, but
not to the level of the control group after immunisation (p=N.S.). There was no increase in
IFN-y mRNA over baseline, and a trend towards a reduced level compared to the control
group post immunisation. IL-10 mRNA levels were similar to baseline and significantly
reduced compared to the control group post immunisation. IL-4 levels were similar in all
groups. The intermediate pattern of pro-inflammatory cytokines is difficult to interpret but
may represent a balance between the pro-inflammatory response to immunisation and the
inhibitory response of the immunoregulatory cells induced after feeding. Measurement of the
immunoregulatory cytokines' mRNA does not provide any definitive data, but are not
consistent with the production Th2 or TR1 cells. Further work is needed to ensure that these
results are reproducible and to investigate whether other cytokines such as TGF-J3 may be
responsible for tolerance production.
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7.3.3 Bystander Suppression
7.3.3.1 Introduction and Rationale
My experiments suggest that feeding KLH to humans induced tolerance to DTH responses
associated with the production of an immunoregulatory cell. The nature of this cell is
unknown. In certain animal models feeding of antigen induces a suppressor cell which can
be identified by both in vivo transfer experiments11 and in in vitro lymphocyte proliferation
assays83. These experiments suggest that suppressor cells are activated in an antigen specific
manner, but act to produce their effects in an antigen non-specific manner such that they can
inhibit the immune response to a second, unrelated antigen. This has been termed bystander
suppression .
In this section I describe the results from experiments using an assay that I developed to
assess bystander suppression in humans. A second unrelated antigen, PPD, to which most
people mount a good immune response was added to mononuclear cells in the in vitro
proliferation assay. Other cells were cultured with KLH and PPD in combination. A
suppression index was calculated by dividing the results of cells cultured with PPD alone by
that of cell cultured with KLH and PPD. Values greater than one imply that there is
inhibition of the PPD response by cells activated by KLH - i.e. there is bystander
suppression.
7.3.3.2 Results ofBystander Suppression Assay
The results are shown in figure 7.4. The dotted line shows a suppression index of one which
would be expected if there were no suppression. Results were obtained from four volunteers
in each of the control group, KLH-fed group 2 and KLH-fed group 3. The numbers in each
group were small and therefore the results should be treated with caution.
There was no evidence of suppression of the proliferation response to PPD in cells co-
cultured with KLH before the subjects had had any exposure to KLH, although two values
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obtained from the control group were greater than one. After immunisation of the control
group, there was no evidence of bystander suppression. Indeed three of the four values were
less than one.
After feeding of the lower dose of KLH, there was no evidence of bystander suppression.
After feeding of the more prolonged course there was an increase in suppression (p=0.03
compared to pre-feeding values). Following immunisation, there was no evidence of
bystander suppression in either KLH-fed group 2 or 3.
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7.3.3.3 Discussion - Has Bystander Suppression Been Generated
To assess bystander suppression, an unrelated antigen that provokes an immune response is
required. PPD was chosen as the second antigen because most people have been immunised
with PPD and should have a good immune response against it. Furthermore, it was found
that lymphocyte proliferation to PPD was better than to other antigens such as tetanus toxoid
and hepatitis B surface antigen. An alternative approach would be to give an immunisation
schedule of an unrelated antigen to induce (or boost) the immune response to that antigen. I
did not wish to do this for two reasons - namely I felt the results would not be directly
comparable to previous experiments since it is possible the two immunisation schedules may
interact and, secondly, I did not wish to impose a greater burden on the volunteers.
When developing a new technique in the laboratory, one has to ask whether the assay
measure what one designs it to measure. This is particularly true in an assay such as this in
which no positive controls were available to optimise the assay. In this respect, the samples
taken before the volunteers were exposed to KLH act as an important negative control. 12 of
these 14 samples demonstrate a value around one. This suggests that the presence ofKLH in
the cell culture does not inhibit cell proliferation to PPD and therefore give falsely positive
evidence of bystander suppression. Two of the baseline samples did give values markedly
greater than one which suggests that false positive values can occur. Both samples were run
at the same time. Further work suggested that one particular batch of KLH induced this
response, and that there was no non-specific inhibition of the PPD response when different
batches of KLH were used. The reasons for this one batch of KLH causing such a problem
are unknown. Thus although non-specific inhibition of the PPD response may occur, it did
not seem to be a common problem in this assay.
After immunisation of the control group, which produced an active immune response as
shown in previous experiments, there was no evidence of bystander suppression. This
suggests that the active immune response to KLH did not inhibit lymphocyte proliferation to
PPD in vitro - i.e. there was not falsely positive evidence of bystander suppression caused by
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two active immune responses interfering with each other in the reaction. Furthermore, in
three of the four subjects the suppression index was less than one, which may imply that the
two antigens caused additive lymphocyte proliferation in the assay. These results also
suggest that the assay is valid.
After feeding of KLH, there was evidence of suppression in KLH-fed group 3, but not in
KLH-fed group 2. In both groups, the presence of a detectable lymphocyte proliferation
response after feeding and changes in the immune response to immunisation compared to the
control group suggested that immunoregulatory cells were induced by feeding. This result
implies that a more powerful regulatory cell was induced by more prolonged feeding, but
does not differentiate between the possibilities that either an additional type of regulatory
cell was induced by feeding or that more prolonged feeding resulted in the development of
greater numbers or an increasingly differentiated regulatory cell that mediated the response
in both groups.
Work from animal studies suggests that suppressor cells can exert their effect by secreting
cytokines83. It would be fascinating to develop the bystander assay to see if one could
identify any suppressive cytokines in humans. One could add anti-cytokine monoclonal
antibody to the assay to assess whether the bystander suppression was attenuated. For
example, one such cytokine that may be involved in the induction of oral tolerance is TGF-
p133. Inhibition of bystander suppression by anti-TGF-P antibody would provide supportive
evidence to the hypothesis that Th3 cells may mediate oral tolerance in humans.
After immunisation, there was no longer any detectable bystander suppression in either of
the pre-fed groups. For KLH-fed group 2, this result is in keeping with the results before
immunisation and suggests that cells with suppressive properties were not induced at this
dose of feeding.
Conversely, for KLH-fed group 3, the fact that suppressor cells were detected after feeding
but not after immunisation is unexpected. This may suggest that the results are related to a
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failure of the assay rather than a genuine finding, particularly as small numbers of volunteers
are included in these experiments. These results need to be replicated elsewhere. If one
assumes these results are genuine and not due to statistical error, potential hypotheses that
may help to explain them include:
1) Human suppressor cells (in this section I use the term suppressor cells to described the
cells that inhibited the PPD response in the lymphocyte proliferation assay, although the
nature of the cell is unknown and may be a powerful regulatory cell) are active only for a
short period of time and are susceptible to clonal anergy which renders them incapable
of reacting in the in vitro bystander suppression assay.
2) The suppressor cells may be induced to undergo apoptosis or clonal deletion. This theory
may be supported by the observation that in vitro lymphocyte proliferation is reduced
after feeding the more prolonged course of KLH. However, the feeding schedule does
influence the immune response to systemic immunisation, which makes this hypothesis
less likely.
3) The route and method of antigen presentation is crucial in determining whether these
suppressor cells are activated so that systemic presentation of antigen does not activate
suppressor cells, but oral presentation does, possibly by providing the necessary co-
stimulation to induce suppressor cells. However, the systemic immune response was
clearly influenced by oral antigen since the DTH response to systemic immunisation was
reduced.
4) Immunisation provokes an active immune response that is attenuated by suppressor cells
in the circulation. Therefore, the balance between the suppressive response and the
active response to KLH in the in vitro assay was altered by immunisation such that the
unrelated response to PPD was no longer inhibited.
5) The suppressor cells that are induced in the gastrointestinal immune system by feeding
may home back to GI sites and therefore not be present in the systemic circulation at the
time of venesection. It is possible that these cells do influence the response to
137
immunisation by altering the immune response at the time of KLH immunisation, but
that they are no longer present in sufficient numbers in the serum at the time of
venesection to inhibit the unrelated PPD response.
The presence of bystander suppression is very important if oral tolerance is to be used as a
therapeutic tool to treat autoimmune diseases. Most human autoimmune diseases are caused
by an immune response to multiple antigens within the target tissue and often the antigen
that initiates this response is unknown. Therefore the induction of a suppressor cell by
feeding antigen from the target organ that will inhibit the immune response to unrelated
antigens in that organ offers the best hope using oral tolerance to treat these diseases. These
results offer some hope that this approach may be feasible. However, they were obtained on
a small sample size and were only demonstrable at one time point shortly after feeding.
Further work is needed to confirm these results, to identify the nature of the suppressor cell
and determine why it was not detectable after immunisation. In addition, these experiments
were perfonned by antigen given orally before systemic challenge. In autoimmune disease,
the immune response is already present and further work is necessary to assess whether oral
tolerance, and particularly bystander suppression, can down regulation an existing immune
response.
7.3.3.4 Conclusion
The experiments using the bystander suppression assay suggest that the immunoregulatory
cell responsible for oral tolerance in KLH-fed group 3 may act to suppressor the immune
response to an unrelated antigen. Thus, the mechanisms by which it exerted its effect must be
antigen independent. This experimental work needs to be confirmed.
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7.3.4 FACS Scanning Data
7.3.4.1 Rationale and Aims of Experiments Using FACS Scanning
The results of feeding KLH to human volunteers altered the immune response to subsequent
systemic immunisation to that antigen and led me to hypothesise that immunoregulatory
cells were induced by feeding. Furthermore, the studies using the bystander suppression
assay raised the possibility that a cell type with suppressor properties was induced. Animal
studies have suggested several cell types that have such properties including CD4+ cells115,
CD8+ cells110 and y8 cells118. I was interested in defining the physical characteristics of the
immunoregulatory cell induced in my experiments as a step towards defining the nature of
this cell.
I developed an experimental protocol to attempt to identify the cells that proliferate in
lymphocyte culture using FACS scanning. As described in the Materials and Methods
section, mononuclear cells were obtained from volunteers before exposure to KLF1, after
feeding and after immunisation. These cells were then cultured with 5pg/ml of KLH for 92
hours. These cells were then incubated with the appropriate monoclonal antibodies before
being examined in the flow cytometer. I hypothesised that any KLH specific lymphocytes
would be activated and proliferate in response to KLH in culture and that they could then be
identified with labelled antibodies to proliferation markers. The proliferation markers that
were chosen were CD25, CD38, CD45RO and HLA-DR. The morphology of these activated
cells could then be characterized by co-staining with antibodies to cell surface markers
labelled with a different chromogen, and I initially chose to investigate whether activated
cells expressed CD4 or CD8.
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7.3.4.2 Results
Four volunteers from the control group and four volunteers from KLH-fed group 3 were
included in this experiment. An example of the results obtained is shown in figure 7.5.
Figure 7.5a illustrates the initial scatter diagram of size (forward scatter) against granularity
(side scatter). The lymphocytes can be identified by their position on the figure and are
highlighted in red. The level of staining of PE and FITC on these selected cells can be
plotted alone as shown in figure 7.5b. This example shows the level of CD25, stained with
FITC-labelled monoclonal antibody, plotted against the level of CD4, stained with PE-
labelled monoclonal antibody. Immunisation resulted in no detectable increase in the level of
staining of any activation marker compared to baseline in either the control group or the pre-
fed group after feeding or after immunisation. There was no difference in the frequency
distribution of cells demonstrating differing amounts of activation markers before and after
encounter with KLH in either the control or pre-fed group. Figure 7.5c illustrates an example
comparing the frequency distribution of CD25 before and after immunisation of a volunteer
in the control group and again no difference in frequency distribution could be detected.
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Figure 7.5a - typical dot plot showing the morphological characteristics of isolated
lymphocytes after 96 hours in culture. The gated cells in red represent lymphocytes. The
smaller "cells" are likely to represent cellular debris.
Forward Scatter
Figure 7.5b - dot plot of the gated lymphocytes showing the surface expression of CD4 vs.
CD25. The cell population in the upper right hand quadrant represent a cell population with
positive surface expression of both markers and therefore are activated CD4+ lymphocytes.








Figure 7.5c - a different method of demonstrating cell surface expression is shown. The
amount of CD25 expressed per cell is expressed as a frequency histogram. In this example,
the cells counted are all from within the gated area shown above. The two peaks represent
cells expressing low levels of CD25 (i.e. non activated cells) and high levels of CD25. The
blue line represents cells obtained from a volunteer in the control group prior to
immunisation, and the pink line represents cells from the same volunteer after immunisation.




This experiment was designed to identify cells that had been activated in the lymphocyte
proliferation assay, and then define the morphological characteristics of these cells. The cell
activation markers used to identify activated cells were antibodies to CD25, CD38, CD45RO
and HLA-DR labelled with FITC. CD25 is the IL-2 receptor and is found on activated T
cells, B cells and monocytes. In addition, CD25 is said to be down regulated on anergic cells
and therefore, if this assay worked well, I may have been able to use this marker to assess for
the presence of anergy. HLA-DR is also up-regulated on activated T cells and
macrophages191. CD38 is found on activated T cells and on plasma cells192. CD45, otherwise
known as leucocyte common antigen, is found on all leucocytes. It is present in two isoforms
- CD45RA which is found on virgin T cells and CD45RO which is found on primed,
activated T cells193. The experiments described were designed to assess whether the
immunoregulatory cells were of CD4+ phenotype, which would be consistent the production
of Tr1 or Th3 cells by feeding, or of CD8+, which implies the production of a suppressor
cell. PE-labelled anti-CD4 and anti-CD8 were therefore added to define the phenotype of
any activated cells identified by the above markers.
The baseline data would have been used as a control group to ensure that the cells were
specifically activated by KLH. Unfortunately, I was unable to detect any rise in activation
markers over baseline and so the experiment failed to yield any positive results.
There are a number of possible reasons for my failure to detect activated cells in this assay.
Firstly it is likely that the number of activated lymphocytes is so small in comparison to the
total number of lymphocytes in culture that no statistical differences can be detected. An
alternative explanation is that immunoregulatory cells may not express the activation
markers that I assayed for, although the wide panel of activation markers that I used makes
this less likely. Lastly lymphocytes activated in this culture system may have an abnormal
size and granularity and therefore be out-with the gated area chosen initially. To allow for
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this possibility, the data was re-analysed without using the initial gating, and again no
differences were seen.
Two possible methods may increase the sensitivity of this technique and may be worthy of
further study. Firstly, it may be possible to stain the nuclei with propidium iodide. This stain
can allow the FACS scanner to identify the stage of the cell cycle that each cell is in. The
computer software can therefore be instructed to run its analysis on actively dividing cells
only. Antigen specific lymphocytes that are stimulated by antigen should be dividing and
therefore running the analysis on these cells may improve the sensitivity of the test. I made
an attempt to develop this technique, but did not successfully optimise the assay in time to
use it in these experiments.
A second technique that may help identify the immunoregulatory cell would be to clone the
cell. Using a population of cloned cells in the FACS scanner would also reduce the number
of lymphocytes that are not reactive to KLH and therefore increase the sensitivity of this
technique. Furthermore, it may be easier to identify the cytokine profile of the
immunoregulatory cell from a cloned population. Cloning is a well established technique and
has been used on both animal and human cells. There are however problems with cloning.
The cloning process itself can alter the expression of cell surface marker and indeed the
cytokine profile produced which may give unreliable results. In addition, it is a technically
demanding and difficult method to develop and my laboratory has no experience of cloning
techniques. For a combination of these reasons, and due to lack of time, I did not attempt to
develop clones of these cells. It may be a method that could be usefully incorporated into
future studies to identify the cells responsible for tolerance production in humans.
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7.4 Evidence for Mechanisms of Tolerance in OVA Group
7.4.1 Summary ofResults of Experiments Using OVA
Immunisation with OVA resulted in no detectable DTH response or in vitro lymphocyte
proliferation. There was a low level of anti-OVA IgG and IgA in the serum of volunteers
before immunisation, but after lifelong exposure to OVA in the diet. Low dose immunisation
did not provoke a rise in levels of either of these antibodies. The four volunteers who
received the higher dose immunisation schedule showed no, or a very modest, increase in
antibody levels. I have argued that these results would be consistent with the induction of
clonal anergy or clonal deletion to prolonged exposure to orally encountered antigen
7.4.2 Absence of Bystander Suppression Induced by OVA
The bystander suppression assay has been described earlier in this chapter. It is possible that
the powerful OVA specific suppressor cells may have been induced by feeding and inhibit
the production of humoral or CMI, particularly if these cells are anergic i.e. do not
proliferation in response to OVA. I therefore used the previously described assay to assess
whether the addition of OVA to cells obtained from OVA immunised volunteers inhibited
the response to PPD. A suppression index was calculated as previously described.
Samples from 10 volunteers were run on this assay. Samples from before the immunisation
schedule (i.e. after oral exposure to OVA) and after immunisation were included. There was
no evidence of bystander suppression in any of the samples (data not shown). These results
do not support the hypothesis that active suppression is an important mechanism in
maintaining oral tolerance to OVA.
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7.4.3 Reversal ofAnergy with IL-2
7.4.3.1 Introduction and Rationale
Clonal anergy is a powerful mechanism of tolerance production and can be defined as a
long-lived state of reduced responsiveness to antigen by antigen specific lymphocytes86.
Clonal anergy has been shown to be responsible for oral tolerance in animal models under
certain feeding conditions144145. The complete absence of CMI responses and the very
sluggish antibody response to OVA immunisation would be consistent with the induction of
clonal anergy by prolonged OVA ingestion.
One experimental method that has been used to imply the presence of anergy in animal
models of oral tolerance has been to demonstrate the reversal of tolerance by culturing
anergic lymphocytes with IL-2148. I attempted to demonstrate reversal of anergy in in vitro
lymphocyte proliferation assay by preculturing lymphocytes with IL-2.
7.4.3.2 Results
The results are shown in figure 7.6. As can be seen, there was no evidence of lymphocyte
proliferation to OVA following pre-culture with IL-2 in cells obtained before or after the
injection schedule. Interestingly, addition of this dose of IL-2 to cells cultured for 96 hours
without antigen stimulation induces an impressive 15-fold increase in lymphocyte
proliferation compared to cells cultured without IL-2 (data not shown).
7.4.3.3 Discussion
These experiments did not provide any evidence to support the hypothesis that clonal anergy
is responsible for tolerance to OVA in humans. There are two possible explanations. Firstly,
clonal anergy may not be the cause of tolerance and another mechanism such as clonal
deletion may be responsible. Alternatively, clonal anergy may be the underlying mechanism
of tolerance, but is not reversed by IL-2 in this assay.
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Figure 7.6 - Results of lymphocyte proliferation to OVA after pre-culture with IL-2. There






There are a number of other technical reasons that may explain why my assay failed. Firstly,
the IL-2 may not be biologically active in the dose I added. This is unlikely since I used the
same dose as reported in previous, successful animal studies144. The observation that the
addition of IL-2 cells cultured without antigen stimulation induces a 15-fold increase in
lymphocyte proliferation compared to cell cultured without IL-2 suggests that IL-2 is
biologically active in the concentration used.
Other potential reasons for failure to reverse tolerance may be that the APCs adhered to the
wells at the first stage of culture and were therefore not transferred with the lymphocytes to
the second stage of culture, or that they did not survive culture with IL-2. If no APCs were
present in the second stage of culture, lymphocytes would not proliferate even if anergy had
been reversed. Three strategies were used to ensure APCs were present in the second stage
of culture. Firstly, in eight subjects a cell scraper was used to ensure all possible cells were
transferred from the first to the second stage of culture. Secondly, lymphocytes were cultured
in the wells to be used for the second stage of culture from the start of the experiment on four
occasions. After the first stage of the experiment, the supernatants from these wells were
removed. If adherence of APCs is the reason for failure of this assay, then functional APCs
should have remained in the wells for the second stage of the experiment. Lastly, to test for
the possibility that APCs did not survive the two-stage culture process, fresh mononuclear
cells were collected from two volunteers between the two stages of the experiment and used
in the second stage of culture. None of these modifications to the experimental technique
resulted in any detectable lymphocyte proliferation to OVA.
Another potential explanation for the failure to demonstrate reversal of anergy may be due to
differences in the protocol between previously reported experiments on animal models and
my experiments on humans. Firstly, the feeding regime used in the animal experiments gave
1 large dose of antigen144 148. Conversely, the volunteers in my study received a lower dose
per weight over a much more prolonged period. It may be that human OVA specific
lymphocytes are more profoundly anergic and therefore do not respond to IL-2. A second
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important difference is that the animal studies obtained cells from the spleen144, whereas I
used peripheral blood cells. Anergic cells may reside in the spleen and not be present in the
peripheral circulation, even after immunisation. Therefore, the difficulties of obtaining
lymphocytes from tissue other than blood in humans may be the explanation for my failure
to demonstrate reversal of anergy with IL-2.
Lastly, the way I chose to demonstrate the reversal of anergy in my experiments differs from
that used in animal studies. Animal studies used adoptive transfer of IL-2 pre-cultured cells
into irradiated mice to demonstrate the return of function. They showed that these mice were
able to produce antibody. This may be an important difference since anergic cells can secrete
cytokines and may therefore be able to provide help to antibody production, without being
able to proliferate190. Thus my method of showing reversal of anergy may not be as sensitive
as these methods. Again, it is impossible to reproduce these animal experiments in humans.
In summary, these experiments did not provide supportive evidence for the presence of
clonal anergy to OVA in humans. However, this may be due to problems obtaining
appropriate samples from humans or in assay techniques that mean that the initial hypothesis
cannot be rejected on this evidence and further work in this area is required.
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8 GENERAL DISCUSSION
8.1 Discussion of Results Obtained from KLH Experiments
8.1.1 Overview of Results of the Induction of Tolerance with KLH
KLH, chosen because of its availability and proven safety in humans, was used to investigate
low dose tolerance in humans. An actively immunised control group demonstrated a good
cell mediated immune response, including positive DTH responses and lymphocyte
proliferation to KLH in vitro, and humoral responses. Three different feeding regimes of
KLH were given to groups of volunteers, before their immune system was challenged by
systemic immunisation with KLH. Any differences between the immune response in the
control group and the pre-fed groups were attributed to oral tolerance.
KLH-fed group 1 ingested lOmg of KLH daily for 10 consecutive days. There was no
difference between the immune response in this group and the control group, which suggests
that a minimum dose of feeding is required to induce detectable changes in the systemic
immune responses.
The feeding regime given to KLH-fed group 2 was 50mg of KLH daily for 10 consecutive
days. When compared to the control group, there was a reduced DTH response associated
with an unchanged lymphocyte proliferation response after immunisation. The relationship
between DTH and in vitro lymphocyte proliferation that was seen in the control group was
lost. Furthermore IgG, but not IgA, antibody responses to KLH were primed. Feeding alone
induced a detectable in vitro lymphocyte proliferation response, but did not induce a
detectable humoral response.
Another group, KLH-fed group 3, was given a more prolonged course of feeding of 50mg of
KLH for 10 consecutive days, a gap of five days followed by a further five daily 50mg feeds.
Following this feeding regime there was a detectable in vitro lymphocyte proliferation
response, but no detectable humoral response. Again, the relationship between DTH and in
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vitro lymphocyte proliferation that was seen in the control group was lost. Following
immunisation, the immune response was similar to that seen in KLH-fed group 2 in that
there was a reduced DTH response and a detectable in vitro lymphocyte proliferation
response. IgG responses were not significantly raised compared to baseline. The immune
responses between KLH-fed group 2 and KLH-fed group 3 was different in two respects.
Firstly, the IgG response after immunisation was no longer raised in KLH-fed group 3
compared to the control group. Secondly the in vitro lymphocyte proliferation response was
significant higher after feeding but significantly reduced after immunisation in KLH fed-
group 3 compared to group 2.
8.1.2 Hypotheses Drawn from Experiments on Tolerance Induction with KLH
The results for KLH-fed group 1 indicate that there is a minimum level of feeding that is
necessary to induce detectable changes in the systemic immune response. There may have
been a low level immune response that was not detectable by the assays that I used and it
would be interesting to rechallenge these volunteers to see if any subsequent immune
response would be brisker or more complete compared to totally naive controls.
The results from KLH-fed groups 2 and 3 convincingly demonstrate that tolerance to DTH
responses have been induced by pre-feeding KLH, but than tolerance in the humoral
compartment of the immune system has not occurred. Priming of the IgG response
associated with suppression of DTH to the fed antigen has been observed in animal
studies1446194. A suppressor cells was identified by transfer experiments as the mechanism of
tolerance16. The results obtained from the experiments with KLH-fed group 2 are similar to
these studies and I therefore hypothesised that an immunoregulatory cell is responsible for
tolerance in my studies. I suggested that proliferation of this cell, induced by feeding, is
responsible for the detectable in vitro lymphocyte proliferation after feeding. This cell
subsequently modifies the immune response to KLH immunisation to suppress the DTH
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responses but enhance anti-KLH IgG production. Putative immunoregulatory cells that may
have these properties include Th2 cells58 and TR1 cells139.
The differences in the immune response in KLH-fed group 3 show more pronounced
tolerance than KLH-fed group 2 in that the post immunisation in vitro lymphocyte
proliferation responses are reduced. In addition both anti-KLH IgG and IgA levels are
reduced after immunisation in the KLH-fed group 3. This pattern has also been seen in
animal studies in which a suppressor or immunoregulatory cell was identified99 I
hypothesised that such a cell was also responsible for feeding in KLH-fed group 3. Feeding
alone causes an increase in in vitro lymphocyte proliferation compared to KLH-fed group 2,
but there is no further priming of the IgG response. I hypothesised that these results were not
consistent with an increased TH2 response but may be consistent with the induction of TR1
cell139 or Th3 cells133. Although I chose to investigate the hypotheos that immunoregulatory
cells were responsible for tolerance to KLH, an alternative hypothesis that would be
consistent with the data is that clonal anergy141 or clonal deletion133 may have been induced
by feeding.
8.1.3 Experiments Designed to Investigate these Hypotheses
Chapter 7 details the results of several lines of investigation that I performed to investigate
these hypotheses. The results for these experiments failed to provide definitive evidence for
the presence of these putative immunoregulatory cells. This may be because the experiments
designed were not adequate to detect them, or because the hypotheses are wrong and that
different mechanisms are in fact responsible for tolerance induction to KLH. In this section, I
will discuss the limitations of each of the experiments performed.
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8.1.3.1 Criticisms of Investigations of Cytokine Production
8.1.3.1.1 ELISA Methods ofCytokine Measurement
Commercially available kits, complete with positive controls were purchased. The positive
controls gave positive results indicating the kits had worked. However, only three specimens
gave any detectable results for IFN-y and all were at or below the lowest value of the
positive control. No IL-4 was detected in any test sample. The reason for the failure of this
experiment is likely to be because the amount of cytokine in the supematent of each sample
is below the detection limit for the assay. Husby et al reported similar problems in their
experiments on oral tolerance in humans9. If further work is performed using such assays,
samples stimulated with conA, which causes a good proliferation response, should be
included as an additional positive control.
8.1.3.1.2 PCR Methods to Detect Cytokine mRNA
The failure of the ELISA methods to detect cytokines led me to develop the PCR based
assays. These have the advantage of being very sensitive. There are several drawbacks,
including the fact that they measure a surrogate marker of cytokine levels (i.e. mRNA) and
that they do not give quantatitive results. I was able to detect cytokine mRNA but the results
were inconclusive.
The addition of further controls may have be helpful to improve our ability to inteipret these
results. Firstly samples obtained from cells cultured without KLH at all stages of the assay
should have been included. This would have allowed direct comparisons between positive
and negative samples cultured at the same time to have been made. Secondly further positive
controls with samples of cells known to produce specific cytokine mRNA at high levels
would have been helpful. The positive controls that I used were stimulated with conA and
the levels of each cytokine mRNA that these controls produce is unknown.
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PCR methods have shown some promise in my hands as I was able to detect cytokine
mRNA. Further work incorporating the above controls would be helpful. Such work should
also attempt to use quantitative PCR techniques to allow direct comparison between groups.
8.1.3.2 Criticisms of FACS Scanning Experiments
The FACS scan experiments were designed to identify the immunophenotypic characteristics
of the cells that gave positive results in the in vitro lymphocyte proliferation assays. I had
hypothesised that the cells that proliferated in the lymphocyte proliferation assay may be
immunoregulatory cells and I was interested in characterising them.
The assay failed to detect the proliferating cells and therefore I could not characterise them.
There were a number of potential problems with this assay. Firstly, the population of antigen
specific cells are a very small proportion of the total number of lymphocytes within the
circulation. Therefore it may be very difficult for techniques such as these to detect any
population of antigen specific lymphocytes. Furthermore it is not known whether the surface
markers used to detect dividing cells (i.e. CD25, CD38, CR45RO and HLA-DR) are
upregulated on immunoregulatory cells in humans and therefore whether the FACS scan
could detect these cells. Finally, there were no positive controls built into the experimental
design. Therefore it is impossible to know whether the negative results obtained in this
experiment are due to the experimental technique or due to the fact that there were in fact no
immunoregulatory cells present. In addition, the negative controls used were cells obtained
from volunteers prior to encounter with KLH. The addition of cells taken at each time point
during the experiment and cultured without KLH would have been a useful additional
negative control.
For the above reasons, it may be very difficult to get positive results with experimental
techniques such as these. If they are used in the future, attempts to include positive controls
should be made. Cells cultured with conA to provoke more generalised T-cell proliferation
would perhaps be one such control. Other methods to improve the sensitivity of the
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technique should be identified. One such possibility would be to stain the cells with
propidium iodide, which identifies actively dividing cells and then limit the analysis to these
cells.
8.1.3.3 Criticisms of the Bystander Suppression Assay
These results implied that there may be regulation of a different immune response by cells
induced by feeding KLH, which would suggest the presence of an immunoregulatory cell.
These results were obtained on a very small sample size and therefore should be inteipreted
with caution, but further work to reproduce these results is warranted. The experiments are
limited by the lack of a positive control (i.e. known immunoregulatory cells that induce
bystander suppression) to ensure that the assay can indeed detect bystander suppression.
Finding such controls would be very difficult, although valuable. In addition in my
experiments I used an already established immune response (i.e. PPD). This was intentional
because I did not want to introduce the potential confounder of giving two immunisation
schedules simultaneously. However the use of an immune response established by
immunisation earlier in life leads to potential problems in that the degree of active immunity
of each individual tested may vary. Further experimental protocols using two separate neo-
antigens, one to induce oral tolerance and one to assess bystander suppression, would be a
useful way to extend this work.
8.1.4 Conclusions from Experiments on Tolerance to KLH
The results from the KLH experiments confirm the earlier observations that oral tolerance to
a neo-antigen can be induced to DTH by short course feeding.
I hypothesised that tolerance may be due to the production of an immunoregulatory cell. I
failed to find any direct evidence of such a cell. As the above discussion emphasises, the
experimental methods used may not have been adequate to detect such cells and the absence
of evidence cannot be taken for evidence of absence. However, it is possible that the initial
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hypothesis was wrong, and that mechanism of tolerance induction other than
immunoregulatory cells are induced. One possibility is that the absence of DTH responses
are the result of T-cell anergy and that feeding primes B-cell responses. Recent work
suggesting that anergic cells can have suppressor functions155'156 would be consistent with
this hypothesis. Further work on oral tolerance in humans should incorporate protocols to
investigate the presence of such mechanisms of tolerance.
8.2 Discussion of Results Obtained from OVA Experiments
8.2.1 Overview ofResults of the Investigation of Tolerance to OVA
Animal studies suggest that high dose feeding results in the induction of different
mechanisms of tolerance such as clonal anergy141'143 and clonal deletion133. To assess
whether similar mechanisms may occur in humans, I used a similar protocol to assess the
systemic immune response to OVA. OVA was chosen because it is a common dietary
antigen, a source of OVA that was safe for injection was available and our laboratory has
experience of assaying for anti-OVA antibodies. The results gave an entirely different
pattern of immune responses compared to the KLH-fed groups. There were no detectable
cell-mediated immune responses at any rime. Low levels of anti-OVA IgG and IgA were
detected at baseline, but there was a very poor humoral response to systemic immunisation.
8.2.2 Hypotheses Drawn from Experiments on Tolerance to OVA
Tolerance to OVA affects both humoral and cell mediated immunity. This more complete
tolerance lead me to hypothesise that more powerful, additional mechanisms of tolerance
may be involved in maintaining tolerance to OVA. One such mechanism would be clonal
anergy. I attempted to develop an assay using IL-2 to reverse tolerance to test this
hypothesis.
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8.2.3 Criticisms of Experiments Using OVA
The major criticism of the experiments using OVA is the lack of a positive control. All test
subjects have encountered OVA regularly in their diet and therefore no group is available to
assess the immune response to OVA in naive controls. In is thus impossible to know whether
the lack of immune response to OVA is because OVA itself is not immunogenic or because
oral tolerance has been induced. This has been discussed more fully in chapter 6. I attempted
to circumvent this problem by increasing the immunisation dose used. Further work on oral
tolerance to prolonged feeding with antigen should address this problem. Two possible
methods are available. Firstly a dietary antigen such as OVA could be used, but the immune
system should be challenge by immunisation containing adjuvant. This would increase the
immunogenicity of the injections, but there would still be no control group. An alternative
method for which a control group could be obtained would be to give prolonged feeding with
a neo-antigen such as KLH. This kind of protocol has the drawbacks of being expensive and
being difficult for the volunteer subjects to follow.
OVA was used to investigate high dose tolerance, and it is true that the volunteers would
have consumed large quantities ofOVA over their lifetimes. However, the amount of OVA
ingested is uncontrolled and the total dose consumed by each volunteer may vary wildly.
Furthermore, in the animal models of high dose tolerance that identified the mechanisms of
clonal anergy and clonal deletion, a single large dose feed was given133;I41. Therefore the use
of a dietary antigen to investigate this type of high dose tolerance may be inappropriate.
Further studies using single, or short course, feeds of neoantigen such as KLH in larger doses
than used in my experiments would be required to investigate this type of tolerance.
I failed to find direct evidence for anergy by IL-2 reversal. There are several differences
between the protocol I developed and those used in animal studies that may explain this
failure. These include the fact that different feeding schedules were given and that the cells
cultured with IL-2 in animal studies were obtained from the spleen and not the peripheral
circulation144. Therefore it is impossible to know whether failure of the assays or a tr ue
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absence of clonal anergy is responsible for the negative results obtained. These difficulties
are compounded by the lack of a positive control sample - i.e. known anergic cells in which
a return of function can be demonstrated in this assay.
8.2.4 Conclusions from Experiments on Tolerance to OVA
There was a marked lack of immune response to OVA after both the low and high dose
immunisation schedules. The experiments that I performed cannot differentiate conclusively
whether this is due to the presence of powerful mechanisms of tolerance induction or to the
fact that the OVA immunisation schedule was not immunogenic. I did hypothesise that
clonal anergy may be responsible for the maintenance of tolerance but no evidence could be
obtained to support this hypothesis.
8.3 Difficulties Encountered During these Experiments on Humans
In this thesis, the KLH experiments successfully demonstrated that oral feeding alters the
systemic immune response to that antigen although 1 was unable to define the nature of the
tolerance. There are a number of difficulties in developing experimental techniques to
investigate mechanisms of tolerance in human studies that do not apply to animal work that
make identifying such mechanisms problematic. Problems encountered include recruiting
large numbers of well-motivated volunteers to take part in these trials. Furthermore, human
study groups are heterogeneous leading to a potential wide variability in their immune
responses. Therefore, in many experiments, one has small groups with a wide range of
values thus reducing the chance of obtaining a statistically significant result. Experiments on
animal strains overcome both these difficulties. There are also limitations on the type of
experiments that can be designed. For example, it is almost impossible to biopsy interesting
tissue such as mesenteric lymph nodes or spleen. For ethical reasons, the immune response
of the volunteers cannot be manipulated in vivo, by, for example, giving monoclonal
antibody to specific cytokines to investigate their effect on the immune process. Similarly
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transfer experiments, which have been used to identify suppressor cells in animal
models13'32'100, are impossible in humans. The investigation oral tolerance in humans is
therefore a real scientific challenge.
8.4 Ideas for Further Research
Further work on oral tolerance in humans needs to be extended in two ways. Firstly the range
of tolerance needs to be delineated. The effect of various feeding schedules, in terms of
length of feeding and dose of feeds, on the immune response have to be defined. In addition
tolerance to different types of antigen, such as other soluble proteins, particulate antigens and
even bacteria, have to be investigated, as has occurred in animal models14;28. Finally,
research on the length of time that tolerance persists after feeding is required.
Secondly further work on the nature of the mechanisms of tolerance in humans is required.
The sections above illustrate many of the difficulties that will be encountered in such
research. In vitro assays, such as the bystander suppression assay, need to be developed and
validated. Manipulations of such assays, for example by adding specific cytokines or anti-
cytokine monoclonal antibodies, will be required if the molecular basis for oral tolerance in
humans is to be elucidated.
8.5 Epilogue
In this thesis 1 have developed a method to demonstrate the presence of oral tolerance in
humans. I have used this method to investigate the effects of feeding different doses of
soluble protein antigen. I have shown that oral tolerance by low dose feeding can be induced
and inhibits DTH response. Investigations of the immune response to a common dietary
antigen suggests that tolerance is more complete to these antigens, although further studies
will be required to confirm these observations. The knowledge of oral tolerance in humans is
analogous to early animal work when investigators were defining the extent of oral tolerance
in animals. Further work to investigate the extent and nature of oral tolerance in humans is
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required before clinical applications of oral tolerance in the treatment of autoimmune
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